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Abstract
Staphylococci are the most common cause of infection in indwelling
medical devices. 1,  2 Their ability to form ‘biofilms’ makes treatment difficult
and can lead to reoccurring infection. This work presents a potential novel
method for imaging biofilm in flow systems utilizing Microbubbles (MBs) as
ultrasound contrast agents. The surface of these MBs were functionalized with
an Affimer protein engineered to bind to Clumping Factor A, a virulence factor
present on the surface of S. aureus cells. These functionalized MBs were
found to bind to the S. aureus biofilm 10 times better than their controls,
demonstrating the ability of these proteins to localize large macromolecular
structures to the biofilm surface under flow conditions. The results show the
potential of targeted microbubbles to be used as a novel method of biofilm
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Bacterial biofilms are ubiquitous in nature and represent the predominant
mode of bacterial growth in the natural world and human infections.3 Biofilms
are surface bound agglomerations of microbes, together with a matrix of
secreted microbial polymers and “scavenged” host molecules.4  They have
complex structures and contain bacteria in a variety of growth and metabolic
states.5 Most bacterial infections will at some point involve a biofilm, which is
associated with a 10-100 fold decrease in susceptibility of bacteria to
antibiotics when compared with a planktonic population.6 Formation of biofilms
on indwelling medical devices such as intravascular catheters, pacemakers
and prosthetic joints makes infection hard to eradicate with antimicrobial
therapy alone. Frequently, formation of a biofilm requires removal of the
device.7
A wide range of bacteria and some yeasts can form biofilm infections
in humans.8 In particular, Staphylococci, including S. aureus and the large
group of coagulase negative staphylococcal species, are the most common
cause of infection in indwelling medical devices.1 In particular, S. aureus is
one of the most lethal causes of bloodstream infection, with a mortality rate of
46% in patients with severe sepsis.9-11 The ability to form biofilms offers a
unique bacterial defence against antimicrobials, making treatment of these
infections a considerable challenge.12
1.1.1 Biofilm life cycle
The life cycle of a biofilm is thought to consist of three stages:
 (i) Initial attachment of cells to a surface; (ii) maturation; and (iii)
detachment.13 Initial attachment has been shown to be facilitated by
interactions between cell surface adhesins and the polymer or host surface
components.14 Once established, the production of an extracellular matrix
allows the cells to proliferate into three-dimensional (3D) structures. The
polysaccharide matrix offers many mechanisms for decreasing antibiotic
activity through the biofilm. The matrix, acting as a pseudo-polysaccharide
and glycoprotein gel can decrease antibiotic motility by a factor of two to
three.15 The antibiotic can be deactivated by an enzymatic reaction (examples
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include beta-lactamases, chloramphenicol acetyltransferases and
aminoglycoside-modifying enzymes), or sequestered by binding proteins that
form part of the biofilm’s matrix. Furthermore, differences in growth states of
bacteria within the biofilm will affect their susceptibility to certain antimicrobial
agents.16 Microbes buried deep in the biofilm tend to exist in a slow growing
state due to poor penetration of nutrients through the biofilm.17  This can affect
the bacteria’s susceptibility to antibiotics such as beta-lactams, that target cell
wall synthesis, which occurs predominantly during cell growth.18
Disassembly of the biofilm in S. aureus is mediated by the agr quorum-
sensing system (1.1.4),19 subsequent detachment of cells can then facilitate
a colonisation at a secondary site.5 The detachment of these cells from the
biofilm then helps to alleviate nutrient depletion and helps sustain the life of
the parent biofilm.20
Figure 1.1. Illustration of the steps in the life cycle of a bacterial biofilm.
Initial attachment is facilitated by the hydrophobicity of a polymer surface or
host matrix proteins. Development of the extracellular matrix is followed by
maturation of the biofilm, then disassembly and detachment of bacteria from
the fully developed biofilm.13
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1.1.2 S. aureus cell surface
The S. aureus cell surface contains a myriad of virulence factors, some
of which facilitate the colonisation of surfaces leading to biofilm formation
(Figure 1.2). These include a range of Microbial Surface Components
Recognizing Adhesive Matrix Molecules (MSCRAMMs), all of which
contribute towards the virulence of the species.21 For instance, clumping
factor A (ClfA),22 clumping factor B (ClfB)23 and fibronectin binding protein
(FnBP)24 are cell wall-associated proteins that contribute towards host-cell
interactions. Protein A (SpA) is a multifunctional protein that binds
Immunoglobulin G (IgG), von Willebrand factor (VWF) and other ligands.25
SpA coats the bacteria in these ligands which results in decreased recognition
of the pathogen by neutrophils, ultimately negating phagocytosis.26  These
proteins are anchored to the peptidoglycan of the cell wall via transpeptidases
known as sortases.27, 28 An example of one of these transpeptidases is
Sortase class A, which recognises an LPXTG sequence present on the
surface of protein precursors, and ligates them to oligoglycine species on the
cell surface.29-31 Other cell surface components such as wall teichoic acids
(WTAs) are complicit in biofilm formation and are associated with the host-cell
interaction.32 These teichoic acids consists of repeat units of phosphodiester-
linked polyol,33 whose negatively charges backbone is implicated in a number
of cell surface interactions.34
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Figure 1.2. Illustration of the S. aureus cell surface.
The surface of the S. aureus bacteria consists of the cytoplasmic outer
membrane, a layer of peptidoglycan and a network of cell surface associated
proteins and glycoproteins.
1.1.3 The biofilm matrix
An important component of the biofilm structure is the network of
proteins and polysaccharides that surrounds the bacterial cells and promotes
intercellular and surface adhesion.35 The main component of this extracellular
matrix in staphylococci is the exopolysaccharide poly β(1,6)-N-
acetylglucosamine (PNAG, structure shown in Figure 1.3), a positively
charged molecule that helps aggregate cells utilising the negatively charged
cell membrane, whilst also isolating the bacteria from antimicrobials.36
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Figure 1.3. Structure of partially deacetylated poly-β-(1,6)-N-
acetylglucosamine.
The main component in most biofilm matrices.
Though PNAG is considered the main component in the extracellular
matrix, other molecules have been found to contribute toward the contents of
the biofilm matrix such as proteinaceous adhesins bound to the cell surface
and extracellular deoxyribose nucleic acid (eDNA) from lysed cells.37 Many of
these extracellular adhesive molecules are categorised as Secreted
Expanded Repertoire Adhesive Molecules (SERAMs).38 Table 1.1 shows the
composite make-up of the S. aureus biofilm matrix. Many of these SERAMs
are able to bind fibrinogen which helps aggregate cells by cross-linking
receptors present on the cell surface.38, 39 Fibronectin-binding proteins
(FnBPs) are a common family of S. aureus cell surface adhesins that facilitate
the colonisation of a biofilm via interactions with mammalian cell-surface
fibronectin.40
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Table 1.1. Components of the Staphylococcus aureus biofilm matrix and their
functions. Taken from 12, 19.
Component Function
Poly β(1,6)-N-acetylglucosamine Aggregate cells
S. aureus Alpha-toxin (Hla) Potent cytolysin and virulence factor.
S. aureus Beta-toxin (Hlb) Sphingomyelinase, haemolytic, lymphocytic
and binds eDNA.
Secreted Expanded Repertoire Adhesive Molecules (SERAMs):
Extracellular Binding Protein Adhesin, helps adhere cells to biofilm matrix.
Fibrinogen Binding Protein A (FbpA) Homologous to coagulase, targets
prothrombin, polymerises fibrin and forms
staphthrombin.
Van Willebrand factor binding protein Binds Van Willebrand Factor, has
antiphagocytic activity.
Extracellular Fibrinogen Binding Protein
(Emp)
Binds fibrinogen, fibronectin, vitronectin,
collagen, adhesions of S. aureus to
immobilised fibrinogen and fibronectin.
Extracellular Adhesive Protein (Eap) Binds fibronectin, fibrinogen, eukaryotic cell
walls, staphylococcal cells, mediates S. aureus
adhesion to matrix protein, decreases
phagocytic activity.
Phenol Soluble Modulins (PSMs) Stability of biofilm, Amyloid formation.
eDNA Intercellular adhesion.
1.1.4 agr quorum sensing system
The agr (accessory gene regulator) quorum-sensing system plays an
integral role in the sustainability of a staphylococcal biofilm. The system
operates by sensing the concentration of autoinducing peptide (AIP).12 The
general structure of an AIP is shown in Figure 1.4A, with the four API variants
identified in S. aureus strains, shown Figure 1.4B.41 All AIP variants contain a
conserved thiolactone linkage that bridges the five C-terminal amino acids via
a cysteine side-chain. AIP is derived from AgrD protein, which is first
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processed by a membrane-bound peptidase to AgrB, that is exported across
the membrane and subject to a second cleavage.42 The mature AIP is then
extracellularly transported.  Once the AIP reaches a certain concentration
(usually ~nM), it binds to the surface exposed histidine kinase AgrC, which
triggers a two-component response, which leads to the activation of
machinery that digests surface proteins associated with biofilm maintenance
(Figure 1.5). Generally, induction of the agr system causes down-regulation
of adhesins and up-regulation of secreted toxins and enzymes that cause
disassembly of the biofilm.12 This machinery plays a pivotal role in maintaining
optimal conditions for biofilm longevity and offers a mechanism for potential
secondary infection, by allowing release of bacterial cells from the biofilm.
Figure 1.4. Structure of Auto-inducing Peptides in S. aureus.
A) Consensus chemical structure of the four AIP S. aureus subgroups. Red
atoms show conserved thiolactone macrocycle common between all variants,
with the R group variations essential for binding. B) Amino acid sequences of
AIP-I, AIP-II, AIP-III and AIP-IV. Adapted from 42 .
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Figure 1.5. Cartoon representation of part of the agr quorum sensing pathway
in S. aureus.
Cascade mechanism by which the agr quorum sensing machinery of S.
aureus up-regulates the production of proteolytic enzymes than digest cell-
surface proteins associates with cellular adhesion. Adapted from 12.
1.2 Imaging biofilms
Microscopy is a powerful tool for imaging biofilms in vitro, allowing
imaging of both living and dead cells and observation of changes in
topography.
Confocal laser scanning microscopy (CLSM) is an imaging technique
that uses fluorescence to generate a real time visualisation of hydrated living
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cells; conventionally it uses an upright or inverted epi-fluorescence
microscope.43, 44 Fluorescence can be achieved either by the inherent
fluorescence of a microbe or more commonly, a specialised dye. In most
cases, the two components of a live/dead stain contain a membrane
permeable dye to stain living cells, and a non-membrane permeable dye to
stain cells with compromised cell membranes.45 Staining kits are available
commercially that selectively dye living and dead cells with different coloured
fluorophores in order to differentiate between the two, an example of which is
calcein-AM and propidium iodide (PI).46 Calcein-AM is a cell-membrane
permeable molecule that once digested by esterase in living cells fluoresces
green.47 In contrast, PI cannot permeate living cells but can pass through
disrupted membranes of dead cells and complex to double helical DNA to
fluoresce red.48
Figure 1.6. Lateral view of a two-day-old S. aureus biofilm imaged by confocal
laser scanning microscopy.
The biofilm was stained with a live/dead stain. Living cells shown as green
and dead cell components shown as red.
Although the use of this stain in tandem with CLSM can be used to
visualise cells, it does not allow for imaging of all biofilm components. Imaging
of the biofilm matrix can be achieved by targeting single components, using
such things as fluorescently labelled polysaccharide binding proteins
(lectins)49 or protein binding dyes.50 The multi-composite make-up of the
biofilm matrix means that there is no dye for comprehensive staining of the
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whole biofilm matrix. Use of multiple dyes in one system can prove
problematic due to spectral overlap of their different characteristic excitation
and emission wavelengths.51
While confocal microscopy is regarded as a powerful tool for imaging
biofilms, new techniques have been developed that allow for greater
resolution almost to a macromolecular scale. Development of cutting edge
microscopic techniques has enabled imaging with greater resolution, thus
expanding our understanding of biofilm structure. The resolution of light
microscopy is usually limited to half the wavelength of the light used for
imaging (diffraction limit). Structured Illumination Microscopy (SIM) illuminates
the sample with a pattern of light at three different angles, which doubles the
conventional resolution of 120 nm.52 Stimulated Emission Depletion (STED)
utilises two lasers; whilst one excites the sample creating a confocal spot, the
second is used for shaping and focussing, however quenching locally requires
high power and limits the imaging time.44 Some commercial STED
microscopes can reach resolutions of between 90-70 nm. However, it should
be noted that though these techniques allow for the highest resolution they
are limited with the regards to the choice of mounting the sample and
thickness of their samples, making them unsuitable for imaging biofilms as
whole entities 53.
1.3 Microfluidics for biofilm study
 Microfluidics is the science and technology of micrometre scale systems
that manipulate small amounts of fluids.54 Biofilm studies have more
commonly been performed on a macroscale. The emergence of microfluidics
as the setting for studying bacterial biofilms has brought many of its
advantages to light: Microfluidic systems allow for tighter control over the
microenvironment, are relatively inexpensive to fabricate and their small sizes
allow them to be easily integrated into a variety of sensing devices.55
The parameters of a microfluidic device design can be manipulated to
allow for complex laminar flow systems: Greener and co-workers developed
a microfluidic system for biofilm growth that restricted bacterial growth to one
surface of the flow chamber.56 By controlling the fluidic dynamics of the system
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they were able to set up a stream of carbon rich media within a larger flow of
carbon deficient media, isolated to one surface of the device. This isolated
carbon rich ‘stream’ which mediated biofilm growth. Benoit and co-workers
used microfluidic approaches to generate systems that mimic a 96-well plate
and therefore could be easily integrated in to plate readers.57 The microfluidic
devices spatially mimicked a 96-well plate, with 96 flow cells in which biofilms
were cultivated. These devices were able to quantify the amount of GFP-
expressing bacteria present using a conventional plate reader and also using
fluorescence microscopy. Yin and co-workers demonstrated the use of
microfluidics to observe horizontal gene transfer between Pseudomonas
putida and Escherichia coli.58 Using microfluidics integrated into fluorescence
microscopy and CLSM, they were able to observe the transfer of plasmid DNA
that encoded for green fluorescent protein (GFP) fluorescence from a P.
putida donor to a non-expressing E. coli strain. The versatility of microfluidic
devices also allows for the easy integration of other materials into the flow cell.
Cao and co-workers developed a microfluidic device that included a forward
osmosis membrane, so that the biofouling ability of Shewanella oneidensis
could be observed in real time using CLSM.59 The use of the microfluidic
device allowed them quantify the degree of biofouling without having to
disassemble the equipment.
Use of microfluidic devices in this project allowed for easy integration of
the fluidic system into a confocal microscope for cell imaging without it
needing to be dismantled. This allowed for imaging of the biofilm when
subjected to reagents, without sacrificing cell viability. These low volume flow
systems allowed for the study of biofilms under flow conditions in an
experimental design that can better mimic the in vivo environment – closer to
that of the vascular system.
1.4 Microbubbles as biofilm therapy in medicine
Microbubbles (MBs) are micron-sized gas filled bubbles encapsulated in
a thin shell of lipid or other surfactant based material.60 MBs were first
discovered in the late 1960’s by Dr Charles Joiner, who observed their
presence during an echocardiogram.61 He observed a transient increase in
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ultrasound (US) signal from the ventricle after each injection of indocyanine,
made through a left ventricular catheter. Later research found this signal had
arisen from small bubbles forming at the catheter tip. Decades later, MBs are
engineered to be used as ultrasound contrast agents (UCAs) and are
commercially available.62-64 Fundamentally, MBs consist of a heavy molecular
weight gas stabilised by an outer lipid monolayer (Figure 1.7. Cartoon
representation of a 1 – 10 µM microbubble.). Typically, the gas core consists
of highly insoluble fluorinated carbon or sulfur gases such as sulfur
hexafluoride and decafluorobutane, which greatly improve microbubble
stability.65 Their ability to increase US signal intensity stems from an acoustic
impedance mismatch between the gas core and its surrounding media.62
Figure 1.7. Cartoon representation of a 1 – 10 µM microbubble.
Outer shell consists of Dipalmitoylphosphatidylcholine (DPPC) and 1,2-
Distearoyl-sn-glycero-3-phosphoethanolamine-PEG2000 (DSPE-PEG2000)
lipids. Structure of the lipid are shown in the lower image.
Ultrasound can also be used to rupture microbubbles leading to a
sudden energy release.66 Although this characteristic may seem a detriment
to viable human cells, it offers a unique pathway to destruction of pathogenic
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bacteria.67 Sonoporation (increase in cell permeability due to US) in
conjunction with MBs can be caused by transient oscillation or complete MB
rupture, both of which are mediated by US properties.68 This method of
membrane disruption using MBs has been used not only to destroy bacteria,
but also to increase intracellular uptake of molecules in human cells.69
It has been demonstrated that microbubbles can be used as a method
for imaging and disrupting biofilms, Kooiman and co-workers investigated a
combination treatment of commercially available microbubbles (Definity UCA)
and ultrasound alongside oxacillin against a blood clot-associated S. aureus
biofilm.70 The use of these components as a combined treatment achieved
greater efficacy for biofilm loss than oxacillin, microbubble and US controls
alone. This work demonstrated the ability of microbubbles to treat biofilm
infections through sonobacteriocide - destruction of bacteria using antibiotics
in conjunction with ultrasound and ultrasound contrast agents.71 Yu and co-
workers demonstrated an increase in S. epidermidis biofilm vancomycin
susceptibility when exposed to vancomycin, MBs and ultrasound via
sonoporation.72, 73 The findings showed the presence of MBs coupled with
ultrasound ameliorated the effects of sonoporation, and thus susceptibility of
the bacteria to vancomycin. Similarly, Qu and co-workers tested the efficacy
of a US-MB treatment on S. epidermidis biofilm-infected polyethylene dishes,
implanted in rabbits.74 These in vivo studies displayed a  significant decrease
in colony forming units of bacteria in rabbits treated with MBs in conjunction
with ultrasound and vancomycin, compared to that of the single treatment
controls.
Although previous work has demonstrated the therapeutic benefit of
microbubbles to aid sonobacteriocide and sonoporation, the efficacy of these
treatments could be optimised if the microbubbles could be localised to the
site of infection. Matter and co-workers demonstrated the synergy of
microbubble and targeted monoclonal antibodies (mAbs) as a novel method
of non-invasive molecular imaging of biofilms (Figure 1.8).75
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Figure 1.8. Cartoon representation of Ultrasound contrast agents (UCAs) used
to treat biofilms.
A) Ultrasound sonification of free floating UCAs, gives a different acoustic
signature to that of biofilm-bound UCAs. B) UCAs specifically bound to biofilm
matrix being detected by ultrasound. Reproduced from 75.
Using biofilm targeted microbubbles as ultrasound contrast agents
(UCAs), they were able to use high-frequency acoustic microscopy to
ascertain the spatial resolution and quantify the biofilm’s mechanoelastic
properties. These results allude to the potency of targeted microbubbles for
not only the imaging of the bacterial biofilm, but also treatment and
destruction. For such a method to be developed one must first identify
potential binding partners for the microbubble and determine their specificity.
A potential issue that may arise from microbubble therapies for biofilm
related infections is potentially putting pressure on the immune system. Some
of the bacteria residing within the biofilm may not invoke an immunogenic
response, but a microbubble mediating therapy may dislodge those bacteria
causing an immune response. A sudden increase in planktonic bacteria within
the blood exposes a number of toll-like receptors (TLRs) on the surface of
immune cells to their bacterial cell wall-associated targets, which in turn
provoke an immune response leading to cytokine production.76 The potential
over-production of these cytokines can cause inflammatory diseases and
pose considerable risk to a patient, such as sepsis.77 Indeed, Shaddox and
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co-workers observed an increase in cytokine production when biofilms were
mechanically disrupted and brought into contact with a patient’s mononuclear
cells.78 The evidence suggests that an augmented immune response may
arise from biofilm dispersal, but an assessment may need to be made as to
whether the need to treat a persistent biofilm infection outweighs the potential
side-effects of its treatment.
1.5 Monoclonal antibodies for biofilm targeting
Monoclonal antibodies are often used to target biologically relevant
species on bacteria including bacterial toxins,79-81 capsular polysaccharides
82-84 and surface proteins.85-88 In particular work has been performed to identify
mAbs that bind to S. aureus specific targets such as cell surface adhesins,89-
95 the biofilm matrix 96-100 and bacterial toxins.101-103
Matter and co-workers (mentioned in section 1.4) utilised an anti-
protein A antibody to target Protein A found on the surface of S. aureus
bacteria.104 This allowed specific binding of the ultrasound contrasts agents to
the bacteria, and thus greatly improved their method’s specificity for the S.
aureus biofilm.
Though varied in their potential applications, mAbs often have their
limitations for therapeutic use. Murine derived mAbs stimulate an
immunogenic response; their uptake into tissue is influenced by molecular
size, shape and valency.105 When the molecular weight exceeds the renal
threshold of around 70 kDa, removal by the kidney glomerulus is prevented.106
Moreover, production costs arising from the need for complex eukaryotic
machinery to manufacture multimeric proteins with multiple disulphide bonds,
and specialised purification columns, often comes at great financial cost.107
These factors have galvanised a move away from conventional antibody use,
towards that of antibody mimetics.
1.5.1 Antibody mimetics as antibody alternatives
As their title indicates, antibody mimetics are proteins that mimic the
properties of antibodies but with fewer structural drawbacks.108 These non
immunoglobulin-based scaffolds are small in size, lack disulfide bonds and
require no post-translational modification. Molecules that fall under the
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umbrella of antibody mimetics include Adhirons/ Affimers,109, 110 Affibodies 111
and DARPins.112 These proteins are selected using a process called phage
display.113
Phage display is an efficient method of identifying polypeptide chains
that specifically bind to a desired target.114 The concept of phage display was
first proposed in 1985, but has now been adapted into a universally used
method in the biopharmaceutical industry.115 More recently, Sir George P.
Winter was jointly awarded the Nobel Prize in Chemistry for 2018 for his work
with the phage display of peptides and antibodies.116
The method of phage display, described below is, used for Affimer
selection as described by Tiede et al.109 Generally the procedure for phage
display is as follows: filamentous phage are a family of non-lytic ssDNA
viruses that infect Gram-negative bacteria.117, 118 Genes encoding for the
protein scaffold (Ig for example) are inserted into the phagemid vector, a DNA-
based cloning vector carried by bacteriophages,119 to generate a fusion
protein between the scaffold protein and a bacteriophage coat protein. This
fusion protein then allows the desired protein to be presented on the surface
of the phage. Within the structure of the expressed protein are a number of
hyper-variable loops, which are designated as the protein’s ‘binding site’. The
peptide sequence of these loops can be randomised by manipulating the
codons that encode for their amino acid sequence using site-directed
mutagenesis. This library is then “screened” against an immobilised target; a
process which allows those phage that express a protein on their surface
which binds to the target (via this ‘binding site’) to bind; this process is called
’bio-panning’. Phage ‘hits’ caused by non-specific interactions are reduced
during rigorous wash steps which can contain denaturants, organic solvents,
different temperatures, or increasing concentrations of competing ligands.
The phage ‘positives’ can then be recovered and further amplified in E. coli
before undergoing another round of ‘bio-panning’ to identify an ideal
candidate. This reiterative process identifies the sequence of amino acids at
the binding regions of the protein that facilitate binding to the target. The gene
for expression of this binding protein is then transfected into E.coli for
overexpression and purification.
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Affibody molecules are also small proteins (size) that can be selected
for binding to a certain target through this process of phage display.120
Lindborg et al  used phage display to identify affibody molecules that
effectively bound staphylococcal protein A with a pM KD, which represents
binding with a high affinity and specificity and would make them attractive
bacterial targeting candidates.121 These antibody mimics have been shown to
have low toxicity and immunogenicity, so have potential for diagnostic and
imaging applications.122
1.6 Mannose Binding Lectin for biofilms targeting
Mannose-binding lectin (MBL, also known as mannose-binding protein)
is an important component of the human innate immune system.123 It acts by
binding to the surface of invading pathogens expressing suitable target
molecules.124 MBL  is  a  member  of  a  Ca2+ dependent family of proteins
characterised by a collagenous region and a lectin (sugar binding) domain.125
It comprises three identical polypeptide chains; α-helices from each monomer
form a coiled coil bundle that holds together the globular carbohydrate
recognition domains (Figure 1.9).126 The structure is often referred to as a
‘bouquet’ due to its arrangement.
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Figure 1.9. Cartoon representation of Mannose-binding lectin and protein
crystal structure.
a) Diagram showing position of Carbohydrate Recognition Domains (CRDs)
and alpha helices involved in the coil coiled interaction. b) crystal structure of
human MBL, lateral view on the left and top view on the right, each single
protomer shown in a different colour. The crystal structure image was created
using PyMol visualisation programme for structure 1HUV taken from the
protein data base (pdb).
MBL binds a variety of different cell surface carbohydrates with the
following selectivity N-acetylglucosamine > mannose, N-acetylmannosamine
and fucose > maltose > glucose>> galactose and N-acetylgalactosamine.127
Although binding to these sugars is weak for a single protomer (Kd ~ 10-3 M),
binding for the overall macromolecule with the three CRDs clustered in the
oligomer allows the protein to achieve a stronger association with the cell
wall.128 In vivo, single iterations of the MBL trimer can conglomerate to form
larger order macromolecules such as dimers, trimers and tetramers.129 These
associations are facilitated by disulfide bonds forming between cysteines in
adjacent coiled coil peptide chains (Figure 1.10).124
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Figure 1.10. Cartoon representation of the tetrameric MBL oligomer.
The coiled coils of adjacent MBL molecules form intermolecular disulfide
bonds.
Once bound to the surface of a bacterial cell, MBL stimulates a number
of responses by the innate immune system (Figure 1.11).124 Surface bound
MBL associates with MBL-associated serine proteases (MASPs). The MBL-
MASP complex can bind directly to phagocytes acting as a cross link between
cell and phagocyte, or the conformational change in MASP once it is bound
to MBL allows it to covert complement proteins 4 and 2 (C4 and C2
respectively), into a C3 convertase enzyme (C4b2a).130 This enzyme anchors
fragments of complement protein 3 (C3) on to the cell wall. These C3b
fragments act as ligands for receptors on the surface of phagocytes, allowing
another pathway for the phagocyte to bind (Figure 1.11).
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Figure 1.11. Cartoon representation of the process by which the MBL-
associated serine proteases (MASP) complex anchors C3b to cell walls.
The binding of MASP-2 to MBL causes a conformational change in the protein
which allows it to covalently link C4 to either the cell wall or the MBL-MASP
complex. C4b then exposes a focus point for the attachment of C2 to C4b by
MASP-2. The resultant C4b2a complex acts as a C3 convertase and converts
C3 into cell surface bound C3b.
Work by Neth et al, demonstrated how MBLs integration in the innate
immune response affords it the ability to bind to the surface of a myriad of
clinically relevant bacterial strains.131 80 clinically relevant microorganisms
were screened for MBL binding and it was found that half, including S. aureus,
bound MBL in some way. It has also been demonstrated that magnetic beads
coated with MBL protein can be used to isolate bacteria using microfluidic
devices.132 The use of a human mannose binding lectin as a potential biofilm
binding partner helps overcome the potential barrier presented by
immunogenicity, as the protein itself is part of the human innate immune
system. Therefore, in theory, the treatment would translate more easily to an
in vivo experimental set up.
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1.7 Project Aims
The overall aim of this project was to develop a novel method for biofilm
imaging and treatment utilising microbubbles with surfaces that had been
functionalised with ligands that bind staphylococcal biofilm components, as
shown in Figure 1.12. This premise can then be brought forward as a novel
method for imaging biofilms within the body on indwelling medical devices. A
secondary aim was to develop a microfluidic system for biofilm growth that
allowed non-invasive imaging of biofilms using confocal microscopy.
Chapter two of this body of work will describe the processes by which
the biofilm targeting proteins were identified and developed, including their
purification and ‘screening’ against biofilm targets. Chapter three will describe
the development of the microfluidic system that was used for biofilm cultivation
and imaging. Finally, chapter four will describe the experimental work
performed to study the interaction between protein-conjugated microbubbles
and S. aureus biofilms cultivated in the microfluidic flow system.
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Figure 1.12. Cartoon representation of project aims.
Microbubbles are bound to staphylococcal biofilm. Microbubbles are coated
in ligands that bind selectively to the surface of the biofilm, localising them to
the site of infection.
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This chapter of work explores the identification of suitable proteins that
target the S. aureus biofilm. As introduced in Chapter 1, the two protein
systems that were investigated were mannose binding lectin (MBL) and
antibody mimetics known as ‘Affimer’ proteins. The practicality of expressing
these proteins in an E. coli expression system was assessed along with the
propensity of these proteins to bind a static biofilm prior to use in a microfluidic
flow system.
2.1 Investigation of mannose binding lectin as a potential
microbubble surface targeting molecule.
Figure 2.1. Work flow for work performed for the investigation into mannose
binding lectin as a protein candidate.
2.1.1 Overexpression and purification of mannose binding lectin
Human mannose binding lectin (MBL) was chosen as a viable
candidate for the protein-conjugated microbubbles. Its role in the innate
immune system theoretically reduces risk of immunogenicity if taken through
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to in vivo human experimentation. The procedure used for overexpression and
purification of the protein in E. coli is detailed in the Biological Methods Section
6.2.4. E. coli cells harbouring the plasmid encoding the expression of the MBL
protein (provided by Kurt Drickamer, Imperial College London) were cultured,
lysed and the protein purified from the cell lysate adapted from work by
Drickamer and co-workers that had already established that the human MBL
protein could be expressed in a prokaryotic expression system, such as that
of E. coli.133 MBL’s ability to bind surface mannose sugars was exploited
during purification using an affinity resin consisting of mannose covalently
linked to insoluble beads (Figure 2.2) to “capture” MBL from the cell lysate.
MBL was then eluted from the resin using ethylenediaminetetraacetic acid
(EDTA), which complexes and sequesters the Ca2+ ions, which the protein
requires for binding. The method used in this project had previously been
employed to isolate MBL by Butler and co-workers, and is a common method
of purifying MBL from various media.134
 Figure 2.2. Cartoon representation of mannose affinity chromatography.
The cell lysate contains a number of soluble proteins including mannose
binding lectin (MBL). When flowed over the mannose affinity resin, only MBL
is retained and the protein impurities elute from the column. The addition of
EDTA removes Ca2+ ions required for binding of MBL to mannose, which
causes the protein to elute from the column.
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Fractions from the mannose affinity column were analysed by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), a
technique that separates proteins by their molecular weight (Figure 2.3).135
This technique helps to determine the protein content of a sample, and using
a set of protein markers as a standard, gives an approximate weight.
Figure 2.3. SDS-PAGE gel of mannose affinity chromatography purification of
MBL from the cell lysate.
The protein marker ladder (PL) gave an approximate position of molecular
weights on the gel. Flow through was the cell lysate after it was flowed over
the resin, lanes show the presence of proteins in the cell lysate that do not
bind the mannose resin. Washes were performed by flowing buffer over the
resin. Protein still bound to the column was removed by buffer containing
EDTA. Presence of bands at around ~ 16 kDa were attributed to MBL.
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Although SDS-PAGE can give an initial indication as to whether the
target protein had been isolated from the cell lysate, this cannot be confirmed
until a precise weight is measured. The elution fractions were therefore
analysed by liquid chromatography mass spectroscopy (LCMS) (Figure 2.4).
Figure 2.4. The deconvoluted mass spectrum of EDTA elutions from mannose
affinity chromatography purification of MBL.
This mass spectrum shows a peak at 16,071 Da. Presence of this peak
indicated that the sample contained MBL. Peaks at 16093 and 16113 Da
associated with sodium and potassium adducts.
2.1.2 Chemical Ligation methods
After successful purification of the MBL protein, work-flow focussed on
employing chemical ligation methods to conjugate the protein to the surface
of the microbubbles. There are a variety of chemical ligation pathways that
can be utilised to functionalise proteins with chemical tags. The first system
investigated was the use of a biotin-streptavidin-biotin interaction.
2.1.2.1 Sortase A Ligation
Sortase A is a transpeptidase enzyme that catalyses the anchoring of
proteins to bacterial cell walls such as that of S. aureus.136 Sortase A
recognises peptides with an LPXTG sequence, where L is leucine, P is
proline, X is any amino acid, T is threonine and G is glycine (Figure 2.5).  A
catalytic cysteine residue at the enzyme’s active site forms a thioacyl
intermediate when the threonine-glycine peptide bond is cleaved. This thioacyl
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intermediate can then accept an N-terminal oligoglycine nucleophile to create
a new peptide bond.137 Sortase A can be applied practically for use as a
protein labelling device, with the essential components for the labelling
reaction being the LPXTG binding motif on the substrate protein attached to a
desired label and a second molecule having an N-terminus with a suitable
number of glycine residues, to act as a nucleophile 138.
The process itself is reversible therefore a large amount of nucleophilic
labelling regent is needed to shift the equilibrium towards product formation.
In contrast, the use of a depsipeptide substrate releases an alcohol upon
ligation, which is a poor nucleophile and does not react with the tagged protein
product to re-establish the depsipeptide reagent (Figure 2.5, b).138
Figure 2.5. The reaction scheme for Sortase A ligation of a tag onto a protein.
Scheme (a) shows when the peptide has an amide bond between the
threonine and glycine residues the reaction is reversible. Scheme (b) shows
that incorporating an ester linkage here instead stops the reverse reaction.
The aim was to conjugate MBL to the surface of the bubble using the
association of biotin to streptavidin, a commonly used conjugation system due
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to the high affinity (Kd = 4 x 10-14 M 139) of the biotin-streptavidin interaction
(Figure 2.6).
Figure 2.6. The proposed system for conjugation of MBL to the microbubble
surface.
The lipid monolayer and MBL will be functionalised with biotin, streptavidin is
then used to bridge the two components together.
The use of the biotin-streptavidin reaction is one common in current
methods for manufacturing targeting microbubbles. Although these targeted-
MBs are more commonly used to target mammalian cells, such as those
concerned with cancers, a common thread is the use of the biotin-streptavidin
association as a strong anchor for targeting molecules.140, 141
In order to label MBL with biotin, a depsipeptide substrate for the sortase
ligation reaction, see Figure 2.5b, incorporating the LPXTG motif and biotin
moiety had to be synthesised.
2.1.2.2 Solid Phase Peptide Synthesis
Although biological systems can generate polypeptide chains hundreds
of amino acids long, synthetic routes for polypeptides chain production are
limited in the length they can achieve. Furthermore, incorporation of a
depsipeptide is impractical through bacterial expression due to the need for
an ester-linked peptide. A common technique used to synthesise peptides of
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relatively short lengths is solid phase peptide synthesis (SPPS). In SPPS,
polypeptides are synthesised from C- to N-terminus, in a step-wise manner
on a solid support (Figure 2.7). The method outlined in Figure 2.8 was used
to synthesise the Biotin-GYLPEToGG (‘o’ denoting the location of the ester
linkage) depsipeptide. Detailed experimental procedures for synthesis can be
found in Section 6.1.1.
Figure 2.7. Solid Phase Peptide Synthesis cycle reaction scheme using 2-
chlorotrityl resin.
The resin is functionalised with the C-terminal amino acid in the intended
sequence. The resin is then coupled with an amino acid building block that
has an Fluorenylmethyloxycarbonyl chloride (Fmoc) chemical group (shown
in blue), preventing the N-terminal amino group from reacting. HCTU and
DIPEA are used as coupling agents. Once coupled, the polypeptide has the
Fmoc protecting group removed with piperidine. From this point the
polypeptide can either be cleaved from the resin and purified, or it can be
coupled again with another amino acid building block. The cycle can be
repeated until the required polypeptide sequence is achieved, with the final
step being cleavage of polypeptide from the resin.
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The polypeptide chain was synthesised by SPPS up to the N-terminal
glycine. It was then functionalised with biotin by reacting the N-terminal amino
group with a biotin N-hydroxysuccinimide (NHS) ester.
The Biotin-NHS could either be coupled with the polypeptide on the
resin, or the polypeptide can be cleaved off the resin and reacted with the
Biotin-NHS in solution. The resin provides an insoluble support for the peptide
reaction and therefore unwanted reactants and products can be removed by
washing through a filter that retains the insoluble resin whilst removing soluble
waste. However this method requires a higher relative amount of the NHS
ester. Performing the reaction with the peptide in solution allows for the use
of fewer molar equivalents of the NHS ester, but purification from all the other
reagents could be more problematic without the insoluble resin support.
In order to preserve Biotin-NHS stocks the reaction was performed in
solution. The purified biotin depsipeptide was aliquoted and freeze dried.
Figure 2.8. Reaction scheme for the coupling of the depsipeptide to Biotin-
NHS ester.
- 42 -
2.1.2.3 Sortase labelling reaction
Sortase ligation was performed with MBL and the synthesised Biotin-
depsipeptide. The N-terminal glycine required for sortase ligation to the
protein was present in the MBL construct.
Variants of the sortase A enzyme that have improved catalytic activity
exist; these are named sortase 5M and sortase 7M, which are named
accordingly to the number of point mutations that differ in the amino acid
sequence from wild-type sortase A. Of these three sortase enzymes, only the
sortase 7M enzyme was successful for labelling MBL with the biotin-
depsipeptide (Figure 2.9). The experiment yielded only a small amount of
biotinylated MBL protein, which may be attributed to the sortase 7M enzyme
hydrolysing the biotin group from the tagged protein. Although only a small
amount of MBL was biotinylated by the enzyme, subsequent attempts to
repeat the experiment with increasing quantities of biotin depsipeptide and
MBL concentration proved fruitless.
The experimental results from Figure 2.9 could not be replicated.
Moving forward it was decided that a different route to labelling MBL with biotin
should be investigated.
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Figure 2.9. LCMS spectra of sortase 7M ligation of MBL.
Time course reaction of Sortase 7M enzyme attaching biotin to the proteins
N-terminus via the biotin-depsipeptide substrate. Spectra show reaction
contents at t = 0 mins and 120 mins. Peak at 16,074 Da shows presence of
MBL and peak at 16,961 Da shows presence of biotin-tagged MBL protein.
2.1.2.4 Mutation of MBL to enable oxime ligation
Oxime ligation involves covalent attachment of a molecule of interest
bearing an oxyamine group to a macromolecule that has an aldehyde or
ketone function to form an oxime bond, which is stable under physiological
conditions (Figure 2.10).142 Site-directed mutagenesis was performed to
change the codon for the N-terminal glycine of MBL to a codon for a serine at
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that position; oxidation of the resulting serine would allow oxime ligation to






































Figure 2.10. Reaction scheme of an oxime ligation.
A plasmid coding for a protein with an N-terminal glycine was modified by site-
directed mutagenesis to yield a protein with an N-terminal serine. The protein
was then oxidised with sodium periodate to yield an aldehyde group. This
aldehyde group was then reacted with biotin-PEG4-O-NH2, covalently linking
biotin to the protein.
2.1.2.5 Site-Directed Mutagenesis of MBL plasmid
Plasmid pINIIIompA2 is a plasmid donated by Kurt Drickamer (Imperial
College London) that encodes for the expression of human MBL. DNA primers
were designed that were complementary to the section of the MBL expressing
plasmid coding for the N-terminus of the MBL protein, with one base pair
change that would change the codon to one that would encode for a serine
residue (see method section 6.2.12). When the primer annealed to the
plasmid during PCR, the amplified DNA would carry the codon for serine at
this position instead of glycine. The mutated nucleotide sequence encoded a
new MBL mutant, named G1S. The first letter of the mutant label corresponds
to the amino acid from the wild-type protein you are mutating, the number is
the position in the amino acid sequence that residue is, and the final letter is
the amino acid you are substituting in. For this mutant, the glycine (G) at
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position 1 in the amino acid sequence was substituted for a serine (S), hence
G-1-S. The nucleotide sequence of the new plasmid confirmed that it had the
correct DNA sequence, for the expression of the G1S mutant.
The new plasmid DNA was extracted and then transfected into E. coli
BL21 Gold cells, which overexpressed the MBL G1S mutated protein. The
protein was purified on a mannose affinity resin as in section 6.2.6.1 and
concentrated. However, during concentration of the protein, a precipitate
began to form. The concentration of the protein was measured by recording
its absorbance at 280 nm using a UV-vis spectrometer.143 A decrease in A280
indicated that the precipitate contained proteins.
Sample analysis using Ultraviolet – visible light (UV-Vis) spectroscopy
was expected to show maximum absorbance at 280 nm, as is the case with
protein in solution, however the spectrum (Figure 2.11) showed the maximum
absorbance of the G1S mutant was at 260 nm, which indicated the presence
of DNA in the sample. As DNA should not have any affinity for the mannose
resin, this observation suggested that the protein itself was somehow
associating with DNA in the cell lysate. If this was the case, DNA fragments
may have been causing aggregation of protein molecules in solution which
could cause the MBL to precipitate.
During lysis of the cells, DNAse enzymes were used to digest any DNA
that was present in the cell lysate, so this process was clearly failing. If the
DNA generating the A260 absorbance maxima in the UV/Vis spectrum was not
being digested by the DNAse, it was hypothesised that DNA was being
protected through an association to the MBL protein.
The pINIIIompA2 MBL plasmid encodes for an N-terminus that has a
periplasmic targeting peptide sequence that shuttles it into the periplasm of
the E. coli cell, known as a signal peptide.144 The targeting peptide is cleaved
to yield the MBL construct.145 To remove the possibility of MBL coming into
proximity to DNA during the purification procedure, a periplasmic extraction
was performed (Section 2.1.3.1) to isolate the protein from the cells but
without the need for cell lysis in an attempt to reduce the risk of exposing MBL
to DNA. By ejecting the MBL from the periplasm, the likelihood of MBL
encountering any DNA was mitigated by omitting the cell lysis step.
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Figure 2.11. UV-vis spectrum of mannose binding lectin mutant G1S, post
mannose affinity purification.
Maxima at A260 indicates presence of DNA in sample.
2.1.3 Solubility issues of MBL
2.1.3.1 Periplasmic Extraction of MBL
Periplasmic extractions were performed by suspending cells in a high
sucrose solution, then re-suspending the cells in cold water. The osmotic
shock causes the outer membrane of the cells to rupture, thus releasing any
proteins within the periplasm without lysing the cells.146 Once the proteins had
been extracted, they were concentrated using ultrafiltration. Again, a
precipitate began to form during ultrafiltration, which was assumed to be MBL
and the experiment was abandoned.
2.1.3.2 Comparison of E. coli Rosetta and BL21 Gold DE3 cells for
expression of MBL.
Subsequent overexpression of the MBL protein was fruitless and it
appeared MBL was being produced in cells at relatively low amounts. Analysis
of the protein’s DNA sequence revealed the presence of a number of ‘rare
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codons’. Rare codons are defined as codons that don’t regularly appear in E.
coli DNA, and are sometimes less frequently translated by the bacteria.147 The
presence of these rare codons may have been contributing to the inability of
the cells to produce MBL in large amounts. A possible solution was to express
the protein in E. coli Rosetta cells, which carry a plasmid encoding the rare
tRNAs and synthetases needed to attach their cognate amino acids when
expressing these rare codons. An expression study was therefore performed
where the ability of these Rosetta cells to express MBL was analysed against
that of the BL21 Gold cells.
The plasmid containing the MBL expressing gene was transfected into
Rosetta E. coli cells which were cultured alongside the traditionally used BL21
Gold E. coli cells. The ability of these cells to express MBL protein was
analysed by monitoring the protein content of different parts of the cell lysate.
The different components of the cell lysate were analysed by SDS-PAGE
(Figure 2.12)
The expression study showed that although the MBL expressing
plasmid did contain ‘rare codons’, Rosetta cells did not synthesise MBL more
efficiently than the previously used E. coli BL21 Gold DE3 cells. Therefore the
issue surrounding the poor expression of the MBL protein did not pertain to its
rare codons. At this stage, issues had arisen for both the solubility of the MBL
protein, and poor expression of the protein in E. coli cells. To ameliorate the
latter, all plasmids designed for protein expression in future experiments had
their nucleotide sequences ‘codon optimised’ to omit rare codons.
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Figure 2.12. SDS-PAGE gel of E. coli expression study.
Numbers 1-3 are samples from Rosetta cell expression and 4-6 for BL21 Gold
cells. 1,4) Proteins precipitated from the surrounding cell media by addition of
ethanol, 2,5) sample of cells post lysis, containing soluble and insoluble
components, 3,6) Soluble components of cell lysis, with insoluble components
removed by ultracentrifugation. Bands at around 16 kDa correspond to MBL.
Relative intensities of MBL bands indicate Rosetta do not overexpress MBL
protein any more efficiently than BL21 Gold cells.
2.1.3.3 MBP-MBL Fusion Protein
It became apparent that in order to successfully express and isolate
MBL protein the issue of solubility needed to be addressed. By incorporating
a protein of choice into a fusion protein, which contains a different protein
whose solubility is significantly higher, the latter protein can be used as a
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solubility tag to help improve the solubility of the whole fusion protein
complex.148 Maltose binding protein (MBP) is a commonly used solubility
tag.149 When incorporated into a fusion protein, its affinity to amylose can also
be utilised as a purification method using amylose affinity chromatography. In
practice, this method aligns exactly with the affinity chromatographies outlined
previously (Figure 2.2), with the protein being eluted from the resin either
using a glucose, amylose or maltose solution 150.
A new protein construct was designed which incorporated MBP into a
fusion protein with MBL (Figure 2.2). MBP was used to purify the fusion protein
by amylose affinity chromatography. The lysate was flowed over amylose
immobilised to an insoluble resin, to capture the fusion protein. A solution of
maltose was then used to elute the protein from the amylose resin, as MBP
preferentially binds maltose over the amylose resin. MBP has a high affinity
for maltose (KD = 2 µM 151) so it is difficult to remove maltose post purification
in order to reuse the protein as a purification tag. To circumvent this issue, a
polyhistidine purification tag (His-tag) was placed between the MBP and MBL
sites. A His-tag is a sequence of usually six histidine residues in a peptide
sequence that can be utilised for purification.152 Histidine’s imidazole ring can
complex to immobilised metal ions such as Nickel. In addition to this, a
tobacco etch virus (TEV) protease cleavage site was added between the two
protein domains, so once the fusion protein had been purified, the two proteins
could be separated by an enzymatic digestion (Figure 2.13, a, b). A TEV
protease enzyme was used that also had a His-tag in its peptide sequence,
so that the MBP and the protease could be sequestered from the MBL solution
in the same purification step (Figure 2.13, c).
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Figure 2.13. Cartoon representation of new MBP-MBL construct, method of
cleavage and its purification.
a) protein construct of MBP-MBL fusion protein and cartoon representation
beneath. b) Proposed method of purification after cleavage of two proteins
with TEV protease. On the left the expected bouquet-like structure of the MBP-
MBL trimer and on the right the cleaved MBL trimer. Both the cleaved MBP
and TEV protease contain a his-tag required for Nickel affinity
chromatography. c) proposed method of purification of MBL from crude
cleaved protein solution. The his-tagged TEV protease and MBP should be
retained on a Ni affinity resin and only MBL should be eluted.
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2.1.3.4 MBP-MBL overexpression and purification
A pMalp5x vector containing genetic code for the expression of the
MBP-MBL fusion protein was designed and ordered from Genscript, then
transformed into E. coli BL21 Gold cells as described in section 6.2.3. The
cells were then used to overexpress the fusion protein. The cells were lysed
and the fusion protein isolated from the cell lysate by amylose affinity
chromatography.
Analysis of the elution fractions by SDS-PAGE showed the presence
of two protein species, one band at ~56 kDa and another at around ~38 kDa
(Figure 2.14, a). Analysis of elution fraction 3 by LCMS showed the presence
of a number of protein species (Figure 2.14, b). The signal at 58924 Da
corresponds to the MBP-MBL fusion protein, while the signals between 42 and
44 kDa are thought to correspond to MBP. These species may have been
wildtype MBP expressed naturally by the cell or variants of recombinant MBP
caused by incomplete expression of the gene i.e. a truncate fusion protein. As
an amylose resin had been used for purification, any proteins with the ability
to bind amylose i.e. MBP and the MBP-MBL fusion protein, were retained on
the column from the cell lysate.
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Figure 2.14. SDS-PAGE gel analysis of MBP-MBL purification and LCMS of
eluted protein.
a) SDS-PAGE gel of amylose affinity chromatography purification. Bands
highlighted in red attributed to MBP-MBL and bands highlighted in yellow to
MBP. b) LCMS of elution 3 from amylose column. Peaks between 42-44 kDa
attributed to MBP species, peak at 58924 Da attributed to MBP-MBL.
2.1.3.5 Purifying the Fusion Protein from MBP.
Two methods of removing the MBP impurity were investigated. If the
MBP protein impurity was a result of natural MBP expression of the E. coli
cells, the fusion protein could be separated from the crude solution by Nickel
affinity chromatography utilising its his-tag. Alternatively, the fusion protein’s
MBL component could be used to purify the protein by mannose affinity
chromatography. If the impurity was due to incomplete expression or
premature cleavage of the fusion protein, then the MBP may still have its own
his-tag as a legacy from the fusion protein. Fractionation of the crude fusion
protein solution was assessed by both of these methods in order to identify
the most effective means of purification (Figure 2.15).
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Figure 2.15. Nickel and mannose affinity chromatography SDS-PAGE gel
analysis of MBL-MBP purification.
A) SDS-PAGE gel of nickel affinity chromatography purification of crude MBP-
MBL stock. Elutions show that the MBP impurity does in fact contain a his-tag.
B) SDS-PAGE gel of mannose affinity chromatography purification of crude
MBP-MBL stock. Absence of MBP band in elutions show that MBP-MBL can
be purified from crude stock with mannose affinity resin.
Though the most effective route to purifying the MBP-MBL fusion
protein was in fact mannose affinity chromatography, the nickel affinity
chromatography SDS-PAGE gel highlighted an important point, that the MBP
impurity had affinity for the nickel resin. Therefore if the crude MBP-MBL
mixture containing the MBP impurity was combined with the TEV protease
cleavage step, then upon passing the whole cleavage cocktail over a nickel
affinity column, the only component that would not adhere to the resin would
be cleaved MBL. This would mean that the crude MBP-MBL stock would not
need to be purified pre-cleavage reaction.
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The crude MBP-MBL stock (100 µM) was combined with TEV protease (25
mol%) and incubated overnight at 4 ºC. The resultant cleavage solution was
flowed over a nickel affinity column containing 3 mL of resin (Figure 2.16).
Figure 2.16. SDS-PAGE gel of cleavage reaction and accompanying nickel
affinity column of MBP-MBL protein.
The reaction mixture shows no band for MBP-MBL indicating full cleavage of
fusion protein. Bands for MBP, TEV-protease and MBL are present in the
reaction mixture. The reaction mixture is then flowed over nickel affinity resin,
then washed. Nickel resin was also loaded onto the gel to ascertain what
species had bound. Flow through indicates that the resin may have been
overloaded due to the presence of the MBP band. Presence of MBL band in
nickel resin indicates that some MBL is adhering to the nickel resin.
The resultant SDS-PAGE gel indicated that both the cleaved MBP and
the cleaved MBL were adhering to the nickel resin. In order to eliminate the
presence of MBP in the flow through, the experiment was repeated with a
higher volume (9 mL) of nickel resin (Figure 2.17, a). SDS-PAGE was
performed on the resultant fractions, and buffer containing 300 mM imidazole
was flowed over the resin to remove any bound protein species. The elution
was then analysed by LCMS (Figure 2.17, b), which showed the presence of
MBL in the elution, indicating MBL was in fact adhering to the nickel resin.
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Figure 2.17. SDS-PAGE gel analysis of MBP-MBL cleavage reaction and
LCMS of reaction mixture.
a) SDS-PAGE gel of cleavage reaction and Nickel affinity chromatography
column. No protein appears to be present in flowthrough, however MBL does
not seem to be present in the resin lane. b) LCMS spectra of elution from
nickel resin, shows nthe presence of cleaved MBL at 16072 Da and cleaved
MBP at 42858 Da, indicating MBL had adhered to the nickel resin.
The binding of MBL to the nickel resin indicated that the MBL complex
had an unexpected affinity for nickel. A possible reason may be that the
trimeric MBL oligomer is forming a complex consisting of two copies of the
MBL monomer and one copy of uncleaved MBP-MBL fusion protein. However,
if there was MBP-MBL within the complex the protein would appear as a band
on the SDS-PAGE gel and have a signal in the LCMS spectrum. This method
of purifying the MBP-MBL cleavage product was deemed ineffective and a
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new method utilising size exclusion chromatography (SEC) was chosen for
further investigation.
2.1.3.6 Size Exclusion Purification of MBP-MBL
Size exclusion chromatography (SEC), also known as gel filtration
chromatography, is a method of purifying proteins according to their relative
sizes.153 This technique employs a column packed with insoluble, but highly
hydrated polymer beads which have pores that act as channels. Small
proteins can enter these pores and therefore have access to a larger volume
of liquid, whereas larger molecules do not and move faster through the
column. This means larger molecules elute more quickly than smaller
molecules (Figure 2.18).
Figure 2.18. Cartoon representation of size exclusion chromatography.
Crude protein mixture is flowed through a column containing polymer bead
resin. The beads contain small pores and channels. Smaller molecules can
move through these channels and thus move through the resin slower than
their larger counterparts.
As before, a cleavage reaction was set up in which MBP-MBL (100 µM)
was combined with TEV protease (25 mol%) and incubated at 4 ºC overnight.
The resultant cleavage mixture was loaded onto a Superdex 75 16/60
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(agarose and dextran polymer beads) size exclusion column, equipped with a
UV-vis spectrometer that monitors the A280 of the eluting solution. The
resulting chromatogram trace shows at what volume a protein species begins
to elute from the column (Figure 2.19a). The chromatogram indicated the
presence of three protein species. The fractions from the SEC column were
analysed by SDS-PAGE (Figure 2.19b). The gel showed that the cleaved MBP
and TEV protease were co-eluting together, and the cleaved MBL had been
isolated from the two components and eluted earlier. MBL unexpectedly
eluted from the column first (it has a lower mass than the other proteins); this
suggested it was eluting as a trimer. However, the trimeric protein would not
be expected to elute as early as it did in the chromatogram, which could be
attributed to aggregation of the protein into higher order oligomers. Also, the
reaction volume of 500 µL was too small to allow effective isolation of the MBL
on the Superdex 75 16/60 column, which had a column volume of 120 mL.
Such a large difference in volume caused a dilution in the products eluted
generating a large volume of eluent that was impractical to concentrate.
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Figure 2.19. SEC purification of MBP-MBL A280 chromatogram and SDS-
PAGE analysis of eluent.
a) chromatogram of the absorbance of eluent at 280 nm. Increase in A280
indicates presence of protein species. Peaks 1, 2 and 3 shows the presence
of 3 protein species at 3 distinct elution volumes. b) SDS-PAGE gel of fraction
corresponding to peaks 1, 2 and 3. Peak 1 appeared to have no protein
species. Bands in lanes corresponding to peak 2 fractions show the presence
of cleaved MBL. Bands in fractions corresponding to peak 3 indicates cleaved
MBP and TEV protease co-eluted from the column.
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2.1.3.7 Consecutive Nickel and mannose affinity purification of MBP-
MBL
Section 2.1.3.5 showed that the MBP-MBL could be purified using two
different kinds of affinity chromatography with the mannose affinity purification
yielding a cleaner sample of MBP-MBL. The protein was expressed in BL21
Gold E. coli cells harbouring the gene for the MBP-MBL fusion protein. Figure
2.20A shows the SDS-PAGE analysis of the fractions taken from these affinity
resins.
Figure 2.20. SDS-PAGE analysis of MBP-MBL purification by nickel and
mannose affinity chromatography.
A) nickel affinity chromatography purification of MBP-MBL fusion protein from
cell lysate and B) mannose affinity chromatography of MBP-MBL from elutions
from nickel affinity chromatography. Bands at ~ 59 kDa associated with the
presence of MBP-MBL protein.
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The SDS-PAGE gels in Figure 2.20 A,B show that the elution from the
mannose affinity column yielded a clean protein solution containing a band
corresponding to MBP-MBL at ~59 kDa. Elution fractions taken from the
mannose affinity column were analysed further by mass spectrometry (Figure
2.21).
Figure 2.21. Mass spectrum of elution fractions taken from mannose affinity
chromatography purification of MBP-MBL.
Peak at 58914 Da associated with MBP-MBL protein MW = 58915 Da.
Though this method of purification yielded a clean MBP-MBL protein,
the amount of protein that could be loaded onto the mannose affinity resin was
low, of the six litres of cell culture only 10 mg of protein could be isolated by
the mannose affinity resin. This included the elution from the mannose column
being reloaded onto the column once the first batch had been eluted.
The experiment showed that the best method for purification of the
fusion protein was initial purification with nickel affinity chromatography then
an additional mannose affinity chromatography step. Future purifications
required larger amount of resin to load protein onto.
Due to time constraints is was decided that future work to study the
interaction between MBL and the S. aureus biofilm would use the MBP-MBL
fusion protein, in order to maintain protein solubility. Protein from this final




Affimers are small (~12 kDa), heat stable binding proteins that are being
developed as stable replacements for antibodies for a wide variety of
techniques.109 Affimer proteins have a conserved cystatin scaffold and two
hyper-variable loops, the amino acid sequence of which dictates the affinity of
an Affimer to its desired target (Figure 2.22). It is the loop sequence which
gives each individual Affimer its own ‘fingerprint’ and unique binding affinity.110
All Affimer protein sequences used in this project contained a polyhistidine tag
for purification and a cysteine residue for chemical ligation utilising the free
thiol group.
Figure 2.22. Crystal structure of the Affimer protein (left) and a cartoon
depiction (right).
The conserved cystatin scaffold is shown in blue on the crystal structure and
the hyper-variable loops shown in pink. Each Affimer protein has a
polyhistidine tag for purification and a cysteine for chemical ligation.
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Previous work by Lia de Faveri (Tomlinson lab, University of Leeds)
and Fayez Alsulaimani (McDowall lab, University of Leeds) generated a
group/selection of ‘Affimer proteins’ that had been found to bind to three
different strains of S. aureus biofilm (SH1000, USA300 and UAMS1) and the
clumping factor A protein found on the surface of S. aureus.154 Affimer protein
constructs were provided by Prof Kenneth McDowall (University of Leeds) and
are identified using the letters in the name of their raised strain and numbers
after to distinguish between them. e.g. an Affimer raised against the SH1000
strain was named ‘SH31.’ Affimers named ‘ClfA’ were raised against clumping
factor A.
Affimer proteins were overexpressed in E. coli cells and purified using
nickel affinity chromatography. Purity of elution fractions was assessed by
SDS-PAGE and if impurities were found, the Affimers were further purified by
size exclusion chromatography (section 6.2.5). Purified Affimers were then
labelled using fluorescein-5-maleimide which modifies the free thiol group with
a fluorescent dye molecule. For all 10 Affimer proteins, 100% protein labelling
was ascertained using mass spectroscopy.
2.2.1 Affimer-Biofilm Binding Assays (ABBA)
The Affimer proteins were then screened against all three S. aureus
biofilm strains in a 96-well plate, cultivated using the protocol outlined in
material and methods 6.2.23. Figure 2.23 shows the relative binding profiles
of 10 Affimers screened. Each point on the curves is an average of the
fluorescent signal observed for the SH1000, USA300 and UAMS1 strains at a
given concentration of Affimer (individual strain curves for each Affimer can
be found in Appendix 7.7).
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Figure 2.23. Plots of average difference in fluorescent emission of Affimer-
fluorescein at a given concentration screened against three strains of biofilm.
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Biofilms were cultivated then washed with phosphate buffer, 50 µL of Affimer-
fluorescein was added at various concentrations and incubated at RT for 1
hour. After this the wells were washed again with phosphate buffer and the
fluorescent emission of fluorescein at 535 nm measured using an Envision
plate reader. Fluorescent emission at 535 nm is associated with the presence
of Affimer-fluorescein and is attributed to the binding of the protein to each of
the S. aureus biofilm and their associated SEM values (n = 3 for each technical
repeat) shown as error bars. Affimers were screened against three strains of
biofilm; A) SH1000, B) USA300 and C) UAMS1. Legend shown on the right.
All 10 Affimer proteins showed some degree of binding to the static S.
aureus biofilm and although none of the curves displayed saturation at the
maximum Affimer concentration, the data may give some indication as to the
relative affinities of each protein. The maximum concentration of Affimer used
was limited by the amount of labelled protein available. ClfA1 is an Affimer
raised against anti-clumping factor A (ClfA); a protein present on the surface
of S. aureus cells. This Affimer had the highest apparent affinity for all three
S. aureus biofilm strains and could be rationalised by the assumption that ClfA
is expressed by all three strains. However, little is known about the binding
partners for the Affimers not raised against ClfA. Generally it is understood
that these Affimers bind the biofilm that they were raised against, but further
work would be needed to ascertain specifically what these Affimers bind and
indeed if their targets are strain specific. The fluorescence data from the
curves for ClfA1 binding to all three bacterial strains is shown in Figure 2.24.
However, the fact that ClfA16 and ClfA27 Affimer proteins - which also bind
ClfA - had much lower fluorescence, contradicted this hypothesis. ClfA(n)
Affimers, where (n) is a numeric label, were raised against an isolate of ClfA
protein and therefore the ClfA16 and ClfA27 Affimers may bind a different
epitope of the protein that is not accessible when it is part of the biofilm.
Regardless, the higher binding of ClfA1 for all three strains made it the ideal
candidate for initial experiments binding in the microfluidic biofilm model.
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Figure 2.24. Plot of fluorescent emission of Affimer-fluorescein at a given
concentration screened against SH1000, USA300 and UAMS1 strains of S.
aureus biofilm individually.
Biofilms were cultivated then washed with phosphate buffer, 50 µL of Affimer-
fluorescein was added at various concentrations and incubated at RT for 1
hour. After this the wells were washed again with phosphate buffer and the
fluorescent emission of fluorescein at 535 nm measured using an Envision
plate reader. Fluorescent emission at 535 nm is associated with the presence
of Affimer-fluorescein and is attributed to the binding of the protein to the S.
aureus biofilm and their associated SEM values shown as error bars. Affimer
was screened against three strains of biofilm; SH1000, USA300 and UAMS1.
Assuming that the wells of the 96 well plate are covered with biofilm, if
the number of ligands on the biofilm outnumbered the number of receptors it
could be argued that the trend in fluorescent signal could be attributed to
increasing concentration of Affimer protein, as opposed to affinity of Affimer
for the ligand. This was further investigated by extending the ABBA binding
curve beyond the top concentration of 20 µM. Should the current binding curve
be a function of the Affimer protein’s affinity for the biofilm and not a product
of surplus binding sites on a comparatively large biofilm, then an extension of
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the curve into higher concentrations should see the formation of a sigmoid that
eventually reaches saturation. The data in appendix 7.8 indicated that the
ABBA assay did not give a clear picture as to which Affimer proteins were
better at binding the S. aureus biofilm than others. In order to characterise the
interaction, ClfA1 was taken forward for further binding studies as the specific
target for this Affimer was known and could be biosynthesised in order to
probe the binding interaction.
2.2.2 Investigation into interaction between ClfA1 and clumping
factor A
For Affimers raised directly against the S. aureus biofilm, further work
outside the scope of this thesis would need to be done to ascertain exactly
what those Affimers bind to at the molecular level; the only conclusion that
can be made is that those Affimer proteins bound to a S. aureus biofilm
component in those specific strains. Affimer proteins (named ClfAn) were
raised against the MSCRAMM protein clumping factor A, present on the
surface of S. aureus cells. Because their specific molecular target was known,
provided ClfA could be produced and isolated effectively, the interaction
between ClfA and ClfA-Affimers could be studied and better understood.
In order to probe the interaction between ClfA1 and ClfA, a plasmid
was designed and ordered from Genscript to induce overexpression of the
ClfA protein in a protein expression strain of E. coli. The clumping factor A
protein was expressed as part of a MBP fusion protein to increase the protein’s
solubility. This was a pre-emptive measure in case the ClfA protein had any
issues staying in solution. Figure 2.25 shows the fusion protein complex. This
included a TEV protease site to allow separation of the two proteins with TEV
protease enzyme. The His-tag would allow purification of the cleaved ClfA
protein using Ni-NTA affinity chromatography.
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Figure 2.25. Cartoon representation of MBP-ClfA complex that was purified
from E. coli cell lysate.
2.2.2.1 Overexpression and Purification of MBP-ClfA.
The clumping factor A protein was first overexpressed in E. coli
(described in section 6.2.4) and purified from the cell lysate via nickel affinity
chromatography, utilizing the polyhistidine tag incorporated into the design,
adjacent to the clumping factor A protein. The elution fractions from the nickel
column were analysed by SDS-PAGE, shown in Figure 2.26.
Figure 2.26. SDS-PAGE analysis of MBP-ClfA purification by nickel affinity
chromatography.
Bands at ~ 79 kDa associated with the presence of MBP-ClfA protein. PL =
Protein Ladder, FT = Flow through, E = Elution, W = Wash.
SDS-PAGE analysis of the nickel elution fractions showed the
presence of impurities that had associated with the Ni-NTA resin, this method
of purification initially seemed ineffective. The elution fraction from the nickel
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column was then further purified by amylose affinity chromatography, which
would isolate components that had MBP protein associated with them. Figure
2.27 shows the SDS-PAGE analysis of the amylose affinity purification.
Figure 2.27. SDS-PAGE analysis of MBP-ClfA purification by amylose affinity
chromatography.
Bands at ~ 79 kDa associated with the presence of MBP-ClfA protein. PL =
protein Ladder, FT = flow through, E = elution, W = wash.
The amylose affinity chromatography method isolated both the MBP-
ClfA fusion protein and also some of the impurities isolated in the nickel affinity
purification step. Both the nickel and amylose affinity purification methods
therefore proved ineffective in removing the lower molecular weight impurities.
In order to remove these impurities, a further purification step was employed
to try to separate out the constituent proteins by size using size exclusion
chromatography. The combined elution fractions from the amylose purification
were run through a Superdex™ 200 16/600 size exclusion column (Figure
2.28). In this chromatogram proteins eluting from the column are detected
using their absorbance at 280 nm. Ten fractions corresponding to different
points on the chromatogram trace were analysed by SDS-PAGE (Figure
2.28B).
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Figure 2.28. Chromatogram and SDS-PAGE analysis of MBP-ClfA purification
by size exclusion chromatography.
Bands at ~ 79 kDa associated with the presence of MBP-ClfA protein. A) The
chromatogram trace of the Size exclusion chromatography purification of the
MBP-ClfA complex. B) SDS-PAGE analysis of fraction taken from the SEC
purification, corresponding to the numbered red sections in A).  PL = Protein
Ladder.
Size exclusion chromatography was not completely effective in
removing the impurities. The lower molecular weight impurities may have
been associating with some of the MBP-ClfA protein in some way, so that they
move through the column resin together. The three purification methods that
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had been employed to remove the impurities were proven ineffective. A
different method of purification was therefore used to further purify the elution
fractions of this size exclusion purification.
Ion exchange chromatography separates proteins out by their overall
net charge at a given pH.155 The isoelectric point (pI) of a protein is the pH at
which the proteins overall net charge is 0 and all the negatively and positively
charged amino acid side chains have cancelled each other out. If the pH of a
buffer is above or below the pI of a protein within it, it will give the protein a
net negative or positive charge, respectively – depending on the relative
values of the pH and the protein’s pI. For instance, the theoretical pI of the
MBP-ClfA fusion protein was calculated (ExPASY Protparam tool) as 4.88, so,
in phosphate buffer of pH 7.4, which is more basic than pH 4.88, acidic amino
acid side chains are deprotonated, giving the protein a net negative charge.
Therefore, the MBP-ClfA protein should have associated with a positively
charged resin via electrostatic interaction. The protein can subsequently be
eluted from the resin by the addition of negatively charged ions that can take
its place. This can be achieved by using the Cl- ions in NaCl. So, if the protein
is loaded onto a negatively charge ion exchange resin, at pH 7.4, with no NaCl
in the buffer, it will associate to the positively charged resin. Any other protein
impurities in the column will have a unique pI and thus have a different net
charge. By flowing buffer over the resin and slowly increasing the NaCl
concentration, the Cl- ions remove and separate proteins by their relative pI
values. This method was used for the elution fractions of the SEC purification
of MBP-ClfA. Figure 2.29 shows the chromatogram trace from the ion
exchange column and the SDS-PAGE analysis of the eluent.
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Figure 2.29. Chromatogram and SDS-PAGE analysis of MBP-ClfA purification
by Ion Exchange chromatography.
A) SDS-PAGE analysis of fraction taken from the Ion Exchange purification,
corresponding to the red sections in B). Bands at ~ 79 kDa associated with
the presence of MBP-ClfA protein. B) The chromatogram trace of the Ion
Exchange chromatography purification of the MBP-ClfA complex. Blue line
shows the absorbance of the eluent at 280nm, and the orange line shows the
change in NaCl concentration as more eluent is removed from the system. Far
Left lane = Protein Ladder.
The ion exchange resin appeared to give the cleanest sample of MBP-
ClfA of all four purification methods. There seemed to be a small amount of
impurity present in the elution fractions, but these were negligible in
comparison to the amount of MBP-ClfA present. The protein stock was
concentrated by ultracentrifugation, aliquoted and flash frozen at -80 ºC.
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2.2.2.2 TEV cleavage of MBP-ClfA
Once a protein stock had been attained through rigorous purification,
TEV protease was used to ascertain if digestion of the complex in to its
constituent proteins would affect solubility. Figure 2.30 shows the planned
method of digestion and purification of the ClfA protein from its MBP-ClfA
fusion protein.
Figure 2.30. Cartoon representation of MBP-ClfA construct, method of
cleavage and its purification.
a) cartoon representation of protein construct of MBP-ClfA fusion protein. b)
Proposed method of purification after cleavage of two proteins with TEV
protease. On the left the fusion protein complex, on the right the isolated ClfA
cleavage product. Both the cleaved MBP and TEV protease can bind amylose
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resin, due to the presence of the MBP fusion protein on the TEV protease. c)
proposed method of purification of MBL from crude cleaved protein solution.
The MBP-tagged TEV protease and MBP should be retained on a amylose
affinity resin and only ClfA should be eluted.
After enzymatic cleavage and separation using an amylose affinity
resin (Method Section 6.2.6.2), the fractions eluted from the amylose column
were analysed by SDS-PAGE, shown in Figure 2.31.
Figure 2.31. Chromatogram and SDS-PAGE analysis of MBP-ClfA TEV
protease cleavage reaction purified by Amylose chromatography.
Bands at ~ 79 kDa associated with the presence of MBP-ClfA protein, band
at ~ 37 kDa associated with ClfA, larger impurities associated with MBP
containing constituents such as cleaved MBP and TEV-MBP. PL = Protein
ladeer, FT  = Flow through, E = Elution.
As ClfA should not have any associated MBP after the enzymatic
cleavage, it should not adhere to an amylose affinity resin and should be
present in the ‘flow through’ solution. A band at ~ 37 kDa was consistent with
the ClfA protein and was analysed by mass spectroscopy, for confirmation,
shown in Figure 2.32.
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Figure 2.32. Mass spectrum of flow through fraction taken from the amylose
affinity chromatography purification of the MBP-ClfA-TEV protease cleavage
reaction.
Peak at 36977 Da associated with ClfA protein MW = 36978 Da.
The mass spectrum shows the presence of pure ClfA protein from the
amylose affinity purification of the cleavage reaction. The results showed that
the MBP-ClfA fusion protein could be cleaved using TEV-MBP protease to
yield a mixture from which pure ClfA could be isolated using amylose affinity
chromatography.
2.2.2.3 Isothermal Titration Calorimetry analysis of ClfA1 and ClfA
Non-specific interaction between ClfA1 and the ClfA may result from
non-specific interaction between the Affimer scaffold and not the binding
loops. The use of an Affimer scaffold control was used to probe the extent of
interaction between the scaffold and ClfA.
The Affimer scaffold was overexpressed and purified from BL21 DE3 E.
coli cells. Figure 2.33 shows the structure of the Aff-Ala-C (AAC) Affimer
scaffold compared to that of the standard Affimer structure. The main
difference is the absence of the hypervariable loops, that have been replaced
with alanine repeats to preserve the tertiary structure of the protein. The
- 75 -
absence of the binding loops allows for observation of potential non-specific
interaction between the cystatin scaffold and ClfA.
Figure 2.33. Structural difference between a standard Affimer and a cystatin
scaffold Affimer control.
Left, crystal structure (PDB: 5A0O) and cartoon representation of standard
Affimer protein. Right, crystal structure of the Affimer scaffold (AAC) and
cartoon representation. Absence of hypervariable loops eliminates binding
ability of Affimer to its particular target.
Isothermal titration calorimetry (ITC) is an analytical method in which
bimolecular interactions can be studied to understand function and
mechanism at a molecular level. ITC was used to measure the heat change
when a ligand binds to its host. From these experiments one could ascertain
such values as binding constants (KD), enthalpy (ΔH), entropy (ΔS) and
stoichiometry (n).156
ClfA1 Affimer (200 µM) was titrated into ClfA (16 µM) in phosphate
buffer. The resultant ITC trace (Figure 2.34) showed a high binding affinity
with a KD = 62 ± 3 nM. The stoichiometry was shown as n ~ 1, confirming that
only one molecule of the ClfA1 Affimer was associating with a single ClfA
protein.
- 76 -
The data shows that the ClfA1 Affimer interacts strongly with the ClfA
protein, when compared with a non-binding Affimer Scaffold. The Affimer was
to be taken forward for use in the flow system, and as part of the targeted MB
conjugation system.
Figure 2.34. ITC trace for the interaction between ClfA1 Affimer and ClfA
proteins and associated thermodynamic data.
ClfA1 Affimer (200 µM) was titrated into ClfA protein (20 µM). Top panel shows
the raw data and the lower panel the integrated heat exchange on each
subsequent addition of protein.
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2.3 Polyvalent Protein Bead Conjugation
Now that a suitable biofilm-targeting protein candidate had been
identified, their ability to function as microbubble conjugation systems was first
probed in a static biofilm model; polystyrene beads were used as testing
parameters for the microbubbles.
Mannose binding lectin is a protein that functions as part of a trimer of
identical proteins. A single monomer has low affinity for mannose than it’s
trimeric counterpart. The polyvalent binding of the three binding sites, in close
proximity, increases the affinity of the whole complex. In the innate immune
response, the trimeric protomers form larger oligomers; dimers, trimer and
tetramers that then further cooperate together to increase their affinity to cell
surface-bound mannose (see Figure 1.10). This multivalency play an
important role in many biological processes and is regarded as essential for
some carbohydrate-protein interactions.157, 158 Single iterations of proteins
conjugated to a common surface, such as on the surface of a microbubble,
may increase their avidity for the cell surface through cooperativity in a similar
way to how the carbohydrate binding domains function in MBL.
As microbubbles are inherently buoyant, they cannot be used in
conjunction with a plate based biofilm assay. In fact, work by Liou and co-
workers demonstrated that MBs are so buoyant that targeted microbubbles
can be used as a method of sorting cells, being able to lift specific breast
cancer cells from a cell pellet.159  Although useful in this context, the buoyancy
raises issues with MB-biofilm contact in a system where the biofilm is grown
on an upright surface, such as that of a 96 well plate. However commercial
products exist that can mimic the physical dimensions of a microbubble
without the inherent buoyancy. Micromod manufacture polystyrene polymer
beads that are 2 µm in diameter, comparable to the size of a microbubble,
with a Ni-NTA functionalised surface. These beads have a density of 1.03 g
mL-1,  similar  to  that  of  water  (1.0  g  mL-1) and therefore can act as diffuse
molecules for short periods of time. Proteins can be conjugated to their
surface using a polyhistidine tag, a feature present on all proteins
manufactured thus far.
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These polystyrene beads can offer a scaffold by which to observe
potential cooperativity effects of proteins conjugated to a common surface that
mimic the same paradigm as will be observed on the microbubble surface.
2.3.1.1 Protein loading efficiency of polystyrene beads
The loading efficiency of the proteins on to the polystyrene bead
surface was determined using fluorescein-labelled ClfA1 Affimer. As
mentioned previously the protein can conjugate to the bead surface via its
polyhistidine purification tag. Lukáč and co-workers showed this method can
also be used to conjugate molecules to the surface of MBs when a Ni-NTA
lipid is incorporated into the lipid monolayer, and allows for a variety of
biomolecules to be incorporated using a common recombinant purification
tag.160 However, issues may arise with nickel toxicity if this method was to be
used with patients.
The polystyrene particles were washed with phosphate buffer by
pelleting the beads via centrifugation, decanting away the liquid and re-
suspending in phosphate buffer.
ClfA1 was diluted to give samples with concentrations varying from 15
µM – 0 µM, the beads were then washed. The concentration of the decanted
protein solution, containing unbound protein was measured. The
concentration difference between protein solutions before and after the beads
were added was used to calculate a loading efficiency. Protein was also eluted
from the protein-treated beads by adding phosphate buffer spiked with
imidazole.
Figure 2.35 shows fluorescence images acquired for the different bead
and protein solutions using a GelDoc camera. Figure 2.35 shows fluorescent
beads after the protein had been added and the beads had been washed. The
bead-bound protein was eluted using imidazole. The fluorescent intensity of
the eluted solution is higher than that of its bead-bound counterpart. This
observation may be due to self-quenching of the fluorescein molecules which
is observed when the distance between molecules is <  42 Å 161, which may
be the case on the surface of the beads. Alternatively, polystyrenes has been
observed to quench fluorescence and therefore the polystyrene within the
beads may be quenching the fluorescent emission of fluorescein.162 Therefore
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future use of polystyrene beads in conjunction with plate based biofilm assays
required a step in which an elution buffer was added to remove the protein
from the beads to allow more accurate determination of fluorescent emission.
Figure 2.35. Composite fluorescent images acquired of different solution
containing both beads both treated and untreated with protein, and the protein
eluted off the treated beads.
Increase brightness of a sample corresponds to higher fluorescent light
emission at 535 nm. Protein conjugated to bead surface appears to emit more
fluorescent light once eluted from the bed surface using imidazole.
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2.3.1.2 Fluorescent label optimisation for polystyrene beads
In this experiment beads were treated with ClfA1 Affimer with two
different fluorescent dyes attached. ClfA1 was used as a model protein
instead of MBP-MBL as more material was available. One ClfA1 stock was
labelled with Alexafluor488 and the other with Alexafluor647. These
fluorophores were attached using their succinimidyl ester derivatives, which
label primary amines on protein molecules (lysine and N-terminal amines).
These two dyes both emit light at different wavelengths (535 and 638 nm
respectively). If the beads absorb light in the range of the alexafluor488 dye
(similar spectral profile to that of fluorescein), then beads treated with the
same concentration of Affimer labelled with Alexafluor647 will be considerably
brighter. As before beads were treated with 15 µM ClfA1 Affimer, and
fluorescent images were acquired at each step using a GelDoc camera
(Figure 2.36).
Beads treated with the Alexafluor647 labelled ClfA1 saw little change
in fluorescent intensity when the polystyrene beads were added. The beads
did not seem to quench the emission from the Alexfluor647 dye compared to
that of the Alexafluor488 dye. When the beads were added to the protein
solution, even before they were washed, a significant dulling of the fluorescent
light emitted was observed. These results indicate that the beads were in fact
affecting the light emitted from the Alexafluor488 dye. Future experiments
using the polystyrene beads required the use of Alexafluor647 as a
fluorescent marker for binding proteins.
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Figure 2.36. Composite fluorescent images at each step of addition of ClfA1-
A488 and ClfA1-A647 to polystyrene beads.
Both alexafluor488 and 647 were imaged at their emission wavelengths (535
and 650 nm respectively). Red colour associated with saturated pixels.
2.3.1.3 MBP-MBL-Alexafluor647 polystyrene bead binding assays
MBP-MBL protein labelled with Alexafluor647 NHS-ester fluorescent
dye which label primary amines (fluorescein was not used as MBP-MBL did
not have the required free thiol for maleimide conjugation), was conjugated
to the surface of the polystyrene beads and screened against three strains of
S. aureus biofilm (SH1000, USA300, UAMS1). These biofilms were
cultivated as described in section 6.2.23.
Polystyrene beads were functionalised with MBP-MBL (15 µM), which
associated to the bead surface by nickel chelation of the polyhistidine
purification tag. For measuring the concentration of the unbound protein in
solution after incubation with beads, the concentration of on-bead protein
can be calculated by subtracting the un-bound concentration from the initial
concentration. In this case it was ascertained to be 2.35 µM at a bead
concentration of 1 ×109 beads mL-1. This was used as the top concentration
in a 1 in 3 dilution series. 50 µL of MBP-MBL beads were added to biofilms
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of each strain of S. aureus, incubated at RT for 1 hour and then washed.
Fluorescent emission at 535 nm was then measured. Protein was eluted
from any beads bound to biofilm using phosphate buffer spiked with
imidazole. The plate was then reloaded into the plate reader and the
emission measured a second time, a fluorescence intensity increase should
be observed as the protein transitions from bead-bound to in solution. A
control was carried out alongside this experiment with unbound MBP-MBL in
solution at the same concentrations.
Figure 2.37 shows a plot of concentration against fluorescent intensity for
each reagent used. The conjugation of the MBP-MBL protein to the surface of
the bead did not seem to have a higher affinity than that of the protein in
solution. This may have been be due to single iterations of the protein complex
being too far apart on the bead surface to have a multivalent binding effect.
The protein bound to the beads are locked in positions across its surface. At
any one time, only a small section of the bead’s overall surface area is in
contact with the biofilm surface, restricting the access for the rest of the
surface-bound protein. Protein in solution has access to a larger area of the
biofilm than that of protein fixed to the bead surface, which is why a higher
signal is observed for the protein in solution.
Alternatively, the dye itself may have labelled a lysine close to the binding
site of the protein and the fluorophore may reduce binding of mannose into
the active site.
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Figure 2.37. Plot of fluorescent emission of alexafluor647 labelled MBP-MBL
protein and labelled MBP-MBL protein bound to polystyrene beads at a given
concentration screened against SH1000, USA300 and UAMS1 strains of
biofilm individually.
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Biofilms were cultivated then washed with phosphate buffer, 50 µL of protein
or beads was added at various concentrations and incubated at RT for 1 hour.
After this the wells were washed again with phosphate buffer and the
fluorescent emission of alexafluor647 at 650 nm measured using an Envision
plate reader. Protein was then eluted with imidazole and emission at 650 nm
was read again. Fluorescent emission at 650 nm is associated with the
presence of MBP-MBL or MBP-MBL beads and is attributed to the binding of
the protein to the S. aureus biofilm and their associated SEM values (n = 3 for
each technical repeat) shown as error bars. Protein was screened against
three strains of biofilm; A) SH1000, B) USA300 and C) UAMS1. Legend
shown on the right
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2.3.1.4 ClfA1-Alexafluor647 polystyrene bead binding assay
ClfA1 protein labelled with Alexafluor647 was conjugated to the surface
of polystyrene Ni-NTA polystyrene beads via the polyhistidine tag, as before.
The concentration of loaded protein was calculated and the bead
concentration varied to yield a 1 in 2 dilution in protein concentration. Unbound
protein of the same concentration was also screened as a control.
Figure 2.38 shows a plot of concentration vs fluorescence intensity for
each reagent. ClfA1 protein conjugated to the surface of the polystyrene
beads gave a stronger fluorescent signal compared to their unbound
counterparts of the same concentration.
Although initially, it appeared that the beads were bound to the biofilm,
the fluorescent signal from the protein beads could mostly be attributed to non-
biofilm-associated Affimer molecules on the bead surface. If the proteins that
bind the bead to the biofilm surface occupy the same number of sites as the
solute proteins in the control, the well containing the protein beads will give a
much higher fluorescent signal. This would be due to the un-utilised
fluorescent protein present across the whole bead surface. The higher
fluorescent signal may be due to the fact that the overall concentration of the
ClfA1 bead wells is higher due to all the loaded protein. What could be
concluded is the ClfA1-beads were interacting with the static biofilm.
It was not possible to conclude with the data from this experiment that
the interaction between the beads and the biofilm was mediated by the ClfA1
Affimer protein. In order to make such a judgement, an extra bead control
would need to be included to ascertain that the binding interaction was
specifically caused by the Affimer protein.
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Figure 2.38. Plot of fluorescent emission of Alexfluor647 labelled ClfA1 protein
and labelled ClfA1 protein bound to polystyrene beads at a given
concentration screened against SH1000, USA300 and UAMS1 strains of
biofilm individually.
Biofilms were cultivated then washed with phosphate buffer, 50 µL of protein
or beads was added at various concentrations and incubated at RT for 1 hour.
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After this the wells were washed again with phosphate buffer and the
fluorescent emission of alexafluor647 at 650 nm measured using an Envision
plate reader. Protein was then eluted with imidazole and emission at 650 nm
was read again. Fluorescent emission at 650 nm is associated with the
presence of ClfA1 or ClfA1 beads and is attributed to the binding of the protein
to the S. aureus biofilm and their associated SEM values (n  = 3 for each
technical repeat) shown as error bars. Protein was screened against three
strains of biofilm; A) SH1000, B) USA300 and C) UAMS1. Legend is shown
on the right.
2.3.1.5 Non-specific bead-biofilm interaction
Affimer bound to beads was detected using an appropriate fluorescent
label, covalently attached to the protein. In order to measure non-specific bead
interactions between unconjugated beads and biofilm, a different technique
needed to be employed due to the absence of a fluorescent species. By
adding fluorescent species to the bead surface, the beads will not represent
non-functionalised bead control. This experiment used light microscopy to
quantify relative bead concentrations for comparison of bead-biofilm affinities.
Biofilms were cultivated using methods outlined in Section 6.2.23. Beads with
and without ClfA1-A647 were screened against the UAMS1 S. aureus biofilm.
Unconjugated beads were suspended in phosphate buffer containing 300 mM
imidazole to prevent interaction between Ni-NTA on bead surface and
histidine residues on cell-surface bound proteins. All bead samples were ~ 1
x 1010 particles mL-1. Wells were then washed, bacteria were killed using a
paraformaldehyde solution and the contents were agitated mechanically with
the end of a pipette tip. The well contents were aspirated and pipetted
between a glass slide and a cover slip separated by 50 µm spacers.
The glass slides were then mounted onto an optical microscope and
images were acquired of the samples at 40X magnification. Figure 2.39 shows
images acquired for each experimental condition.
All images taken for each sample were then analysed using MATLAB.
Script written by Damien Batchelor (University of Leeds) which counted the
number of circular (spherical) entities present, and their sizes. For each
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sample, the program provides a histogram of the size distribution and
extrapolates to give their concentration in the sample. Figure 2.40 shows the
size distribution histograms of samples taken from each experimental
condition. Peaks for both the beads at 2 µm and for S. aureus cells at 1 µm
were seen.
Figure 2.39. Images acquired at 40X magnification of UAMS1 S. aureus
biofilm samples treated with polystyrene polystyrene bead species.
Left column shows images taken from samples of biofilm not treated with any
beads. Middle column shows images of biofilm treated with unconjugated
beads. Right column shows images of biofilm treated with ClfA1-A647
conjugated beads. Scale bar shows 20 µm. Species with dark halos and
brighter centres are attributed to the presence of the polystyrene beads.
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Figure 2.40. Size distribution histograms for biofilm samples treated with
ClfA1-A647 beads and unconjugated beads.
Top, size distribution histogram of a biofilm control sample; middle, biofilms
treated with unconjugated beads; bottom, biofilms treated with ClfA1-A647
beads. For each histogram the concentration of species is given along with
the mean size, polydispersal index, relative standard deviation, % of species
< 10 µm, % species < 8 µm and the max diameter of the counted species.
Populations at ~2 µm associated with beads and populations at ~ 1 µm
associated with S. aureus cells.
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Beads were present in both samples with and without ClfA1 conjugated
to the surface. The presence of beads in the unconjugated bead samples
indicated that there were non-specific interactions between beads and biofilm
components; indicated by objects between 1.9 – 2.1 µm in size. Figure 2.41
shows the average concentration of entities in this size range for the three
experimental conditions. Biofilm samples treated with unconjugated beads
have a higher concentration of beads present at 6.44 x 107 particles/ mL
compared to that of ClfA1-A647 treated beads at 3.7 x 107 particles/ mL.
Figure 2.41. Bar chart showing concentrations of species between 1.9 – 2.1
µm in biofilm samples treated with 2 µm beads.
x-axis shows contents of wells and y-axis the concentrations of particles
between 1.9 - 2.1 µm in particles mL-1. Biofilm samples were treated with 50
µL of reagent. Standard error of the mean (n = 20, for 20 images taken across
each set of experimental conditions) shown as error bars.
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Calculations of particle concentration using the MATLAB script relies on
species being perfect spheres. Images in Figure 2.39 shows the presence of
large clumps of particles that appear more frequently in the sample with bead-
bound ClfA1 than in that of the unconjugated beads. The formation could be
attributed to the cross linking of beads on adjacent proteins via the S. aureus
cells. These clumps were largely ignored by the MATLAB software which may
have contributed to a lower experimental calculated concentration. Though
the inability of the software to delineate the number of particles in these
clumps can explain the difference in concentration, the presence of beads in
the unconjugated control shows that the beads do interact with biofilm
component and therefore non-specific interactions will play a factor in the
association of Affimer-beads to S. aureus biofilms.
The presence of these clumps may infer a specific interaction between
Affimer-beads and bacteria. The images form this experiment were
reanalysed, species consisting of five or more beads clustered together were
considered ‘cluster positive’ and any other species ‘cluster negative’, the
number of clusters was then plotted in Figure 2.42.
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Figure 2.42. Bar graph showing the number of cluster species formed when
UAMS1 S. aureus biofilm was treated with bead species.
Graph shows results for non-specific beads, which do not have protein on the
surface and are supplemented with imidazole to prevent interaction between
the Nickel-NTA on the surface and biofilm components. ClfA1-A647 beads
have surfaces functionalised with ClfA1 Affimer which a covalently attached
to a Alexafluor647 molecule. Wash buffer : Phosphate Buffer with 150 mM
NaCl. Error bars show SEM values (n = 20, for 20 images taken across each
set of experimental conditions) associated with means and their associated P
value (paired student’s t test, < 0.05).
To minimise non-specific interaction between non-conjugated beads and
ClfA1-A647 beads, the salt concentration of the phosphate buffer was
increased from 150 mM NaCl to 500 mM NaCl. Furthermore, the nickel
present on the surface of the beads was stripped by the addition of 100 mM
EDTA. The EDTA sequesters nickel atoms attached to the beads, which
should have eliminated the ability of the beads to interact with any histidine
residues present on proteins at the biofilm-bead interface. Figure 2.43 shows
the concentration of beads in each sample calculated for each bead type,
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Figure 2.44 shows the observed number of clusters in each experimental
sample compared with that of the experiment.
Figure 2.43. Bar chart showing concentrations of species between 1.9 – 2.1
µm in biofilm samples treated with 2 µm beads, both with ClfA1-A647 attached
and ones stripped of Nickel with EDTA.
The x-axis shows contents of wells and y-axis the concentrations of particles
between 1.9 - 2.1 µm in particles mL-1. Biofilm samples were treated with 50
µL of reagent. Standard error of the mean (n = 20, 20 images acquired for
each set off experimental conditions) shown as error bars.
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Figure 2.44. Bar graph showing the number of cluster species formed when
UAMS1 S. aureus biofilm was treated with bead species.
Graph shows results for non-specific beads, which do not have protein on the
surface and have had nickel removed to prevent interaction between the
Nickel-NTA on the surface and biofilm components. ClfA1-A647 beads have
surfaces functionalised with ClfA1 Affimer which a covalently attached A647
molecule. Wash buffer : Phosphate Buffer with 500 mM NaCl. Error bars show
SEM values (n= 20, 20 images acquired for each set of experimental
conditions) associated with means and their associated P value (paired
student’s t test, < 0.05).
The addition of a higher salt wash buffer and sequestering of the nickel
from the polystyrene beads has caused a relative increase in ClfA1-A647
bead concentration to that of the stripped non-specific beads. The number of
clusters observed generally decreases between experiments but a statistically
significant increase is observed between ClfA1-A647 and stripped beads. The
general decrease in cluster population can be explained by the elimination of
non-specific cluster formation by the high salt buffer. The reproducibility in
high cluster formation in ClfA1 conjugated bead samples indicates that the
ClfA1 Affimer is responsible for increased cluster formation. This maybe be
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being caused by crosslinking of beads by cells or by other biofilm components
via the ClfA1 Affimer.
However, by only treating the control beads with EDTA, and not using
EDTA to sequester Nickel ions from the beads with Affimer bound, the controls
used in this experiment may not represent the most accurate data set. There
is still a possibility that the un-conjugated Ni-NTA species on the beads loaded
with the Affimer protein may be contributing towards their interactions with the
S. aureus bacteria, as well as the Affimer itself. Given time, this experiment
should be repeated using either some sort of blocking species to occupy the
Ni-NTA sites on the control beads and also empty sites on the Affimer-beads,
maybe using the control AAC Affimer as mentioned previously.
2.4 Chapter conclusions
The overall aim of the body of work covered in this chapter was to
ascertain a protein target that could effectively bind the S. aureus biofilm and
could be used in conjunction with microbubbles to localise them to the site of
a biofilm infection.
Of the two candidates investigated, the ClfA1 Affimer was identified as a
prime candidate for use in the microfluidic flow system. Throughout this body
of work many issues arose working with the MBL protein, and even when
expressed as part of a MBP fusion protein, purification of the complex proved
problematic. Though the application of this protein for use in the context of this
project may eventually prove successful, this claim falls outside the scope of
this thesis due to time constraints.
The ClfA1 Affimer protein, through static biofilm screening and binding
interaction experiments was shown to bind to the S. aureus biofilm. The ITC
showed a tight binding interaction between ClfA1 and its binding partner
ClfA, found on the S. aureus cell surface. This data coupled with the
demonstrated ability of the ClfA1 Affimer to localise the polystyrene bead to
a static biofilm indicated that it was the front running candidate for use in
conjunction with microbubbles in a microfluidic system. From this point, work
with ClfA1 was prioritised over the use of MBL protein due to the abundance
of material and ease of use.
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There may be some limitations using ClfA1 to target biofilms. The ClfA1
Affimer targets a cell surface protein (ClfA), whose expression on the cell
surface can be dictated by different stages in cell growth.163 This variation in
cell surface expression of the target may affect the efficacy of the Affimer to
localise the MBs to the biofilm. Furthermore, if the target is cell surface-
associated, the Affimer protein’s ability to bind the biofilm will be dictated to
by the bacterial composition of the biofilm and the instances of cells existing
at the edge of the extracellular matrix. The bacterial composition of a biofilm
varies between 5-20 % of the total volume and are usually distributed
randomly which may decrease the amount of possible interactions with
bacteria cells.164
Mannose binding lectin is a protein that functions as part of a trimer of
identical proteins. A single monomer has low affinity for mannose than its
trimeric counterpart. The cooperativity of the three binding sites, in close
proximity, increases the affinity of the whole complex. In the innate immune
response, the trimeric proteomers form larger oligomers; dimers, trimer and
tetramers that then further cooperate together to increase their affinity to cell
surface-bound mannose. Single iterations of the Affimer proteins conjugated
to a common surface, such as on the surface of a microbubble, may increase
their avidity for the cell surface through cooperativity in a similar way.
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An aim of this thesis was to design a microfluidic system to allow the
study of biofilms under conditions of flow. In pursuit of this aim, a microfluidic
device was designed based on simple flow systems previously described in
the literature. The benefits of using a microfluidic flow system is that their small
size allows them to be integrated into a number of different imaging
techniques; they are more efficient; and, they allow control experiments to be
run in parallel, under the same conditions as the test. The use of microfluidics
within this project allowed for the imaging of the biofilm by confocal laser
scanning microscopy (CLSM) without having to dismantle the experimental
system or disrupt the cultivated biofilms.
3.1 Initial microfluidic device design
For preliminary proof of concept, a microfluidic device was designed
utilising the dimensions of a flow cell used by Greener et al.56 Though research
exists that uses more complex systems effectively (described in section 1.3)
a more ‘stripped-back’ system was used that could cultivate biofilms easily,
without the need for too strenuous optimisation. Figure 3.1 shows the
proposed microfluidic device. The height was set to 180 µm to keep the
volume of the device small, and width and depth of 4 mm and 20 mm,
respectively, to provide a large surface area for potential bacterial
colonisation.
The proposed biofilm chip was electronically designed using AutoCAD
(AutoDesk, CA, USA) software by Dr Peng Boa (University of Leeds, School
of Physics and Astronomy). The microfluidic ‘chip’ was then manufactured
using method described in section 6.3.1. A glass slide (50 x 22 x 1 mm) was
chosen as the base of the chip for use on a confocal microscope, as it allowed
for both dry and oil immersion lens use. The polymer used for the device was
polydimethylsiloxane (PDMS). PDMS is often chosen for cell culture use in
microfluidic devices due to a number of favourable characteristics:165 PDMS
is optically transparent which allows for the use of many optical detection
methods; The polymer is also gas permeable;166 inert so can allow for coating
of the chamber surfaces with protein;167 and has low auto-fluorescence.168
These factors make the device biocompatible and ideal for biofilm cultivation.
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Once the device was manufactured, a bespoke 3D printed bracket was
designed and manufactured by Dr Ben Johnson (University of Leeds,
Department of Physics and Astronomy) to integrate the microfluidic chip onto
a CLSM. The chip consisted of three parts; a base plate into which the chip
was inserted, and two mounting brackets that were magnetically held in place
by the base plate to secure the chip in the bracket (Figure 3.2). This bracket
kept the chip rigid during image acquisition, minimising movement caused by
mechanical stress from oil immersions lenses and movement of the
automated stage.
Figure 3.1. Diagram depicting the dimensions and design of the biofilm growth
flow cell on the microfluidic device V1.0.
Lateral (top) and top view (middle) shown. Flow cell was designed to eliminate
90 º corners, which cause areas of dead volume. Bottom image shows side
view of the chip.
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Figure 3.2. Photograph of 3-D printed microfluidic chip-holding bracket.
Top view shows bracket deconstructed, with interlocking top plates and base
plate. Magnetic fixtures indicated by the red arrow secure chip in place in the
holder. Lateral view shows bracket fully constructed.
3.1.1 Initial biofilm flow system V1.0.
To supply media and bacteria to the microfluidic chamber, a flow
system was developed in collaboration with Dr Ben Johnson (University of
Leeds, School of Physics and Astronomy), that would allow for a constant flow
of media through the microfluidic chip in a controlled temperature incubator.
Figure 3.3 shows a schematic of the initial biofilm growth chamber, consisting
primarily of Tygon tubing, Luer lock fittings, sterile sample tubes and a mp6
piezoelectric diaphragm micro-pump (Bartels mikrotechnik) pump. A
piezoelectric diaphragm micro-pump moves liquid by the vibration of a
diaphragm;169 their small size allowed easy integration of the flow chamber
into a bench-top incubator. All fixtures and fittings were connected using male
and female Luer lock adapters.
To secure the flow system in place, 3-D printed brackets were designed
and manufactured to house all necessary components of the flow system. The
thermoplastic Acrylonitrile-Butadiene-Styrene (ABS) was used as the 3-D
filament material for the housing due to its excellent heat retention
properties.170 This meant that any media reservoirs housed in 3-D printed
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brackets would retain their heat for short periods of time, if removed from the
incubator. The chamber was magnetically held in place in the incubator using
magnets integrated into the brackets and the base of the incubator. Liquid was
pumped through the system by the piezo pump connected to a control box.
The system was designed to minimise risk of contamination of, and from, the
surrounding environment, with the air being drawn in and passed out  passed
a 0.22 µm male Luer lock filter. Tygon tubing inserted directly into the
microfluidic chip was sealed with UV-curable adhesive to prevent leakage.
The system operated as a closed flow system without instances of leaking;
movement of the system from one location to another could be performed
easily using a secondary closed container without disruption to the system.
Figure 3.4 shows the final manufactured biofilm growth chamber placed within
a bench-top 37 ºC incubator. Mobility and constant flow integrity were not the
only facets of the design that needed to be demonstrated, the sterility of the
system needed to be tested to ensure experimental reproducibility and
validity.
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Figure 3.3. Schematic representation of Flow system V1.0.
30 mL sample tubes were used as media and waste reservoirs. Both were
fitted with a metal needle via a male Luer lock connector. Luer lock connectors
were fitted to sample tubes by drilling a hole in the tube lids, and sealed with
UV curable adhesive. Tygon tubing (I.D. 1.0 mm) was used to supply media
to the microfluidic chip and back to waste. A one-way stopcock was used to
isolate the media inlet from the inoculum syringe. Needle-free Luer check
valve fitted to incorporate the inoculum syringe into the system. This allowed
for introduction of the inoculum to the chip without contaminating the media
reservoir. Tygon tubing was inserted into holes in the PDMS of the microfluidic
chip to allow for flow of media through microfluidic chamber. 0.22 µm filters
were fitted on the media and waste lids in order to prevent air contamination
of system.
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Figure 3.4. Photograph of biofilm growth chamber in an incubator.
Top image shows whole flow system in incubator and the bottom image a
close up of the inoculation injection point and tap. Tap is designed to prevent
flow of inoculum in to pump. More detailed description of biofilm chamber can
be found in ‘Microfluidic Methods’.
3.1.2 Sterilisation protocol
To establish a robust sterilisation protocol, different sterilisation
techniques were investigated for use with the biofilm flow system. Samples of
all components were autoclaved to determine reusability of each element
should they be repeatedly steam sterilised. Any component that contained
moving parts (stock-cocks and inoculation port) were found to become warped
during the autoclave process and was more susceptible to cause leaks in the
sterilised system. Components such the microfluidic chip, micro-pump and
tygon tubing were able to survive the autoclave process. Those that did not
survive the autoclave were washed with 70% aqueous ethanol and incubated
under a UV lamp for 30 minutes. Table 3.1 shows the sterilisation techniques
used to sterilise each component of the system.
- 104 -
Table 3.1. Sterilisation techniques used to sterilise flow cell components.
Shows each components and the sterilisation technique used before
inoculation. If a component was not autoclaved it was rinsed with ethanol,
allowed to dry and placed under a UV light for 30 minutes.
To check the success of sterilisation, autoclaved brain heart infusion
(BHI) broth was flowed through the system, incubated at RT overnight and the
effluent media was plated out onto a 2% horse blood agar and Sabouraud
agar plates (the former is a general medium able to support growth of a wide
range of bacteria and Sabourauds was used to culture fungi). These plates
were incubated at 37 ºC for 72 hours, after which no colonies were observed
on either agar dish. Once the flow chamber and all its components had been
constructed and sterilised, its ability to cultivate biofilm was tested.
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3.2 Microfluidic Biofilm study system (MBSS) development
and optimisation
3.2.1 Initial biofilm cultivation
The system was sterilised and equilibrated with BHI broth as described in
protocol in 6.3.4. The microfluidic chip was then inoculated with a culture of S.
aureus SH1000 lux cells (provided by Dr Chris Randall, University of Leeds,
Faculty of Biological Sciences), that had been cultured overnight. The lux
strain is bioluminescent, which presented an opportunity for imaging the
bacteria cells. Figure 3.5 shows images of species attributed to biofilms
cultivated in the microfluidic device (V 1.0).
The bioluminescence of the cells proved an ineffective way of imaging the
cells as bioluminescence requires long exposure times in order to accumulate
enough photons to detect a signal.171 Biofilm formation occurs when bacterial
cells adhere to surfaces in the body (i.e. medical devices), followed by cell
proliferation.3 It was initially assumed that the cells would adhere to all
surfaces in the microfluidic device and form biofilms over all surfaces within it.
However, the biofilms observed in this experiment appeared to be patchy and
polymorphic, with no real correlation between biofilm location and size. While
this first biofilm cultivation experiment showed a promising start to being able
to study biofilms in this novel flow cell, the bacteria could not be imaged using
their innate bioluminescence and an alternative imaging method needed to be
investigated.
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Figure 3.5. Bright Field light microscopy image of biofilm chamber at three
points.
A) towards the end of the chamber, B) the middle of the chamber and C) the
start of the chamber. In all images the direction of nutrient flow is from left to
right. The dark shapes are assumed to be biofilms consisting of SH1000 lux
S. aureus cells.
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3.2.2 LIVE/ DEAD staining of biofilms
The use of LIVE/ DEAD stain when imaging cells for use in confocal
microscopy is common practice.172 Using such stains also allows use of a
wider range of cells strains without the need of innate luminescence/
fluorescence. The dyes used were DMAO and EthD-III (Ethidium bromide
homodimer – III)  Live/ Dead stain (Biotium). DMAO is a membrane permeable
dye that fluoresces when it binds double stranded DNA.173 DMAO stains both
living cells and dead cells and causes these cells to fluoresce green (λem
maxima = 535 nm), as DNA from cells with disrupted membrane (dead cells)
will still make contact with the dye. EthD-III is also a DNA binding molecule
but is not membrane permeable and therefore can only bind DNA from cells
with compromised cell membranes (dead cells).174 Once bound, EthD-III
fluoresces red (λem maxima = 590 nm). In this experiment the parent strain of
the S. aureus SH1000 lux strain, SH1000,  was used to inoculate the system
and the biofilm was cultivated over the course of 48 hours at a flow rate of ~
80 µL min-1. The dye was introduced using a syringe into the tubing upstream
of the media inlet, which caused some bubbles to enter the system. Figure 3.6
shows a composite image of the bright field images taken of the microfluidic
chip. Each image has been arranged to show their relative position on the
device. Figure 3.7 shows some of the images acquired utilising the
fluorescence from the LIVE/ DEAD cell viability stain.
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Figure 3.6. Bright field images of 3 distinct areas of the microfluidic device
after 48 hour biofilm cultivation at 2X magnification.
Green arrow shows direction of nutrient flow and arrows to the left and right
show inlet and outlet of media and waste. Dark ‘meteorite’ species show
biofilms formed in the flow chamber, large bubbles visible attributed accidental
introduction of air into system during addition of dye.
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Figure 3.7. Biofilm species cultivated on a microfluidic chip stained using a cell
viability LIVE/ DEAD stain.
Top left, bright-field image of the biofilm at 2X magnification. Top right,
overlaid image of DMAO and EthD-III LIVE/DEAD stain imaging channels.
Bottom left, DMAO stained species representing living and dead cells. Bottom
right, EthD-III stained cells, representing dead cell components.
Initially, it seems that bacteria within the biofilms have been stained by
the LIVE/ DEAD stain, with the overlay displaying that the biofilm comprised
viable cells, indicated by the predominantly green colour in the overlays (as
opposed to a more red colour associated with greater DEAD stain emission).
Dead cell components within the biofilm should show orange/ red in overlaid
images. It is assumed the intensity of the red colour may be attributed to the
proportion of EthD-III fluorescence in that area of the image. Those cells with
more damaged membranes will likely display a more intense red colour than
those with little to no membrane integrity.  The low signal associated with the
dead stain was attributed to the cells with compromised membranes and
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eDNA in the biofilm matrix. However, only the peripheral cells had been
stained, indicating poor dye penetration to the centre of the biofilm. This is not
uncommon among biofilm staining procedures for CLSM, and poor dye
penetration can lead to an underestimation of biofilm thickness.175
A z-stack is a composite image of images taken in the xy plane
arranged by their relative positions moving through the z plane, the result is a
rendered 3-D image of the confocal sample. Analysis of these biofilms by
compiling a z-stack showed that the dye had indeed not been able to
penetrate the whole biofilm (figure 3.8). The issue of penetration was not a
huge detriment to the develop of the flow system, as enough of the outer layer
of bacteria cells were stained in order to give a representation of interactions
at the surface. Having demonstrated that the flow system was suitable for
cultivating biofilms, the next steps were to develop methods to introduce other
reagents (MBs, proteins, etc.) into the chamber
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Figure 3.8. Z-stack analysis of a biofilm cultivated on chip.
Top left, a bright field image of the middle third of the chip including a
highlighted biofilm. Top right, a 3D rendering of a z-stack performed on the
biofilm in the green circle of the left image. Bottom, images taken through the
centre of the biofilm through the xy plane. From left to right shows live and
dead staining with DMAO, dead staining with EthD-III and an overlay of the
two staining channels. The predominant green colour in the overlay shows
presence of mostly live cells.
3.2.3 Introduction of reagents to microfluidic chip
The successful introduction of reagents to the flow cell was essential for
further work. In order to introduce these reagents to the cultivated biofilms, a
hole was punched in the PDMS downstream of the media inlet port, shown at
the top of Figure 3.9. Tygon tubing was attached through this port, which
allowed reagents to be flowed in from an Eppendorf through a secondary
piezo pump, shown in the flow system diagram in . Figure 3.10 shows red dye
being flowed through this inlet in a flow system test experiment and indicates
minimal backflow to the media inlet.
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A reoccurring issue with the system associated with Figure 3.9 is that
bacteria were found to colonise surfaces upstream of the inoculum inlet, and
in some cases, the back-flow contaminated the media reservoir. Biofilms
growing in the tubing increased the likelihood of a leakage forming. If a
blockage formed, the back pressure prevented the piezo pump from working.
A modification was made to the biofilm incubation chamber to prevent biofilms
growing up-stream of the media piezo pump and contamination of the media
reservoir. Figure 3.11, shows the layout of a new flow system (V1.2). The
inoculum was injected into the microfluidic device at a secondary introduction
point on the chip. When the one-way stopcocks are closed, backflow of cell
culture from the inoculation point was minimal and therefore little to no biofilms
grew upstream of the chip.
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Figure 3.9. Flow cell design and 2D schematic of biofilm growth chamber with
integrated port for treatment of biofilms in flow cell, flow system V1.1.
Above, Top view of microfluidic flow cell (V 1.1). Point A indicates location of
hole where reagents was be introduced. Below shows flow system schematic.
Reagents were introduced into flow cell by a new hole punched in the PDMS.
This is connected to tubing with a one-way stopcock on the end. The tap is
then connected to a secondary piezo pump and Eppendorf that contained the
desired reagents.
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Figure 3.10. Photograph of microfluidic chip integrated in to the flow system.
Media in and waste out tubes indicated with arrows whose directions signify
direction of flow. Reagent flow is labelled with direction of flow. Red dye
flowing into the flow cell seems to flow from reagent inlet to waste out with
minimal back flow to media in. Pump supplying media through the media inlet
is switched off.
Figure 3.11. Schematic representation of biofilm flow model V1.2.
Inoculation point was introduced further downstream of the T-junction via a
hole punched in the PDMS. The reagent is introduced at the T junction
between the microfluidic chip and media stop-cock.
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The system was sterilised and constructed; S. aureus UAMS1 was
used to inoculate the system using the new inoculation port. A bright field
image was taken at three points along the whole microfluidic chip, shown in
figure 3.13.
Figure 3.12. Composite images of bright field images taken from 3 areas on
the microfluidic chip after SH1000 S. aureus biofilm growth.
The grey outline in the background approximates the relative location of the
images on the chip. The arrow indicates direction of flow. The biofilm shown
in the red circle was selected as the biofilm to be studied in the experiment.
This biofilm appeared to have fewer biofilms growing in its proximity to inhibit
flow of media around it.
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Figure 3.13, shows a bright field image of the studied biofilm (a
magnified section shown in the red circle of Figure 3.12) before the flow
experiment. Fluorescein-labelled UAMS11 Affimer (10 µM, 1 mL) was flowed
through the microfluidic device. Figure 3.13 shows fluorescence images of the
biofilm over the progression of the experiment. The biofilm was first rinsed
with buffer and a ‘pulse’ of protein was introduced at t ~ 14 minutes. The loss
of fluorescent signal between 16 – 44 minutes resulted from the protein
solution no longer flowing through the system. At this point a blockage formed
in the tubing downstream of the chip and the flow rate had to be increased to
clear it. The image at t = 50 minutes shows a second pulse of fluorescent
protein flowing through the system. This could be explained by fluorescent
protein pooling up in an area of dead volume upstream of the biofilm, and
increasing the flow rate eventually ruptured a nearby biofilm and releasing the
pool of fluorescent protein (illustrated in Figure 3.13). The final image at t = 56
minutes indicated the biofilm had also changed morphology over the course
of the experiment, likely caused by the increasing flow rate. The fluorescein
isothiocyanate (FITC) channel image at t = 56 minutes, modified to increase
the brightness (right), revealed a region of low fluorescence intensity at the
biofilm periphery, indicating that there is an area where UAMS11-Fluorescein
was still bound.
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Figure 3.13. CLSM images of UAMS1-F Affimer biofilm binding experiment in
microfluidic device.
Each box shows fluorescein isothiocyanate (FITC) emission channel CLSM
images with a cartoon representation of the experimental environment
surrounding the biofilm. At t = 16 minutes, Affimer UMAS1A-F has filled the
flow cell. At t = 44 minutes buffer is washing the biofilm, but a “reservoir” of
retained Affimer is hypothesised to exist upstream of the biofilm. The spike in
fluorescence around t = 50 minutes was attributed to the “spillover” of protein
solution from the hypothesised “reservoir”. This reservoir may have been
caused by an area of static volume within the flow cell, likely caused by the
shape of an upstream biofilm. At t = 56 minutes the biofilm is being washed
again with buffer. The final box shows the bright field image of the observed
biofilm and the FITC images adjusted for brightness to show areas on the
biofilm with low fluorescent signal associated.
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Images acquired every two minutes of the observed biofilm were
analysed using ImageJ software version 1.8.0 (FIJI). The software used the
brightness values of the pixels in the image to assign a numerical value to the
fluorescent signal in regions of interest set by the user. In a standard 8-bit
JPEG image, pixels can have a value between 0 – 255, a zero value
corresponding to black (no fluorescence), 255 corresponding to a white
(maximum fluorescence or ‘saturation’). These fluorescent emission values
for regions of interest shown in Figure 3.14 labelled ‘control area’ and ‘biofilm
area’ were taken for each time point image. Figure 3.14 shows these values
plotted against time, for both the control area and the biofilm area.
The analysis area for each of the fluorescence curves are set by the
user in the ImageJ software. Therefore, areas set for the control were chosen
by eye, in parts of the image considered to not contain biofilm. Without a
LIVE/DEAD stain (not used here as DMAO and fluorescein have overlapping
emission spectra), it could not be presumed that the area was devoid of
bacteria species, and may not have represented an accurate control for the
experiment. Since the image was acquired in the xy plane and was not
acquired at the glass-liquid interface (in the z plane), the area where buffer
was being flowed through ‘dead’ space was used to give control values. The
control could therefore give an idea if any difference in fluorescence was due
to biofilm or background fluorescence from the buffer.
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Figure 3.14. Mean Grey Value analysis of fluorescent CLSM images.
Top shows the regions of interest (ROIs) where mean grey valued was
measured for FITC emission images acquired using confocal microscopy. The
average pixel brightness for each area is plotted against time (values ranging
from 0 – 255). Red arrow indicates introduction of UAMS11-F protein pulse,
blue arrows shows reintroduction of protein pulse from a disrupted biofilm
upstream. By 56 minutes, there is a higher fluorescent signal associated with
the biofilm ROI compared to that of the non-biofilm associated ROI.
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By the final time point, the fluorescent signal associated with the biofilm
area was higher than that of the control area and its initial fluorescent signal
value: indicating that protein was bound to the biofilm. The biofilm moved over
the course of the experiment, which caused the biofilm to ‘drift’ in and out of
the region of interest. This issue was attributed to the increase in fluorescence
for the biofilm area between 50 – 56 minutes in Figure 3.14. During this time,
the edge of the biofilm drifted into the ROI bringing protein bound to the
biofilm’s edge into the analysis window; although this was the case, the final
fluorescence values are higher for biofilm than that of the control area,
indicating bound UAMS11-F protein.
The experiment showcased the functionality of flow cell V1.2 which
allowed the introduction of reagents to biofilms cultivated on the microfluidic
chip. However, the system was prone to regular blockages. Changes needed
to be made to the microfluidic system that would allow for uninterrupted flow
experiments.
3.2.4 Flow cell design V2.0 modification to prevent blockage
Although the system had produced some evidence that it could be used
to cultivate and study biofilms, issues were consistently arising due to
blockages in the system. When a biofilm forms in the body on a medical
device, the initial attachment is mediated by interactions between the surface
of the bacteria and the artificial surface.13 Therefore, it can be assumed that
interactions of this nature will occur at every point in the flow system where
bacteria meet an artificial surface. This would include tubing from the inoculum
port to the microfluidic chip, and tubing from the chip to the waste reservoir.
In practice, this was an issue that caused blockages along the whole system
during an overnight incubation period. Biofilms cultivated in the presence of a
blockage, grew under flow for only part of the 18 hour incubation period; i.e.
once a blockage had formed the system would become ‘static,’ with no flow
of media. When being prepared for analysis the following day, the blockages
needed to be cleared in order to stain the biofilms. The flow rate of the system
therefore had to be increased in order to clear the blockage. In the process,
the sheer stress of flow, once the blockage had cleared, would weaken the
structural integrity of the remaining biofilms, or in some cases strip the
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microfluidic chamber of all its biofilm. Blockages could occur from the point of
the staining the biofilm right up to, and during, the flow experiment. Sheering
off all or part of the biofilm could cause secondary blockages, repeating the
cycle up to the point of experimental failure.
It was hypothesised that a build-up of biofilm was causing the blockages
and that the narrowest parts of the system might be most susceptible . One
way to mitigate against the risk of blockage was therefore to increase the
diameter of the tubing supplying and draining the media to and from the
microfluidic chip. The tubing was changed to have an internal diameter of 1.6
mm (previously 1.0 mm). However, due to the size of the pump inlet ports, the
tubing was kept at 1.0  mm either side of the pump for a length of 2.0 cm. The
smaller tubing that bridged the gap between the media tubing and the chip
was replaced with metal rod adapters with an ID of 2.0 mm. This meant that
the hole punched into the PDMS chip needed to be 2.0 mm wide, therefore
the chip had to be redesigned to accommodate the change in tubing size.
When designing the new microfluidic chip layout, some other
improvements were incorporated. Flow cell designs were undertaken in
collaboration with Jordan Tinkler, and fabrication of flow cells was performed
by Jordan Tinkler. In previous experiments, when biofilms did form they were
distributed randomly at points that spanned the surface of the flow chamber,
indicating that there was no preference for site of biofilm formation. This
allowed for the design of a shorter flow chamber with the future aim of
eventually fitting multiple chambers on the same chip. The bacterial inoculum
was introduced via a channel on the microfluidic chip to prevent biofilms
growing on tubing upstream of the media inlet. The channel taking the ‘waste’
off-chip to the waste reservoir was increased in width (1.2 mm from 1.0 mm)
to prevent blockages forming downstream of the flow cell. Figure 3.15 shows
the design of the proposed flow cell (V 2.0).
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Figure 3.15. Schematic of new flow cell design (V 2.0).
Top image shows the lateral view and direction of flow from media in, inoculum
in and waste out. Dimensions of all channels in the flow cell shown in top view.
Blue arrow indicates direction of flow.
The new flow cell design (V 2.0) was tested using the same protocol as
used in previous biofilm experiments (outlined in section 6.3.4). Figure 3.16
shows the layout of the new flow system. The presence of a ‘reagent loop’
was added to subvert problems arising from the introduction of bubbles to the
chamber when flowing the LIVE/ DEAD stain through the system. Figure 3.17
shows the layout of the reagent loop. Using four three-way stopcocks in the
given configuration, the loop could be primed with buffer without introducing
bubbles. Introduction of a three-way stopcock at the T-junction between the
chip and media reservoir allowed for the introduction of reagents into the loop
whilst being isolated from the main flow system. Media reservoirs were
changed from 30 mL SELECT tubes to 100 mL Duran bottles to allow for
longer incubation periods before they needed refilling.
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Figure 3.16. Schematic representation of microfluidic biofilm study system
V2.0.
New system includes a reagent loop connected to a buffer reservoir. Reagents
were pushed into cell using a secondary piezo pump located between the loop
and the buffer reservoir.
Figure 3.17. Schematic representation of reagent loop.
Loop designed to be primed with media or buffer using media in and other
inlets with the blue two way stopcocks in various configurations to pull liquid
through with a syringe via a female Luer lock adapter. Loop could be loaded
by injecting sample into the sample in, through the loop, to waste out with
stopcocks leading to media in and out to chamber isolated. The system could
be purged to remove bubbles before adding reagent.
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S. aureus UAMS1 biofilms were grown in the flow cell (V 2.0). Once the
system had been washed, LIVE/ DEAD stain (1X DMAO/ EthD-III, 200 μL)
was loaded into the reagent loop and pumped into the microfluidic device
using the reagent pump. Figure 3.18 shows images attained from 10× and
40× magnifications of a selected biofilm that had been isolated to the flow
chamber of the microfluidic chip.
Images taken at 10× magnification show the presence of a biofilm
containing both living and dead cell components. In the overlays, orange/ red
pixels are associated with dead cells and green with live. For both overlays at
10× and 40× magnification, the biofilm contains both living and dead cells
components. Interestingly, most of the dead cells in the biofilm were located
at the periphery. These cells may not be encapsulated effectively within the
biofilm matrix, which means they may not experience the homeostatic benefits
afforded to those within the matrix.176 Regardless of this, 0.85% NaCl is not
known to be cytotoxic to bacteria and is therefore unlikely to have caused the
death of these peripheral cells. This buffer was recommended for use with this
dye and the salt concentration provides osmotic protection for microbial cells.
There seemed to be better penetration of the dye throughout the biofilms
cultivated in this experiment compared to experimental results from section
3.2.2, which could be attributed to the comparatively lower thickness.
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Figure 3.18. Confocal microscope images of biofilms grown on a microfluidic
device V2.0 at 10× and 40× magnification.
For each magnification (column) the Bright Field, DMAO, EthD-III and
DMAO/EthD-III overlay images are shown. Green is associated with living and
dead cells, orange / red is associated with dead species.
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3.2.4.1 Quantification of biofilm volume
For each magnification of the biofilm, a z-stack composite image
showing DMAO (live and dead) and EthD-III (dead) stains was acquired
(Figure 3.19). The xy ‘slices’ were analysed using ImageJ software to quantify
the fluorescent signal. The brightness of a pixel was attributed to a fluorescent
signal, as described in section 3.2.3. These pixels were counted and an
approximate area of ‘fluorescent’ pixels was calculated. Using MetaData from
the confocal image one can set the physical dimensions of a pixel for each
magnification. In the case of 10×: 1 pixel was 1.29 µm2. This can then be used
to quantify the physical size of the pixelated area and thus the area of biofilm
component, per ‘slice.’ It is then possible to convert this information to give a
3-dimensional volume by multiplying the ‘slice’ fluorescence coverage area by
the z-distance between xy ‘slices. This then transforms the pixel unit (2-D
measurement of area) to a voxel unit (a pixel in 3 dimensions), which can be
used to quantify the biofilm volume. Table 3.2 shows the translation of values
attained from the image into physical dimensions. Using this method the
volume of a biofilm can be ascertained from experimental images obtained
from the confocal microscope.
The final volume for the biofilm shown in the 10× z-stack was shown to
be 1.17 ×10-5 cm3, which converts to 11.7 nL. The use of voxels limits the
approximation of the biofilm to these defined cuboidal blocks (voxels),
meaning that in some areas of the biofilm, a voxel will overestimate the volume
of the biofilm contained within it, illustrated by Figure 3.20. However, the
volume of each voxel (7.1 µm3) in comparison to the calculated biofilm volume
(1.17 ×107 µm3) makes this effect negligible.
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Figure 3.19. Overlaid images of DMAO and EthD-III stained biofilm.
a) 10X and b) 40X magnification, right is a composite image of slices taken in
the xy plane to form a ‘z-stack’ at both magnifications. Green indicates living
cells where red and orange indicate dead cell components.
Figure 3.20. Illustration of how the above volume calculation overestimates
biofilm volume.
The voxel is a defined 3-D cuboidal shape, during measurement, only part of
the biofilm will occupy this space, leading to an overestimation of that area of
the biofilm. The observed biofilm volume will be higher than the actual biofilm
volume.
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Table 3.2. Pixel counting values taken from analysis of confocal images using
ImageJ software.
Columns coloured in orange are values attained from ImageJ, columns
coloured in blue are values calculated using the Excel. Area in μm2 is
calculated by multiplying values in Av. Area column by the pixel size (in this
example 1 pixel = 1.29 μm2) for each slice. This value is then multiplied by
the distance between Z- stack slices to give a volume for the pixelated area.
This value in then converted into a mm3 and cm3 value. The total volume is
then calculated for the biofilm using the sum of all the individual slice
volumes.
3.2.5 Fibrinogen coating of biofilm chamber
In previous experiments, there was a persistent issue with biofilm
detaching under the mechanical stress of flow and moving through the device
during experiments, which in some cases led to the complete stripping of the
biofilm from the flow cell. It may have been that in previous experiments the
biofilms were growing as species trapped or ‘pinched’ between the PDMS and
the glass slide. These biofilms may only have had a small proportion of their
surface area attached to the glass slide and therefore did not have a rigid
Slice # Count Total area Av. size %Area IntDen Area/ µm2 z/ µm µm3 mm3 cm3
1 2937 11996 4.084 1.144 1041.532 15474.84 4.272 66108.5165 6.61E-05 6.61085E-08
2 3044 16580 5.447 1.581 1388.929 21388.2 4.272 91370.3904 9.14E-05 9.13704E-08
3 2965 23345 7.874 2.226 2007.749 30115.05 4.272 128651.494 0.000129 1.28651E-07
4 2980 31209 10.473 2.976 2670.569 40259.61 4.272 171989.054 0.000172 1.71989E-07
5 2929 41256 14.085 3.934 3591.765 53220.24 4.272 227356.865 0.000227 2.27357E-07
6 3149 52607 16.706 5.017 4260.014 67863.03 4.272 289910.864 0.00029 2.89911E-07
7 3310 65037 19.649 6.202 5010.403 83897.73 4.272 358411.103 0.000358 3.58411E-07
8 1375 54667 39.758 5.213 10138.24 70520.43 4.272 301263.277 0.000301 3.01263E-07
9 1359 69394 51.063 6.618 13020.95 89518.26 4.272 382422.007 0.000382 3.82422E-07
10 1344 87068 64.783 8.303 16519.6 112317.72 4.272 479821.3 0.00048 4.79821E-07
11 1435 57125 39.808 5.448 10151.13 73691.25 4.272 314809.02 0.000315 3.14809E-07
12 1219 61208 50.212 5.837 12803.97 78958.32 4.272 337309.943 0.000337 3.3731E-07
13 1801 69202 38.424 6.6 9798.173 89270.58 4.272 381363.918 0.000381 3.81364E-07
14 2595 83983 32.363 8.009 8252.665 108338.07 4.272 462820.235 0.000463 4.6282E-07
15 4355 99633 22.878 9.502 5833.85 128526.57 4.272 549065.507 0.000549 5.49066E-07
16 7455 116972 15.69 11.155 4001.054 150893.88 4.272 644618.655 0.000645 6.44619E-07
17 10691 119948 11.22 11.439 2860.98 154732.92 4.272 661019.034 0.000661 6.61019E-07
18 13211 119075 9.013 11.356 2298.397 153606.75 4.272 656208.036 0.000656 6.56208E-07
19 11699 106838 9.132 10.189 2328.72 137821.02 4.272 588771.397 0.000589 5.88771E-07
20 8956 241415 26.956 23.023 6873.697 311425.35 4.272 1330409.1 0.00133 1.33041E-06
21 12583 217471 17.283 20.74 4407.145 280537.59 4.272 1198456.58 0.001198 1.19846E-06
22 9757 141428 14.495 13.488 3696.232 182442.12 4.272 779392.737 0.000779 7.79393E-07
23 7242 94811 13.092 9.042 3338.415 122306.19 4.272 522492.044 0.000522 5.22492E-07
24 5916 65639 11.095 6.26 2829.267 84674.31 4.272 361728.652 0.000362 3.61729E-07
25 5253 43304 8.244 4.13 2102.136 55862.16 4.272 238643.148 0.000239 2.38643E-07
26 4820 29263 6.071 2.791 1548.146 37749.27 4.272 161264.881 0.000161 1.61265E-07




foundation, illustrated by Figure 3.21. This hypothesis is based on the
morphology of biofilms from previous experiments. These biofilms often have
a ‘tear-drop’-like structure and tend to move in response to flow, such as the
one observed in Figure 3.13 of section 3.2.3. Some method of ensuring better
biofilm adhesion to surfaces needed to be established for the flow cell.
A literature search found that fibrinogen is often used to promote
bacterial adhesion to surfaces used for biofilm cultivation.177, 178 Interaction
between fibrinogen on an experimental surface and fibrinogen binding
proteins (FnBPs) on the bacterial cell surface initiates bacterial adhesion and
begins the process of biofilm formation.
Figure 3.21. Illustration of proposed ‘pinched’/ trapped biofilm model.
Instead of growing upwards from a solid foundation, the biofilms are growing
and becoming trapped between the PDMS and the glass slide.
 At this juncture, whilst the design of the flow cell was being optimised
for experimental reproducibility, a new device was designed in which the chip
had three tandem flow chambers. The presence of three flow chambers would
allow for on-chip controls for a given experiment. Figure 3.22 shows the layout
of the new triple flow cell chip V3.0. Using the new flow cell design, an
experiment was performed to ascertain the efficacy of fibrinogen for promoting
more ‘stable’ biofilms on the chip.
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Figure 3.22. Schematic of flow cell with three parallel chambers (V 3.0).
Media in, inoculum in and waste out specified by arrows indicating direction
of flow. All three chambers are supplied by the same media channel and feed
to the waste outlet.
The protocol was performed for on chip biofilm cultivation as outlined
in section 6.3.4, S. aureus UAMS1 was used to inoculate the biofilm
chambers. The morning before inoculation with bacteria, fibrinogen (5 mg/ mL)
in PBS buffer was injected into the flow cell via the inoculum point using a 5
mL syringe. Once the solution was in the chamber it was incubated statically
at RT for 6 hours to allow the protein to coat the microfluidic chip surfaces.
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Figure 3.23. Composite confocal image of the middle biofilm chamber of the
microfluidic chip at 2X magnification.
Top image is bright field, middle is DMAO stained biofilm and bottom EthD-III
stained biofilm.
Figure 3.23 shows the presence of a well-established biofilm spanning
across the flow cell. The morphology of this biofilm is  different from that seen
in previous experiments. The biofilm seems to be one continuous body instead
of intermittent ‘tear drop’ like shapes. The bright field image shows the
presence of larger structures appearing in the middle of what seems to be
shallower regions of biofilm growth.
Further imaging by confocal microscopy analysis showed that biofilms
in these shallower areas were comparatively thinner, with a layer of cells
- 132 -
growing over the glass slide surface. Figure 3.24 shows a 3-D rendered z-
stack (Leica LasX software) of a biofilm taken at 100× magnification
Figure 3.24. 3-D Z-stack image of biofilm grown on microfluidic device.
Green species represents living cell components and orange/ red
representing dead cell components. Darker areas of image indicate 3D
structures growing upwards of the glass slide surface. Biofilm height (from
highest point) = 24 µm, volume = 0.3 nL.
The addition of fibrinogen to the flow cell surface caused the growth of
these ‘lawn-like’ biofilms. The darker areas on the image show additional 3D
structures growing above the ‘lawn’. Though the biofilms are growing in a
uniform manner, there is still propensity for more complex 3-D structures.
These ‘lawn-like’ biofilms appear to have a large surface area, maximising the
biofilm-buffer interface. This large surface area is ideal for observing
interactions between reagents and biofilm components under flow. The
composite xy images in this z-stack were analysed using ImageJ software.
The height of the biofilm in Figure 3.24 is 24 µm at its highest. The volume of
the biofilm area is 0.3 nL.
Figure 3.25 shows an overlaid image acquired in the xy plane at 100×
magnification. In this image the resolution of single cells can be seen within
the biofilm. Resolution to this degree would give a useful insight into the ratio
of living to dead cells when using the LIVE/ DEAD stain, for experiments that
assess the effect of different reagents on cell viability.
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Figure 3.25. Overlaid image of Live/ Dead (DMAO) and dead (EthD-III)
acquired by confocal microscopy of a S. aureus (UAMS1) biofilm.
Green represents living cells whereas orange/ red represents dead cells.
Scale bar represents 5 µm.
Figure 3.26.  Bright field of microfluidic device taken at 10× magnification and
confocal z-satck at 40×.
Area in red is shown as a Z-stack taken at 40× magnification on the right.
Green is associated with living cells and orange/ red is associated with dead
cell components. Species indicated with white arrow assumed to be biofilm
growing on PDMS surfaces in the device.
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Another 3-D z-stack showed the presence of a biofilm growing on the
PDMS surfaces in the microfluidic flow cell. Figure 3.26 shows the z-stack of
an area taken at 40× magnification. The presence of bacterial cells detached
from the glass-bound biofilm bulk on the upper PDMS surface is indicated by
the white arrow.  The presence of two larger regions of biofilm indicated that
biofilms grown using this method can vary from the ‘lawn-like’ biofilms
observed above, to more traditional ‘mushroom-cloud-like’ structures regularly
illustrated in the literature.13
For the most part, the majority of the biofilms grown have done so on
the glass slide surface of the microfluidic chambers; fibrinogen coating
facilitated the cultivation of biofilms with a larger surface area and a shallow
volume, but did not facilitate biofilm growth that completely covered every
chamber surface. However, Figure 3.26 shows evidence of growth on the
upper PDMS surface in the microfluidic chamber alongside the glass-surface-
bound biofilm.
The use of fibrinogen for promoting bacterial cell adhesion to
microfluidic chamber surfaces had proven successful. From this point on,
fibrinogen-coating was incorporated into the standard operating procedure for
biofilm cultivation.
3.2.6 Living and dead cell quantification
As the relative fluorescence emission intensities for each of the dyes is
not known for a given concentration of living/ dead cells, the percentage of
living and dead cells in the sample cannot be calculated from their absolute
fluorescence intensity values. This is further complicated by the fact that the
dead DNA dye can diffuse away from the dead cells as they do not become
cross-linked to DNA, meaning the intensity may decrease over time.179
Nonetheless, the ratio of fluorescence intensities for live and dead to dead
cells can be used to give a measure of changes in cell death over time. Photo-
bleaching of the dyes, when exposed to UV light, may also affect the ratio of
these relative intensity values. The aim of this experiment was to see how the
ratio of DMAO and EthD-III emission changes over time after multiple
exposures with the excitation lasers, to ascertain if this could lead to photo-
bleaching of the dyes between excitations. The experimental protocol was the
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same as the previous experiment and involved coating the chamber with
fibrinogen. Figure 3.28 shows the composite z-stack of a biofilm grown in the
flow cell (V 3.0, Figure 3.22) at five different time points.
Figure 3.27. Composite Z-stack images of biofilm area imaged with a 5 minute
acquisition time starting at 15 minute intervals.
Cells are stained with DMAO and EthD-III Live/ Dead cell dyes. Green pixels
represent living and dead cell components whereas red represents dead cell
components. Scale bar represents 30 μm.
- 136 -
For a z-stack at a given time point, each image in the xy plane of the
stack was imported in to ImageJ, and the total pixel brightness (fluorescent
signal) was measured across the whole stack. The fluorescence intensity will
scale with concentration of activated dye. For each image, the total brightness
of all the pixels was measured using the ImageJ software. For both the DMAO
and EthD-III dyes, the z-position of each slice of the stack was plotted against
total pixel brightness (fluorescent intensity). The graph plotted shows how the
fluorescence intensity of the biofilm changes as you move through the z-axis.
An example of one of these plots is shown in Figure 3.28 for time point t = 75
mins. The area under the curve was then calculated to give the total
fluorescence emission of the whole z-stack, and therefore the studied biofilm.
Figure 3.29 shows the ratio of the total DMAO emission to total EthD-III
emission for each time point.
Figure 3.28. Plot of fluorescent emission vs position in the z-plane of stacks
taken of an S. aureus biofilm at t = 75 mins.
Top curve represents fluorescence from DMAO (living and dead) and bottom
curve fluorescence from EthD-III (dead cells). The area under the curve is
calculated for each dye giving the total fluorescence of the z-stack.
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Figure 3.29 shows the change in the ratio of the EthD-III emission to
DMAO emission increase over the course of the experiment. This could either
be attributed to an increase of cell death, photo bleaching of the DMAO dye
or diffusion of the activated EthD-III dye towards the region of interest.
Throughout the whole experiment the system was static in HEPES buffer (pH
7.4), therefore it is likely that some cell death would occur with no fresh
nutrients being supplied to the biofilm. It could also be that the DMAO bound
to DNA in living and dead cell components is the result of photo bleaching,
whilst still remaining bound to its target; preventing a new molecule of DMAO
from binding and regenerating the fluorescent signal. In either case the
experiments suggest that when imaging cells in future experiments, the time
between dye addition and acquisition of confocal images needs to be
minimised.
Figure 3.29. Bar chart showing the ratio of DMAO and EthD-III dye emission
for the studied biofilm at 5 different time points from 0 – 75 mins.
DMAO emission is associated with the presence living and dead cell
components, whereas EthD-III emission is associated with only dead cell
components. As time progresses the ratio of DMAO to EthD-III emission
changes.
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3.2.7 Parallel flow cell microfluidic design
The results of the previous experiment proved that the three-chamber
device could be used to cultivate biofilms in parallel. The three chamber
device needed to be modified further so that each chamber could be subjected
to a different flow of reagents. This would allow for on-chip controls for a given
experiment and would form a more robust experimental model. Work by
Arellano and co-workers had demonstrated the ability to use microfluidic to
simultaneously test a number of experimental conditions on the same
microfluidic ‘array’.180 Their system allowed for the screening of up to 48 drug
combinations on 48 different cell-tissue samples. The new design needed to
incorporate channels for the flow of reagents into each of the flow chambers.
 Introducing the reagents from above, as described previously in section
3.2.3 (chip V 1.1, Figure 3.9), caused experimental impracticalities as the
confocal microscope both excites the sample with the laser lines, and reads
the incoming emission from the same plane (from underneath the sample).
The bright field module of the microscope is read from below the sample with
light being supplied from above the sample. At 100× magnification, it is quicker
and easier to find the z position in which the biofilm is situated using the bright
field microscope as a guide, before switching to the confocal imaging system.
Supplying reagents using tubing fed from above biofilm chambers would
obstruct the light used for bright field image acquisition. Therefore, it was
proposed to introduce the reagents using a channel on the chip, with the
tubing located nearer the media inlet, away from the biofilm growth chambers.
Microfluidic chamber design was undertaken in collaboration with Jordan
Tinkler with fabrication being solely performed by Jordan Tinkler. Figure 3.30
shows the design of the microfluidic chip (V 4.0).
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Figure 3.30. Schematic of flow cell with 3 parallel channels (V 4.0).
Media in, inoculum in and waste out specified by arrows indicating direction
of flow. The top and bottom flow chambers have their own reagent inlets that
are fed by tubing at the points indicated by red arrows. All three channels are
supplied by the same media channel and feed to the same waste outlet.
The flow of reagents was expected follow the path of least resistance and
therefore only flow through one chamber - out to waste. However, preliminary
flow experiments with this chip design showed that flow could not be isolated
to just one chamber by flowing media into its associated reagent inlet. Figure
3.31 shows red food dye being flowed through the system (flow rates 0 – 100
µL/ min) via the reagent in 1 port. The schematic shows how the dye was
expected to flow through the system, how it actually flowed and a picture of
the experimental result. As all three chambers lead to the same waste outlet,
dye flowing into the top chamber is moving upstream of the reagent inlet and
flowing into the other two chambers, even when flow via the other reagent
inlets were isolated using one way stopcocks off chip.
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Figure 3.31. Proposed direction of flow in chip V 4.0 and photograph of
experimental flow.
Top, schematic of proposed flow of media through top chamber of device.
Middle, direction of flow under experimental conditions. Bottom, picture of flow
cell when flow is isolated to only reagent in. Presence of red dye in all three
chambers indicates an inability to isolate flow to just one chamber. Back flow
via other inlets prevented by the closing of stopcocks off chip.
It was anticipated that modifying the flow cell so that each chamber had
its own waste outlet channel would rectify the isolation problem. Figure 3.32
shows the amended design of the new microfluidic device (V 5.0). The flow
experiment outlined previously was repeated and the device was observed to
have an isolated flow of reagents through the desired chamber at flow rates
ranging from 0 – 100 µL/ min. Figure 3.33 shows the flow directed through
one chamber via its associated reagent in port.
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Figure 3.32. Schematic of flow cell with 3 Parallel channels each with their
own waste outlet (V 5.0).
 Media in, inoculum in and waste out specified by arrows indicating direction
of flow. The top and bottom flow chambers have their own reagent inlets that
are fed by tubing at the points indicated by red arrows.
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Figure 3.33. Photograph of flow cell when flow is isolated to only ‘reagent in
1’.
Presence of red dye in only the top chamber indicates the flow has been
isolated to one chamber. Flow to media in, inoculum in, reagent in 2, waste
out 2 and waste out three preventing by closing stopcocks off chip.
The new microfluidic chip design (V 5.0) allowed for treatment of the
top and bottom chamber with a unique reagent flow and allowed for on-chip
controls for a given experiment. The middle chamber could be used as a
untreated biofilm control if subjected to required reagents last, via the media
inlet. Figure 3.34 shows a schematic of the final iteration of the microfluidic
biofilm growth model.
One-way stopcocks are placed on all tubing that is connected to the
microfluidic chip to allow for isolation and movement of the microfluidic device
for ultrasound equipment integration.
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Figure 3.34. A schematic of the biofilm growth chamber V5.0.
Legend indicates what each components is and diagrams shows their relative
position in the system. Direction of flow from reservoirs is downstream to
waste reservoir. Every inlet has an off chip one way stopcock so that flow
through the tubing can be stopped at any point.
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3.3 Chapter Conclusions
The aim of this work was to develop a microfluidic flow model that could
cultivate biofilms under flow and for treatment of these biofilms with numerous
reagents. This model could then be used to study the interaction between
microbubbles and S. aureus biofilms under flow.
Many issues arose over the development of this microfluidic system
resulting from the blockage of channels with biofilm species. Initially, these
blockages caused considerable problems as clearing obstructions required an
increase in flow rate that would then cause further biofilm disruption leading
to further blockages. These issues were mitigated primarily by increasing the
tubing diameter and the addition of a fibrinogen-coating step. The wider bore
prevented tubing blockages both upstream and downstream of the microfluidic
chip. Coating the microfluidic chip with fibrinogen pre-inoculation encouraged
the growth of more ‘lawn-like’ biofilms that were considerable shallower than
their predecessors. These shallower biofilms prevented the formation of on-
chip blockages. Furthermore, the ‘lawn-like’ biofilm allowed for a greater
surface area to be observed for biofilm-reagent interaction.
The use of a LIVE/DEAD stain gave a firm foundation for observing biofilm
morphology. The stain may also be used to understand the ratio of living to
dead bacteria provided the dye is replenished before each image acquisition,
and the time between dye introduction and image acquisition is minimal. Using
this flow system biofilms could be imaged using CLSM to give cellular biofilm
resolution at high magnifications (40× and 100× objectives)
The development of the triple flow chamber microfluidic device, allowed
for on-chip controls in subsequent experiments. Each biofilm chamber could
be subject to its own bespoke flow of reagents, with no backflow to the other
two isolated channels. The introduction of on-chip controls made the
experimental design more robust and would allow for multiple control
experiments to take place in parallel flow cells.
Although the microfluidic biofilm study system at the end of this chapter
seems relatively robust, there are some caveats to the system. The system
can consistently grow an uncontaminated biofilm in all three of its chambers,
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however there is little control over biofilm morphology and composition. This
may cause inter-experimental variability in the structure of the biofilms
cultivated. The introduction of the fibrinogen coating step minimised the
likelihood of cultivating a biofilm that was so thick that there was poor dye
penetration. Should such a biofilm exist within the chamber, an inability of the
dye to penetrate to the biofilm centre may cause issues for quantifying cell
death as a function of biofilm destruction. The stain may not be able to
delineate the difference between recently killed bacteria and cells that exist in
the ‘un-stained’ part of the biofilm that are already dead. This may also need
to be taken in to account when using the confocal pixel data to quantify biofilm
volume, as the centre mass of the biofilm may not be represented in the data
set due to absent pixels.
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The aim of this work was to investigate the interaction between the S.
aureus biofilm and targeting protein (Affimer), and then both targeted
polystyrene beads and microbubbles, using the flow model (development
described in chapter 3). With an Affimer for microbubble targeting identified,
the flow model was used to ascertain if binding occurred under flow conditions
for both the unbound protein receptors, the protein attached to polystyrene
beads and the protein as part of targeted microbubbles.
4.1 Confirmation of Affimer binding to biofilms
In order to justify the use of an Affimer protein as targeting agent for
localisation of microbubbles to the biofilm, their ability to bind biofilms in
solution was first investigated.
4.1.1 ClfA1-fluorescein binding to UAMS1 biofilm
The aim of this experiment was to investigate if the Affimer proteins in
solution could bind the S. aureus UAMS1 biofilm. Biofilms were cultivated in
the flow system using the protocol described in 6.3.4. The protein was flowed
over the biofilm, in a single channel of the triple flow cell microfluidic design
from section 3.2.7.
Work outlined in section 2.2 identified the ClfA1 Affimer protein to be
the leading candidate for targeted microbubble conjugation. ClfA1 Affimer
proteins were labelled with a maleimide-fluorescein derivative, using a
cysteine towards the C-terminus of the protein to make ClfA1-F (protocol
described in section 6.2.22). Once a S. aureus UAMS1 biofilm was
established, a ‘pulse’ of ClfA1 (5 µM, 500 µL) was flowed over at ~ 250 µL
min-1. As the emission spectra of fluorescein (λem maximum = 521 nm) and
DMAO (λem maximum = 535 nm) overlap, the LIVE/DEAD stain was not used
in this experiment. Figure 4.1 shows a composite of fluorescence images of
the z-projection (top view of z-stack) taken at four time points during the
experiment. Image at t = 6 mins was acquired mid-way through the ‘pulse’ of
ClfA1-F protein; time points taken after were acquired under a constant flow
of phosphate buffer. The presence of fluorescent elements at t = 38 and 98
minutes indicated that there was interaction between ClfA1-F and the biofilm.
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The Affimer-biofilm interaction was confirmed by comparing the fluorescent
images with their bright field image counterparts in Figure 4.2.
Figure 4.1. Z-projection of images of flow cell at set time points shown as a
collapsed 2D image.
Images acquired viewing light emission at ~535 nm, corresponding to
fluorescein emission. Images acquired at time points 0, 6, 38 and 56 minutes.
Presence of fluorescent signal is associated with fluorescent Affimer.
This was confirmed by comparing the image taken at t = 6 minutes to
the bright field image taken at t = 0 minutes in Figure 4.2. The overlay indicates
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that localisation of Affimer to areas of the biofilm chamber is associated with
features that were present before the ‘pulse’ of Affimer, presumed to be
biofilm. This observation also eliminates the possibility that the observed
fluorescence represents clumps of precipitated Affimer protein.
Figure 4.2. Confocal z-stack projections and overlays, taken at t = 0 and t = 6
minute time points.
From left to right. Composite z-stack images of flow cell at t= 6 for fluorescent
species, Bright field image taken at t = 0 and an overlay of the two. Overlay
shows that fluorescent species associated with features present before ‘pulse’
of protein.
4.1.2 ClfA1-Alexafluor647 binding to LIVE stained biofilm
The experiment was repeated as before (section 4.1.1) but the method
was modified to label Affimer with Alexafluor647 NHS ester fluorescent dye
so that the DMAO stain could be used to image bacteria cells alongside
Affimer, to confirm that the protein was associating with the biofilm. Unlike the
fluorescein-maleimide, the Alexafluor647 NHS-ester dye is covalently
attached to primary amines groups associated with lysine residues and N-
terminal amines, as opposed to the thiol group on a cysteine residue. This
means the NHS-ester is more promiscuous and makes labelling less selective
for a specific amino acid residue. Once the biofilm was established, it was
stained with DMAO stain and washed with phosphate buffer. These two stain
have minimal to no overlap in their emission and excitation spectra and can
be viewed simultaneously using confocal microscopy.
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ClfA1-A647 was then flowed over the biofilm in a ‘pulse’ (at ~ 250 µL min-
1), after which the system was washed with phosphate buffer at the same flow
rate. The experiment was then repeated with Alexafluor647-labelled AAC
Affimer scaffold (introduced in section 2.2.2.3) as a control.
Figure 4.3. Composite 3-D rendered Z-stacks of biofilm cultivated on chip at
different time points of a binding experiment with ClfA1-Alexafluor647 and
AAC- Alexafluor647.
Time point t = 0 shows the biofilm before the protein pulse being washed with
phosphate buffer. Time point t = 10 the protein pulse of Affimer-Alexafluor647
(5µM, 1 mL) is flowing over the biofilm. Time point = 60 minutes, the system
had been washed with phosphate buffer for 40 minutes. Green represents
bacterial cells in the biofilm (S. aureus UAMS1) stained with DMAO, red
represents Affimer.
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By the final time point of this flow experiment, ClfA1 protein was still
associated with biofilm components in the flow cell, in contrast to the AAC
control in which almost no AAC protein was observed. In each Affimer
solution, not all of the protein had been labelled with the Alexafluor647 dye,
meaning each protein solution had different levels of fluorescent protein
content. Mass spectra from the reaction of each of the Affimer proteins in
Appendix 7.8 shows that only around 20% of ClfA1 Affimer was labelled,
compared to 100% of AAC Affimer. Therefore, the absolute fluorescence
values are not directly comparable, as two protein solutions of the same
concentration will give different fluorescence values. The mean grey value for
the z-stacks corresponding to A647 and DMAO (live stain) were taken for
images at time point t = 60 (using the method from section 3.2.6). By
calculating these mean grey values normalised to the live stain, the values
indicated the amount of A647 fluorescence in proportion to live stain or
biomass fluorescence.
Figure 4.4 shows that after 50 minutes of washing with phosphate
buffer, the proportion of Affimer to biofilm mass is higher for ClfA-A647
compared to that of AAC-A647. The results indicates that more ClfA1 Affimer
has bound biofilm components than its AAC control. The qualitative results
shown in Figure 4.3 and the quantitative data of Figure 4.4 indicate that the
specific interaction between the ClfA1 Affimer and the S. aureus UAMS1
biofilm is mediated by the binding loops of the Affimer under flow conditions.
Once it had been determined that ClfA1 bound the biofilm under flow
in a solution, it was then necessary to investigate whether attaching these
Affimers to larger scaffold (such as microbubbles) affected their ability to bind
the biofilm. The large difference in degree of labelling of each Affimer may
indicate that even more ClfA1 Affimer is bound. However, for experiments
described in the rest of this chapter, the labelling is only used to visualise
beads and MBs and not to quantify protein binding, so the current protein
stocks were continued forward.
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Figure 4.4. Bar chart showing the normalised mean grey values for the z-
stacks of DMAO and A647 image channels at t = 60 mins for ClfA1 and AAC
Affimer proteins.
Bar for DMAO represents the mean grey value of DMAO stained biofilm
components, normalised to 1, and A647 showing the mean grey value of
species associated with alexafluor647 labelled Affimer proteins. For AAC-
A647, the value for A647 represents 3% and for ClfA1 A647 gives 60%.
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4.2 Targeted polystyrene beads under flow conditions.
As described in Section 2.3, due to their similar size and shape,
polystyrene beads of ~2 µm diameter provide a good approximation to the
microbubbles. These beads were used as a scaffold for monitoring the effect
of polyvalency of proteins bound to a solid support. The Affimer’s ability to
localise the beads to the biofilm’s surface was used to infer the potential of the
MB to do the same.
4.2.1 ClfA1-A647 beads with static pulse
Biofilms were cultivated as before, using S. aureus UAMS1 in the V5.0
flow cell (Section 3.2.7) as described in section 6.3.4. All biofilms were stained
with DMAO, to image cellular biofilm components, and washed with
phosphate buffer. The reagent loop was then loaded with protein-conjugated
beads (1 mL, 108 particles mL-1). A pulse of bead solution was flowed through
the biofilm chambers at 250 µL mL-1. Once the bead solution had filled the
chamber, flow was stopped leaving the bead solution static in the chamber for
10 minutes. Flow was then resumed for 30 minutes in order to clear chambers
of unbound beads. In each experimental chamber, 15 z-stacks were acquired
at 100× magnification, each up to a height of 30 µm from the chamber bottom
(glass slide surface). Figure 4.5 shows The z-projections and 3D rendered z-
stacks for areas of the biofilm chamber that contained closest to the average
number of beads per z-stack for the experiment.
The number of beads in each z-stack was counted and a concentration
was calculated using the dimensions of the z-stack (116 × 116 × 60 µm). The
experiment was repeated twice under the same conditions. Figure 4.6 shows
the average concentration of beads, across all three experimental repeats,
remaining in the chamber after 30 minutes of washing with phosphate buffer
– post pulse.
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Figure 4.5. Z-stack images acquired using confocal microscopy of S. aureus
UAMS1 biofilms treated with ClfA1-A647 and Aff-Ala-C-A647 conjugated
beads.
Left image shows z-projection (top view) rendered in ImageJ software and
right image a 3D render of the z-stack from the side created in LasX software
(Leica). A pulse of beads was flowed over the biofilms and left stationary for
10 minutes, it was then washed for 30 minutes with phosphate buffer at a flow
rate of 250 µL min-1. A) Beads conjugated with Aff-Ala-C-A647 Affimer. B)
Beads conjugated with ClfA1-A647 Affimer. Green shows cells stained with
DMAO and red, beads with Alexafluor647-labelled Affimer attached to their
surface.
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Figure 4.6. Bar graph showing the average bead concentration of ClfA1-A647
and Aff-Ala-C-A647 conjugated beads in the microfluidic chamber after 30
minutes of washing.
Biofilms cultivated in microfluidic chamber V5.0 were treated with a pulse of
Affimer conjugated beads, and then washed with phosphate buffer for 30
minutes at a flow rate of 250 µL/min. Error bars show averages associated
with SEM values, n = 60 (20 z-stacks acquired from three technical repeats).
Paired student t-test analysis gave P <0.001 (paired student’s t test).
The results from Figure 4.6 show a statistically significant increase in
bead concentration when ClfA1-A647 Affimer is conjugated to the bead
surface, compared to the Affimer scaffold control. Although the average bead
concentration across the three experiments gave a statistically significant
increase in bead concentration for ClfA1 Affimer-beads, there still existed a
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large amount of variability in concentration between experiments. Figure 4.10
shows the bead concentrations for each experiment.
Figure 4.7. Bar graph showing the average bead concentration of ClfA1-A647
and Aff-Ala-C-A647 conjugated beads for each experimental iteration.
Biofilms cultivated in microfluidic chamber V5.0 were treated with a pulse of
Affimer conjugated beads, and then washed with phosphate buffer for 30
minutes at a flow rate of 250 µL/min. Error bars show averages associated
with SEM values, n = 20 (20 z-stacks acquired for each experimental condition
in each of the technical repeats). Legend shows experiment number and the
date it was performed on.
Data collected for the Aff-Ala-C-A647 beads remained consistent across
all three experiments with an average of 11.4 ± 0.8 beads µL-1; conversely the
average for ClfA1-A647 beads was 103.5  ± 8.0 beads µL-1. The experimental
variability between ClfA1-A647 bead experiments may derive from how the
beads were prepared. For instance, beads used in Exp 1 and 2 were taken
from the same 10× stock, which had originally been flash frozen for storage:
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the stock was thawed for Exp 1. Between Exp 1 and Exp 2 the 10× was flash
frozen and thawed again, which may have had some impact on the binding
ability of the beads. For Exp 3 the beads were made fresh, made into their 1×
stock then flash frozen. The freeze / thaw process may be having a detrimental
effect in the protein conjugated beads. An experiment wherein the beads were
produced using a erroneously high concentration of protein showed no binding
at all to the biofilm. This may have been caused by a high Affimer density on
the surface precluding binding. The conditions by which the beads and
produced and stored are essential for preservation of the beads binding ability.
This results from Figure 4.5 and Figure 4.6 both demonstrate the specific
binding of the ClfA1 Affimer to the biofilm via the binding loops, and the ability
of the Affimer to localise 2µm beads to the surface of a biofilm. Considering
the similarity in size between the polystyrene beads and clinically relevant
microbubbles ( ~ 2 µm), the ability of the ClfA1 Affimer bead to bind the biofilm
inferred that an ClfA1-microbubble should also be able to bind the biofilm.
However, the experiment introduced the beads as a static ‘pulse’ in which the
flow had been stopped for 10 minutes once the beads had reached the
chamber. If a similar experiment were to be performed using microbubbles in
vivo, a static pulse would not be possible under the constant flow of the
vascular system. Therefore, the experiment was repeated, but flow was not
stopped during bead introduction.
4.2.2 ClfA1-A647 beads under constant flow
The previous experiment showed the ClfA1 Affimer’s ability to localise
the polystyrene beads to the biofilm surface in the flow system, with the beads
having first been left static in the flow chamber for ten minutes to promote
bead adhesion. This experimental format did not mimic a more in vivo-like
paradigm in which the beads would potentially be introduced to the
bloodstream, and therefore under constant flow. The experiment was
repeated as above but the beads were not allowed to stand statically in the
chamber for any amount of time. The bolus of ClfA1-A647-beads (~ 108 beads
mL-1) was flowed into the chamber and then immediately washed with
phosphate buffer under constant flow ( ~ 250 µL min-1). The control chamber
replicated experimental conditions from the previous section in which the
beads were left static in the chamber for 10 minutes before the phosphate
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buffer wash was commenced. Figure 4.8 shows the concentration of beads
calculated (as in section 4.2) for each experimental chamber.
Figure 4.8. Bar graph showing the average bead concentration of ClfA1-A647
conjugated beads in the microfluidic chamber after 30 minutes of washing for
both the flow pulse and static pulse conditions.
Biofilms cultivated in microfluidic chamber V5.0 were treated with a pulse of
Affimer conjugated beads, and then washed with phosphate buffer for 30
minutes at a flow rate of 250 µL min-1. Error bars show averages associated
with SEM values, n = 10 (10 z-stacks acquired for each of the experimental
conditions). Paired student t-test analysis gave P = 0.003 (paired student’s t
test).
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From this data a significant decrease in bound beads can be seen
under conditions of constant flow over the biofilm. Figure 4.9 shows composite
z-stack images acquired from the experiment where the number of beads in
the z-stack represents the average number of beads calculated from
acquisition across the whole flow cell.
Figure 4.9. Z-stack images acquired using confocal microscopy of S. aureus
UAMS1 biofilms treated with ClfA1-A647 conjugated beads under static and
constant flow pulse conditions.
Left image shows z-projection (top view) rendered in ImageJ software and
right image a 3D render of the z-stack from the side created in LasX software
(Leica). A) beads were flown over and washed for 30 minutes with Phosphate
at a flow rate of 250 µL/ min with uninterrupted flow. B) beads were flown over
and washed for 30 minutes with phosphate at a flow rate of 250 µL/ min with
a 10 minute static pulse. Species in green are cells stained with DMAO, and
species in red are beads with Alexafluor647-labelled Affimer attached to their
surface.
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The data suggest that applying the beads to the biofilm under a constant
flow regimen has a detrimental effect on their ability to bind the biofilm.
Following 30 minutes of washing, there was a greater increase in the number
of beads bound to the biofilm when they were incubated statically with the
biofilm for 10 minutes, compared to being applied under a constant flow. This
may have been due to the beads being slightly more dense than water (beads
density = 1.03 g/ dm3 , water density = 1.0 g/ dm3 ). During the 10 minute
incubation period, as the beads moved around the chamber, more beads may
have come in to contact with biofilm. Conversely in the constant flow system
there may be comparatively fewer beads actually making contact with the
biofilm. This may mean that binding of the beads to the biofilm is dependent
on the kinetics of association for ClfA1 binding to its ClfA target. If the
association of the two proteins is slow, static incubation time may be essential
to establish enough protein-protein interactions to secure the bead at the
biofilm surface.
Whichever the reason for the decrease in binding, the experiment gives
insight into how translatable the system is to a biological system, such as the
human body. As the vascular system is under constant flow, it is important
that future biofilm-binding candidates are explored that can capture targeting
species to the biofilm under constant flow conditions. However, it was decided
that for future microbubble experiments using the ClfA1-A647 protein, a 10
minute static incubation application would need to be used.
The main question that needed answering was: what was causing poor
binding under flow? It may have been down to the number of beads making
contact with the biofilm as opposed to the binding interaction being too weak
to capture the beads onto the biofilm under constant flow conditions. The
results of the ITC experiment in section 2.2.2.3 showed a tight binding with a
KD = 125 nM, but ITC does not give an idea of binding kinetics. The affinity
may be high, but the protein’s association (ka) and dissociation (kd) rate to its
target may affect how quickly the beads can establish an interaction with the
ClfA target on the biofilm surface, under constant flow. Surface Plasmon
Resonance was used to experimentally measure the ClfA1 Affimer’s ka and kd
rate constants.
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4.2.3 Surface Plasmon Resonance (SPR) analysis of ClfA1 and
ClfA.
Surface plasmon resonance (SPR) is an analytical method that allows
real-time monitoring of biological and chemical interactions.181 First, one of the
binding partners is immobilised to a gold chip, e.g. using the interaction
between biotin and streptavidin. In this case, ClfA1 was biotinylated with
biotin-maleimide, which covalently links a biotin molecule to the thiol group of
the Affimer protein’s cysteine residue. The biotinylated ClfA1 was passed over
a gold chip with a streptavidin coated surface. Light from a light emitting diode
(LED) is shone at the gold chip surface and is reflected back to a detector.182
Electrons within the gold surface absorb energy from light of a certain
wavelength, causing them to resonate (surface plasmons). The reflected light
form the chip experiences a loss of intensity as a function of this resonance
energy. These surface plasmons are sensitive to interactions between ClfA1
and its binding partner ClfA, which changes the resonance frequency of the
electrons in the gold surface. This change in the reflected light is then
converted to a response unit, and as the nature of the interaction changes
over time, so does the observed response unit.
 SPR can give an indication of the rate of association (ka), the rate of
dissociation (kd) and the binding affinity (Kd). The biotinlated ClfA1 protein was
used to functionalise the gold chip surface at different relative densities, (low,
medium and high). The ClfA protein ligand was then flowed over the
immobilised Affimer at different concentrations. As the ClfA protein bound to
the ClfA1 Affimer, a change of response unit (RU) was observed. The RU
increased until the protein exists in an equilibrium where on rate is equal to
the off rate, at this point the RU plateaued and remained constant. Once this
equilibrium has been reached, the flow of ClfA protein was replaced with a
flow of buffer. During this step, the ClfA protein slowly dissociated from the
immobilised Affimer and the RU then decreased, as the chip surface
transitioned back to its initial unbound state. Figure 4.10 shows the output
data from the Biacore SPR apparatus for association between ClfA1 and ClfA
using the low density Affimer surface.
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For each of the curves shown in Figure 4.10A, the maximum RU was
plotted against the concentration of ClfA protein (Figure 4.10B). A curve was





RUmax is the maximum RU of the fitted curve.
Kd is the binding constant for the interaction.
The calculated Kd taken from the SPR data 97.8 ± 8 nM corresponds
to a similar value calculated form the ITC studies performed in section 2.2.2.3
Kd = 125 ± 51 nM. The association rate constant for the interaction between
ClfA1 and ClfA was found to be 5.84 ± 2.52 ×105 M-1 s-1. Association therefore
happens at a rate that is limited by diffusion i.e. < 105 M-1 s-1.183 In solution,
the limiting step for the binding of ClfA1 to ClfA is the speed at which the
proteins diffuse to each other. Therefore, the binding of the two proteins does
not require a conformation change in order for a binding event to occur.
Instead, the lower concentration of biofilm-bound beads in section 4.2.2 for
beads under a constant flow pulse may be dependent on the sheer number of
bead-biofilm interactions. In the static pulse, the beads have a 10 minute
window in which the beads can diffuse around the whole chamber, and
therefore have a greater chance of eventually making contact with the biofilm.
In the constant flow chamber, the beads only have the time they are flowed
through the chamber to interact with the biofilm. The amount of beads bound
to biofilm under constant flow conditions could be dictated by concentration:
by increasing the concentration of beads, the frequency of bead-biofilm
interactions would increase. This may mean that when translated in to a
therapy, the concentrations of MBs used may need to be higher to increase
MB-biofilm interactions. Alternatively, the concentration of targeting molecule
on the surface could be increased to make sure that when an interaction does
occur, there is a higher probability of a binding event happening between the
MB and the biofilm.
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Figure 4.10. SPR sensogram and plot of RUmax vs [ClfA] for the interaction
between ClfA1 and ClfA.
A) Sensogram data for response unit (RU) vs time for ClfA concentrations
(400, 200, 100, 50, 25, 12.5, 3.625, 1.56 nM) for the interaction between ClfA1
Affimer and ClfA protein. Black line indicates line of best fit for each curve
used to calculate ka and kd. Rate of association ka = 5.47 ×105 M-1 s-1, rate of
dissociation kd = 5.02 ×10-5 s-1 . B) Plot of max response vs [ClfA]. A non-
linear curve is fitted, from which the maximum response (Rmax) and and
binding affinity (Kd) have been calculated.
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4.2.4 ClfA1-MBP-MBL hybrid bead biofilm interaction
It been demonstrated that the ClfA1 Affimer can be used to localise the
polystyrene beads to the biofilm surface. Using ClfA1 Affimer protein, a protein
based on a consensus sequence from the plant protein cystatin, may invoke
an immunogenic response when introduced into the bloodstream. The use of
a human protein, such as MBL, could be used as a way to conjugate the MBs
to the biofilm surface, and may be less likely to generate an immune response.
In order to ascertain whether MBL could be used as a part of a targeted
microbubble system, its ability to localise the polystyrene beads to the biofilm
surface was investigated.
A biofilm was cultivated with S. aureus UAMS1 in the flow system (V5.0)
as described in 6.3.4. Protein conjugated beads were prepared as described
in 6.2.25. One set of beads were treated with ClfA1-A647 protein (10 µM in
phosphate buffer), one set with MBP-MBL-A647 protein (10 µM in MBL buffer)
and one set of beads with both ClfA1-A647 to MBP-MBL-A647 proteins
attached to the surface (1:1, 10 µM of each protein in MBL buffer).
The biofilm was first washed with the buffer that the beads were
suspended in, then the beads for a certain experimental condition were flowed
into the chamber at ~250 µL min-1. Once they had reached the chamber, flow
was stopped and the beads incubated at for 10 minutes, static in the flow
system. The biofilms were then washed for 30 minutes at ~ 250 µL min-1 with
buffer, before 15 z-stacks were acquired for each biofilm chamber. ImageJ
was used to count the number of beads per unit volume (dimensions of z-
stack). Figure 4.11 shows the relative bead concentrations of each chamber
after the buffer wash.
Initially it was seen (Figure 4.11) that the presence of the MBP-MBL
protein on the bead surface had an inhibitory effect on binding for the ClfA1
conjugated beads, decreasing the bead concentration by almost a factor of
10. However, when the z-stacks are consulted in Figure 4.12, the MBP-MBL-
A647 protein conjugated beads appear to have no fluorescent signal
associated with them.
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Figure 4.11. Bar graph showing the average bead concentration of ClfA1-
A647, MBP-MBL-A647 and MBP-MBL-A647-ClfA1-A647 conjugated beads in
the microfluidic chamber after 30 minutes of washing under static pulse
conditions.
S. aureus UAMS1 biofilms were cultivated in microfluidic chamber V5.0 and
were treated with a pulse of protein conjugated beads, and then washed with
buffer for 30 minutes at a flow rate of 250 µL min-1. Error bars show averages
associated with SEM values, n = 15 (15 z-stacks acquired for each set of
experimental conditions). Paired student t-test analysis gave P< 0.002 (MBP-
MBL-A647, MBP-MBL-A647-ClfA1-A647), P<0.001 (MBP-MBL-A647, ClfA1-
A647), P<0.001 (MBP-MBL-A647-ClfA1-A647, ClfA1-A647).
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Figure 4.12.  Z-stack images of ClfA1-A647, MBP-MBP-A647-ClfA1-A647 and
MBP-MBL-A647 beads from a top z-projection view and a 3D rendering made
in LasX (Leica) software.
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Top box, ClfA1-A647 beads associated to biofilm. Middle box, MBP-MBL-
A647-ClfA1-A647 beads associated to biofilm. Bottom box, MBP-MBL-A647
bead data. Top row, Z-projection of MBP-MBL-A647 beads associated with
biofilm; bottom row, z-projection of A647 associated species and its bright field
components. Yellow circles show the MBP-MBP-A647 associated beads
 that did not display a fluorescent signal for Alexafluor 647 dye. Green species
represent stained bacteria species, and red with Alexafluor647 associated
species.
The presence of the MBP-MBL protein on the surface of the beads not
only had a detrimental effect on the bead-biofilm interaction, it also caused the
formation of bead clusters. This occurred in both samples that had the MBP-
MBL protein present, which may have contributed towards the decrease in
binding of the ClfA1 beads spiked with the MBP-MBL protein. This may be
due to the ‘unravelling’ of the coiled-coil of the MBP-MBL complex, and ‘re-
winding’ of MBP-MBL monomers on adjacent beads forming the associations
in the clusters. However, work by Verde and co-workers demonstrated that
triple coiled-coils, like the one associated with the MBL trimer structure 129, are
resistant under high mechanical stress and coil ‘opening’ is unlikely to occur
184. Alternatively, trimers of the MBP-MBL fusion complex may be cross-linking
the beads via their polyhistidine purification tags. With each iteration of the
MBP-MBL fusion protein binding a different Ni-NTA bead, and the trimeric
coiled-coil crosslinking them together.
Although the bright field image in Figure 4.12 indicates that there was
some interaction between the MBP-MBL-A647 beads and the biofilm, there
was no fluorescent signal from the beads for A647-associated species, as
seen in the z-stack. This initially indicated that there was no MBP-MBL-A647
conjugated to the bead surface.
However, SDS-PAGE analysis (Figure 4.13) of the beads shows the
presence of fluorescent protein on the surface of the MBP-MBL-A647 beads,
indicating that the protein was present on the surface of the beads during the
confocal image acquisition during the flow experiment. The bead clustering
may have been caused by the change in buffer (phosphate to TRIS), as MBP-
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MBL conjugated beads were in a TRIS buffer. Given more time, the
experiment should be repeated with all three beads suspended in TRIS buffer
to see if buffer conditions affect the clustering of beads.
Figure 4.13. SDS-PAGE analysis of proteins on the surface of each
conjugated bead sample.
MBP-MBL-A647 indicated in red and ClfA1-A647 indicated in green. For all
bead types the correct proteins were shown to be present on the surface with
their fluorescent ability still in-tact.
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4.3 Targeted microbubble under flow conditions
Section 4.2 demonstrated the ClfA1 Affimer protein’s ability to localise
polystyrene beads to the biofilm surface. In order for the MBs to interact with
the biofilm surface, and imaged using the 100× confocal objective, the system
had to be manually inverted to allow the buoyant MBs to make contact with
the glass-slide-bound biofilm. Issues regarding buoyancy of bubbles had been
observed in preliminary test experiments. In practice this process had often
caused detachment of tubing from the system. In order to mitigate this in
subsequent experiments, tubing connected to the microfluidic chip was
secured with high strength adhesive. This allowed for inversion of the system
with low risk of tubing detachment.
Affimer proteins were conjugated to the MB surface using maleimide
chemistry. This method for MB conjugation has been demonstrated previously
by Klibanov and co-workers who attached a thiol-containing BODIPY dye to
the surface of a microbubble that had a maleimide-containing lipid on its
surface.185
4.3.1 ClfA1-MB interaction with biofilm under flow
A biofilm of S. aureus UAMS1 was cultivated in the flow system as
described in section 6.3.4. After 24 hours of incubation the biofilm was washed
with phosphate buffer at a flow rate of ~ 250 µL/ min. The biofilm was stained
with DMAO so that the biofilm biomass could be imaged. Microbubbles were
manufactured by Jordan Tinkler using the Horizon v3 Microspray production
equipment, described in section 6.3.5. Once the microbubbles had been
manufactured, Affimer solution was added (7.5 µM, 1 mL) and the bubbles
incubated at RT for 1 hour. After this time, the bubbles were washed with
phosphate buffer by gentle centrifugation, and decanting away of un-bound
Affimer protein. Affimer-MB stocks were diluted to a concentration of 1 x 108
MB/ mL, similar to the bead concentration used in section 4.2.
The microfluidic chip was inverted, and all tubing between the reagent
loop and the device was held vertically so as to reduce the risk of the buoyancy
of the bubbles preventing them from reaching the microfluidic device. The
microbubbles were flowed into the microfluidic chip using reagent loop, and
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once the bubbles had reached the device the flow was stopped and the device
remained inverted for a 10 minute incubation period. After this, the device was
returned upright and mounted on the confocal microscope. The system then
washed with phosphate buffer for 30 minutes at a flow rate of ~ 250 µL min-1.
As before, 15 z-stack scans were taken at 15 random points across each
experimental chamber. The number of bubbles in each z-stack was counted
using ImageJ software and a concentration per unit volume (of the z-stack)
was calculated for ClfA1-A647-MBs and AAC-A647-MBs data sets. Figure
4.14 shows a z-stack images taken from each experimental chamber that
reflects the average number of MBs across all z-stacks.
Figure 4.14. Z-stack images acquired using confocal microscopy of S aureus
UAMS1  biofilms treated with ClfA1-A647 conjugated microbubbles and AAC-
A647 conjugated microbubbles.
Left image shows z-projection (top view) rendered in ImageJ software and
right image a 3D render of the z-stack from the side created in LasX software
(Leica). A) ClfA1-A647-MBs were flowed into an inverted chamber, incubated
for 10 minutes and washed for 30 minutes with phosphate buffer at a flow rate
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of 250 µL/ min. B) AAC-A647-MBs treated as before.  Green regions are cells
stained with DMAO, and  red indicates areas  have Alexafluor647-labelled
Affimer attached to them.
Figure 4.15. Bar graph showing the average MB concentration of ClfA1-A647
and Aff-Ala-C-A647 MBs in the microfluidic chamber after 10 minutes of static
incubation in an inverted system and 30 minutes of washing with phosphate
buffer.
Biofilms cultivated in microfluidic chamber V5.0 were treated with a pulse of
Affimer conjugated MBs in an inverted system, and then washed with
phosphate buffer for 30 minutes at a flow rate of 250 µL min-1. Error bars show
averages associated with SEM values, n = 44 (15 z-stacks acquired for two of
the technical repeats, and 14 acquired for the final due to a data acquisition
error). Paired student t-test analysis gave P = 3.9 x 10-14 (paired student’s t
test).
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For the ClfA1-A647-MBs there is a statistically significant increase in MB
binding compared to that of that of the AAC-A647-MB Affimer scaffold control.
Not all species that have Affimer-A647 bound to them are associated with
microbubbles.
When quantifying the number of MBs per image, one has to compare with
the bright field in order to  accurately calculate thebubble concentration. Figure
4.16 shows that  A647also  bound to the biofilm not in association with intact
MBs. Only areas indicated with the yellow circles were assumed to be
microbubbles due to the A647 fluorescent signal associated with them. Non-
MB-associated fluorescent species are attributed to debris found in the MB
sample, either from the MB manufacture process or from MBs that have
ruptured whilst bound to the biofilm.
Figure 4.16. Z-projections of A647 channels taken from z-stacks from both
ClfA1-A647-MB and AAC-A647-MB data sets, their bright field counterparts
and an overlay of the two.
Top row shows the AAC-A647-MB z-stack, and the bottom row the ClfA-A647-
MB z-stack. In all images MB  are indicated by a yellow circle. There are some
A647 in the z-stacks is not associated with intact MBs.
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The ClfA1-A647-MBs have demonstrated the ability of the ClfA1 Affimer
to successfully bind MBs to the surface of the biofilm, better than the non-
specific Affimer scaffold. This shows that the ClfA1 Affimer protein can be
used as an effective targeting system for microbubbles.
4.4 Chapter Conclusions
At the end of this body of work, it has been observed that the ClfA1 Affimer
candidate brought forward from work in Chapter 2 has the ability to bind S.
aureus UAMS1 biofilm in the microfluidic system.
The ability of the ClfA1 Affimer to localise larger structures to the biofilm
surfaces such as 2 µm beads has been observed. When conjugated to the
bead surface, the ClfA1 Affimer mediated an interaction between the bead
and the biofilm surface. However, under constant flow conditions, the bead
concentration at the biofilm surface was lower than when introduced as a
static pulse with an incubation time of ten minutes. Further investigation of the
ClfA1 and ClfA protein interaction by SPR revealed that the rate of association
is probably limited by diffusion, and is therefore unlikely to limit the interaction
between beads and the biofilm. It has been concluded that the difference in
bead concentration at the biofilm surface is dependent on the frequency of
biofilm-bead interactions, which is much higher during a static 10 minute
pulse, compared to a constant flow pulse.
Polystyrene beads that had MBP-MBL conjugated to their surface showed
little ability to interact with the biofilm, and caused clumping of beads. These
observations may have been caused by poor buffer conditions, or interactions
between the MBL-MBP proteins on adjacent beads.
When displayed on the surface of the microbubbles, the ClfA1 Affimer
further proved its effectiveness at localising species to the biofilm surface. The
presence of ClfA1 on the MB surface increased the MB concentration at the
biofilm surface ten-fold compared to the non-binding AAC protein counterpart.
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5 Conclusions and future work
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5.1 Conclusions
This thesis focussed on an important human pathogen, Staphylococcus
aureus, a major cause of bloodstream infection and sepsis. S. aureus
bacteraemia is associated with a 30-day mortality rate ranging from 15 - 40%
even when antibiotic therapy is involved.186 Notoriously, methicillin-resistant
S. aureus (MRSA) brought this strain of bacteria into the spot light in the early
21st century. The prevalence of antimicrobial resistance is being marked
worldwide, prompting The World Health Organisation to declared it as one of
the biggest threats to global health.187
More specifically, S. aureus causes many biofilm infections from infective
endocarditis to medical device infections associated with intravascular
catheters and pacemakers.188, 189 Biofilm related infections are well known to
be a challenge to treat, with a 10-100 fold decrease in antibiotic susceptibility
associated with bacteria within the biofilm.6
Once S. aureus has invaded the bloodstream, it is able to seed infection
in distant parts of the body, often causing severe illness which is difficult to
locate and subsequently treat, causing ‘metastatic foci’ of infection, distant
from the original focus.190
The aim of this thesis encapsulated everything from the identification of a
biofilm-targeting protein that could be used to localise MBs to the S. aureus
biofilm surface, to the development of a microfluidic flow system.
Two protein systems were investigated for their potential to mediate
selective attachment of MB to S aureus biofilms: Affimer proteins and MBL.
Ten Affimer proteins were found to bind, to varying degrees, three different
clinically relevant strains of S. aureus, including a methicillin-resistant strain
(USA300). Of the ten Affimer proteins investigated, ClfA1 emerged as the
prime candidate to be taken forward for use on the MB surface. ITC studies
on ClfA1 protein indicated a high binding affinity for its ClfA target.
Poor solubility of the MBL complex, led to further probing of
overexpression and purification of the protein. The presence of a DNA impurity
caused issues with purification, and different expression methods to isolate
the protein from the DNA from lysed cells proved ineffective. Eventually, the
production of an MBP-MBL fusion protein increased solubility, with successful
purification of the fusion protein from overexpressing cells. Cleavage of the
MBL from the fusion protein was investigated and shown to be successful, but
purification of MBL from the cleavage mixture proved problematic. Time
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constraints only permitted a full investigation into the ClfA1 protein conjugation
system.
In tandem to protein development, a microfluidic flow system was
developed to study biofilms under flow conditions without sacrificing cell
viability. Many iterations of the flow system lead to the development of a flow
cell with three parallel biofilm growth chambers, that allowed for multiple on-
chip biofilm experiments as addition to controls. Issues arising from tubing
blockages and flow system components were rectified by increasing the bore
of the tubing used. The end result was a robust flow system in which biofilms
could be observed under flow conditions via CLSM, using a LIVE/ DEAD cell
viability stain. The addition of a fibrinogen coating step facilitated the
cultivation of more reproducible and stable S. aureus biofilms that were less
likely to become dislodge under the stress of flow.
Once the microfluidic system had been developed, it was used to study
the interaction between the S. aureus UAMS1 biofilm and the targeting
proteins. The ClfA1 Affimer protein was shown to bind to the biofilm under flow
conditions, better than the AAC Affimer control. ClfA1 demonstrated the ability
to localise polystyrene beads to the biofilm surface in the flow system.
However, beads flowed into the chamber and incubated as a static pulse
resulted in a higher biofilm-bound bead concentration than that of a constant
flow pulse. The addition of the MBP-MBL protein to ClfA1 conjugated beads
lead to a loss of binding between the beads and the biofilm. The precise nature
of this inhibition was unknown, repeats were required to confirm that MBP-
MBL protein’s presence was hindering bead-biofilm association.
The conclusion of this project was marked by a proof-of-concept
experiment in which MBs with ClfA1 conjugated to their surface were shown
to bind to the biofilm in the microfluidic flow system, and remained bound to
the biofilm after 30 minutes of washing.
5.1 Future Work
The interdisciplinary nature of this project meant that all branches of this
body of work had to be performed in parallel, with the aim acquiring proof-of-
concept data that validated further research into the use of targeted
microbubbles for biofilm imaging and destruction. Given time, there are areas
of this project that could be further developed in pursuit of this aim.
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5.1.1 Biofilm-targeting proteins
The most underdeveloped area of work for the development of the biofilm-
targeting proteins was the utilisation of the MBL protein. Although it was
successfully expressed as a MBL-MBP fusion proteins, worked needs to be
done in order to successfully purify the MBL protein from its MBP fusion
protein. An up-scaled version of the TEV cleavage reaction may yield a
soluble solution of the MBL protein with further purification by SEC. Minor
success had been observed using this method, and it may result in a pure
MBL protein stock.
It was concluded that the Affimer-biofilm binding assay screening
experiment did not give a clear indication of relative biofilm affinity, due to the
variability in biofilm biomass between each experimental well. ClfA1 was
brought forward as its binding partner, ClfA, had already been identified. This
infers the possibility that the other nine affimers screened may have higher
affinity for the S. aureus biofilm. As demonstrated, the integration of these
Affimer proteins into the microfluidic flow system experiments may bare fruit
as potential MB-conjugates. The other ClfA binding Affimers (ClfA16, ClfA27)
could be investigated using ITC and SPR to determine if their affinity is higher
than that of ClfA1, and therefore could be better MB candidates.
Other proteins could be developed to target different parts of the
biofilm. Proteins such as wheat germ agglutinin (WGA) and Concanavalin A
(ConA) have been shown to bind S. aureus biofilm matrix components 191-193.
These protein could be used in conjunction with the MBs or as a biofilm matrix
imaging method.
5.1.2 Microfluidic system development
A robust system for studying biofilms was developed using a microfluidic
flow system that met the needs of the proof-of-concept experiment described
previously. Further development of the system may allow for a greater number
of flow chambers confined to one microfluidic chip, which could enable
multiple MB experiments to be run at once.
Time-course experiments could be performed to understand how much
time elapses during biofilm growth before the cell density reaches an
equilibrium. Knowing this information may optimise the amount of time taken
per experiment, allowing for multiple experiment to be ran in at the same time.
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5.1.3 Interactions with biofilms under flow
Incorporation of the other Affimer proteins onto the bead and MB flow
experiments may identify Affimer proteins that bind the biofilm better.
Further probing of the static vs constant flow pulse experimental findings
should be investigated, as the vascular system is incapable of being ‘stopped’
to allow for MB binding. This could involve repeating the constant flow
experiments with differing bead concentrations, which will test the hypothesis
that the biofilm-bound bead concentration is mediated by the frequency of
bead-biofilm interactions.
The next step from the proof-of-concept experiment is to investigate
whether the microbubbles could be used in conjunction with ultrasound to
image the biofilm and/or destroy the biofilm. The former may involve repeating
the proof-of-concept experiment, and integrate US into the system to see if a
signal is observed. Biofilm destruction could be quantified using the LIVE/
DEAD stain imaging method described in section 3.2.6. Alternatively, the
amount of cell death could be observed by monitoring the uptake of the EthD-
III dye during bubble destruction.
Future work may include the incorporation of multiple different biofilm-
targeting molecules on the surface on the each MB. Dual-targeting MB have
been employed by Willmann and co-workers to target the VEGFR2
angiogenesis marker.194 Warram and co-workers have taken this concept one
step further by developing triple-targeted MBs that contained antibodies which
bound a number of receptors expressed in tumour vasculature.195 Although
this previous work revolves around targeting mammalian cells, the premise of
a multiple-targeting MBs is likely translatable to one that targets a biofilm.
Should these experiments prove effective, there is potential for the use of
these targeted microbubbles to deliver therapeutic agents to the site of biofilm
infection and use bubble destruction as a method of increasing drug uptake




This section provides the experimental procedures performed for the
laboratory work pertaining to this PhD project.
6.1 Chemical Methods
6.1.1 Solid phase peptide synthesis of biotin depsipeptide
Pre-loaded 2-chlorotrityl glycine resin (50 mg) was suspended in DMF
(3 mL) in a fritted 8-ml polypropylene reservoir fitted with a two-way stopcock
and agitated on a rotary mixer for 3 mins. The DMF was drained by filtration
under vacuum, Fmoc-Thr-Gly-(tBu)-OH (75 mg, 55 mM)196 was dissolved in
DMF (3 mL) and added along with HCTU (67 mg, 54 mM) and DIPEA (61 µL)
to the syringe. The syringe was then agitated for 60 mins at RT, washed with
DMF (3 x 3 mL x 1 min) and deprotected with piperidine (2 x 3 mL x 2 mins),
and washed again with DMF (5 x 3 mL x 1 min).  Fmoc-Glu-(tBu)-OH (102 mg,
92 mM) was dissolved in DMF (3 mL) and added along with HCTU (111 mg,
89 mM) and DIPEA (102 µL) to the syringe. The syringe was then agitated for
60 mins at RT, washed with DMF (3 x 3 mL x 1 min) and deprotected with
piperidine (2 x 3 mL x 2 mins), and washed again with DMF (5 x 3 mL x 1 min).
Fmoc-Pro-OH (93 mg, 91 mM) was dissolved in DMF (3 mL) and added with
HCTU (111 mg, 89 mM) and DIPEA (102 µL) to the syringe. The syringe was
agitated for 60 mins at RT, washed with DMF (3 x 3 mL x 1 min), deprotected
with piperidine (2 x 3 mL x 2 mins) and washed with DMF (5 x 3 mL x 1 min).
Fmoc-Leu-OH (97 mg, 71 mM) was dissolved in DMF (3 mL) and added with
HCTU (111 mg, 89 mM) and DIPEA (102 µL) to the syringe. The syringe was
agitated for 60 mins at RT, washed with DMF (3 x 3 mL), deprotected with
piperidine (2 x 3 mL x 2 mins) and washed with DMF (5 x 3 mL x 1 min). Fmoc-
- 181 -
Tyr-OH (111 mg, 92 mM) was dissolved in DMF (3 mL) and added with HCTU
(111 mg, 89 mM) and DIPEA (102 µL) to the syringe. The syringe was agitated
for 60 mins at RT, washed with DMF (3 x 3 mL x 1 min), deprotected with
piperidine (2 x 3 mL x 2 mins) and washed with DMF (5 x 3 mL x 1 min). Fmoc-
Gly-OH (84 mg, 94 mM) was dissolved in DMF (3 mL) and added with HCTU
(111 mg, 89 mM) and DIPEA (102 µL) to the syringe. The syringe was agitated
for 60 mins at RT, washed with DMF (3 x 3 mL x 1 min), deprotected with
piperidine (2 x 3 mL x 2 mins) and washed with DMF (5 x 3 mL x 1 min). To
biotinylate the depsipeptide, Biotin-NHS ester (96 mg, 94 mM, 5 Equiv) was
dissolved in DMF (3 mL) and added to the syringe along with DIPEA (95 µL).
The syringed was agitated overnight at RT, washed with DMF (3 x 3 mL x 1
min), DCM (3 x 3 mL x 1 min) and MeOH (3 x 3 mL x 1 min). Resin was then
dried under high vacuum for 4 h, peptide was cleaved off resin by the addition
of a cleavage cocktail containing TFA:H2O:TIS (95:2.5:2.5) (3 mL) and spun
for 2 h at RT. Cleavage cocktail was removed by filtration under vacuum in to
a 10 mL RB flask. Toluene (2 mL) was added and solvent was removed using
a rotatory evaporator to leave a brown solid. The brown residue was re-
dissolved in minimal ddH2O, analysed by LCMS and then freeze dried to yield
a fluffy white solid, Yield: 5 mg, 8.7%.
Mass Spectrum: m/z = 1020.56 [M + H+]
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6.1.2 Production of mannose affinity resin
10 mL of Sepharose 6B resin (Sigma Aldrich) was washed with H2O
(3 × 10 mL) on a glass sinter funnel under vacuum. Resin was then
suspended in 0.5 M Na2CO3 at pH 11 and incubated at RT with agitation
(Fixed speed rotator, Stuart) for 30 minutes. To this divinyl sulphone (1 mL)
was added, turning the suspension orange, it was then incubated at RT with
agitation for 70 minutes until the orange colour abated.
The resin was again washed using H2O (5 × 10 mL) on a glass sinter
funnel. Resin was then suspended in 20% mannose (w/v) in 0.5 M Na2CO3
pH 10, and incubated overnight at RT with agitation. Resin was then washed
with H2O (5 × 10 mL) and suspended in 0.5 M Na2CO3 pH 8.5 with the
addition of 200 µL 2-mercaptoethanol. Suspension was the incubated at RT
with agitation for 2 hours. Resin was washed with H2O (5 × 10mL), re-




PHOSPHATE BUFFER – 150 mM NaCl, 50 mM Sodium Phosphate (6.4 g L-
1 Na2HPO4, 1.6 g L-1 NaH2PO4), 10% glycerol v/v, pH 7.4.
HEPES BUFFER – 150 mM NaCl, 50 mM HEPES, pH 7.4.
SORTASE BUFFER – HEPES buffer + 5 mM CaCl2
MBL BUFFER – 1.25 M NaCl, 25 mM Tris-HCl, 5 mM CaCl2, pH 7.8
PROTEIN LOADING BUFFER – 50 mM Tris HCl, 2% (w/v) sodium dodecyl
sulfate, 2 mM Dithiothreitol (DTT), 10% (v/v) glycerol and bromophenol blue.
All buffers contents dissolved in H2O purified using a PURELAB® Option-Q
system (ELGA LabWater) with a resistivity of 18.2 MΩ.
6.2.2 Growth media contents
BHI BROTH –  37   g  L-1 BHI broth freeze dried powder (Sigma Aldrich).
Contains 12.5 g L-1 calf brains (infusion from 200g), 5 g L-1 beef heart (infusion
from 250g), peptone 10 g L-1,  NaCl 5 g L-1,  D(+)-glucose 2 g L-1, Disodium
hydrogen phosphate 2.5g L-1, final pH 7.4 at 25 ºC.
LB MEDIA – 25 g L-1 LB freeze-dried powder (Fischer) in H2O. Contains 10
g L-1 Tryptone, 5 g L-1 Yeast extract and 10 g L-1 NaCl.
LB-AGAR MEDIA – ‘LB media’ + 15 g L-1 of Agar powder (Fisher) in H2O
AUTO INDUCTION MEDIA – 10 g L-1  tryptone, 5 g L-1 yeast extract, 4%
v(v/v) 25 × salts, 1000 × metals and 4.3 mM MgCl2 in H2O. Brought as
hygroscopic powder (Formedium).
2YT MEDIA – 16 g L-1 Tryptone, 10 g L-1 yeast extract, 5 g L-1 NaCl.
All media was sterilised using an autoclaved at 120 ºC for 20 minutes.
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6.2.3 DNA transformation.
Freshly thawed (having been stored at – 20 ºC in 50 µL aliquots in
glycerol) competent E. coli strains (BL21 (DE3) Gold or XL10, Agilent) (50 µL)
was held in ice for 10 minutes before the desired plasmid was added and
thoroughly mixed by pipetting up and down for a few seconds. The mixture
was incubated on ice for 20 minutes before being heated to 42 ºC for 20
seconds in a heating water bath (Grant Instruments) and immediately returned
to ice for 2 minutes, 500 µL 2YT media  was then added and the solution
incubated with shaking (200 rpm, Orbital incubator, Stuart Equipment) at 37
ºC for 1 hour in air. A sample of culture (50 µL) was streaked onto an LB-agar
plate containing ampicillin (50 mg mL-1, Thermo Scientific) to provide single
colonies after incubating statically, overnight at 37 ºC in air.
A single colony from the LB-agar plates was used to inoculate LB media
(10 mL) containing ampicillin (50 mg mL-1). The mini-culture was grown
overnight at 37 ºC with shaking (200 rpm, Orbital incubator, Stuart Equipment)
in air. Aliquots of the overnight culture (0.5 mL) were taken and thoroughly
mixed with 80% (v/v) glycerol (0.5 mL) and stored at -80 ºC, until required.
6.2.4 Protein overexpression from E. coli (general)
A flake of frozen glycerol stock of a BL21 expression strain of E. coli
containing the desired plasmid for protein expression was used to inoculate
LB media (15 mL, 50 µg mL-1 ampicillin). This culture was incubated overnight
at 37 ºC with shaking (200 rpm, Orbital incubator, Stuart Equipment) in air.
The cells in the overnight culture were isolated by centrifugation (3000 xg, 10
min, 20 ºC, Multifuge 3 S-R centrifuge, Heraeus™), the pellet retained and the
supernatant discarded. The cell pellet was re-suspended in LB media (10 mL,
50 µg mL-1 Ampicillin) and then used to inoculate LB Media (6 x 1 L, 50 µg
mL-1 Ampicillin), cells were allowed to grow at 37 ºC in air, 200 rpm for 5-7
hours until OD550 reached ~0.8. Protein overexpression was then induced with
addition of isopropyl β-D-1-thiogalactopyranoside - IPTG (2 mL, 10 mg mL-1)
and CaCl2 (100 mL, 0.1 M), the cultures were incubated overnight at 24 ºC
with 200 rpm shaking in air. Cells were isolated by centrifugation (6,500 rpm,
20 mins, JA-10 rotor, 4 ºC), pellet retained and supernatant discarded. Pellets
were either frozen or immediately harvested for purification.
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Bacterial pellets were re-suspended in 15 mL of MBL. Cells were then
disrupted using a Constant Systems Cell Disrupter (20 kpsi, 40 kpsi head, 10
mL injections, 4 ºC). The lysate was then cleared by centrifugation (17,000
rpm, 45 mins, JA-30.5 rotor, 4 ºC), the pellet discarded and the supernatant
retained.
6.2.5 Affimer Protein overexpression in E. coli
A flake of frozen glycerol stock of BL21 DE3 GOLD expression strain
of E. coli containing the desired plasmid for protein expression was used to
inoculate LB media (15 mL, 50 µg mL-1 ampicillin). This culture was incubated
overnight at 37 ºC with shaking (200 rpm, Orbital incubator, Stuart
Equipment). The cells in the overnight culture were isolated by centrifugation
(3000 xg, 10 min, 20 ºC, Multifuge 3 S-R centrifuge, Heraeus™), the pellet
retained and the supernatant discarded. The cell pellet was re-suspended in
autoinduction LB media (400 mL, 50 µg mL-1 ampicillin), cells were allowed to
grow overnight at 25 ºC, in air at 200 rpm shaking. Cells were isolated by
centrifugation (6,500 rpm, 20 mins, JA-10 rotor, 4 ºC), pellet retained and
supernatant discarded. Pellets were either frozen or immediately harvested
for purification.
6.2.6 Affinity Chromatography
Desired affinity resins were packed into a Glass Econo-Column®
(BioRad) of an appropriate size (where the desired amount of resin settles as
a bed at least 3 cm from the column’s porous polymer bed. After use, the
column should be stripped of protein using the appropriate elution buffer,
washed with 5 column volumes of H2O, purified using a PURELAB® Option-
Q system (ELGA LabWater) with a resistivity of 18.2 MΩ, then 2 column
volumes of 20% EtOH (aq) before being stoppered and stored at 4 ºC.
6.2.6.1 Mannose Affinity Chromatography
Lysed cell supernatant was passed over a mannose affinity resin
(volume dependant on amount of cell lysate) equilibrated with desired MBL
buffer. The column was then washed with 2 x column volumes of lysis buffer
and protein was eluted with 2 x column volumes elution buffer (MBL buffer
without CaCl2 + 2.5 mM EDTA, pH 7.8). Fractions collected that contained
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desired protein were identified by SDS-PAGE and ESMS. Fractions combined
as desired and continued to next purification step; or pooled concentrated,
flash frozen in liquid nitrogen and stored at -80 ºC.
6.2.6.2 Amylose affinity chromatography
Lysed cell supernatant was passed over a Amylose affinity resin (New
England Biolabs) (volume dependant on amount of cell lysate) equilibrated
with desired lysis buffer. The column was then washed with 2 x column
volumes of lysis buffer, and then washed with wash buffer (lysis buffer + 10
mM maltose) until the eluent no longer turned Bradford Reagent blue. Protein
was eluted with elution buffer (Lysis buffer + 300 mM maltose), until the eluent
no longer turned Bradford Reagent blue. Fractions collected that contained
desired protein were identified by SDS-PAGE and Mass Spectrometry.
Fractions combined as desired and continued to next purification step; or
pooled concentrated, flash frozen in liquid nitrogen and stored at -80 ºC.
6.2.6.3 Nickel affinity chromatography
Lysed cell supernatant was passed over a Ni-NTA affinity resin
(Abbkine) (volume dependant on amount of cell lysate) equilibrated with
desired lysis buffer. The column was then washed with 2 x column volumes
of lysis buffer, and then washed with wash buffer (lysis buffer + 30 mM
imidazole) until the eluent no longer turned Bradford Reagent blue. Protein
was eluted with elution buffer (Lysis buffer + 300 mM imidazole), until the
eluent no longer turned Bradford Reagent blue. Fractions collected that
contained desired protein were identified by SDS-PAGE and Mass
Spectrometry. Fractions combined as desired and continued to next
purification step; or pooled concentrated, flash frozen in liquid nitrogen and
stored at -80 ºC.
6.2.7 Size exclusion chromatography
An NGC™ Chromatography system (Bio Rad) was used to purify
proteins by size exclusions chromatography. Sephadex™ 75 column was
used to purify proteins by their relative size. Protein was eluted from the
column using 0.22 µm filtered buffer of choice. Eluent protein content was
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monitored by observing the A280. Fractions containing protein were analysed
by SDS-PAGE or ESMS.
6.2.8 Ion exchange chromatography
An NGC™ Chromatography system (Bio Rad) was used to purify
proteins by their relative net charges at a given pH. A HiTrap Q FF anion
exchange chromatography column (GE Healthcare) was connected to the
system and purification method from the in-house software was used. Eluent
protein content was monitored by observing the A280. Fractions containing
protein were analysed by SDS-PAGE or ESMS.
6.2.9 Protein concentration determination
Protein concentration was determined by using a Nanodrop2000 UV/Vis
spectrophotometer (Thermo Scientific) by observing the absorbance of the
protein at 280 nm. Protein concentration was then calculated using the Beer-
Lambert Law.
= 	 	
A is the absorbance at 280 nm, ε is the molar extinction coefficient (ε for all
proteins can be found in the appendices), C is the protein concentration and
L is the path length (1 cm).
6.2.10 Sodium Dodecyl Sulphate – Polyacrylamide Gel
Electrophoresis (SDS-PAGE)
SDS-PAGE was carried out in hand cast 10-15% SDS-PAGE, 15 well
gels made using recipes shown below.
Resolving gel recipe
Reagent 10% 12% 15%
ddH2O 10 mL 8.76 mL 7.52 mL
1.5 M TRIS pH
8.8 5 mL 5 mL 5 mL
10% APS 200 µL 200 µL 200 µL
10% SDS 200 µL 200 µL 200 µL
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40% Acrylamide
solution 5 mL 6.24 mL 7.52 mL




1.5 M TRIS pH
8.8 2.5 mL
10% APS 100 µL




Protein loading buffer (15 µL) was combined with 5 µL of protein
sample and incubated at 95 ºC. Samples were ran in a miniPROTEAN® Tetra
Cell gel electrophoresis tank and power source (Bio-Rad) along with 1X SDS-
PAGE running buffer (125 mM TRIS, 960 mM Glycine, 0.5% w/v SDS) for 45
minutes at 180 V. 2-212 kDa Protein Marker (NEB) was used as a reference
marker for molecular weight. Gels were then stained for imaging for 2 hours
using Coomassie blue stain (2.5 g Coomassie blue, 100 mL water, 400 mL
Methanol, 500 mL water), destained overnight by in house de-stain (1:4:5,
Acetic Acid: Methanol: Water) and imaged using a GelDoc XR Molecular
Imager (Bio-Rad).
6.2.11 Sortase Labelling of MBL
Labelling with biotin depsipeptide: For a total volume of 200 µL, MBL
(43 µL, 30 µM), Sortase 7M enzyme (6 µL, 10 mol%) and biotin depsipeptide
(2.4 µL, 120 µM) were mixed together thoroughly and incubated at RT for 1 h.
Reaction was monitored by Mass Spectroscopy.
6.2.12 Site Directed Mutagenesis
First, the peptide sequence requiring alteration was identified using
SnapGene software, by translating the DNA sequence information for the
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plasmid encoding for protein expression. The nucleotide alteration required to
make the desired mutation was identified and primers were then designed in
order to generate a 1 base pair mismatch that coded for a different amino acid
at a certain point in the peptide sequence. The criteria for primer design were
as follows:
· 25-45 bases in length
· Tm greater than or equal to 78 °C
· 40% minimum G/C content
· One or more C or G at the end
The primer melting temperature (Tm) was calculated using the following
formula:
Tm = 81.5 + 16.6 x (log10W) + 41°C x (%GC) – 500/L
Where W corresponds to the concentration of salt in molarity in the
reaction, which was typically 0.04 M, and where L is the length of the primer
in nucleotides.
Under these criteria the following primers were designed for mutation of N-
terminal glycine to a serine, and insertion of 2 glycines at the N-terminus. The
mutated genes were named MBL G1S and MBL G1GGins, respectively.




For site direct mutagenesis of N-
terminal glycine to serine in MBL. MBL
gene is pINIIIompA2 plasmid provided










For site direct mutagenesis of MBL, to
insert 2 more glycine residues at N-
terminus. MBL gene is pINIIIompA2








6.2.13 Polymerase Chain Reaction
Polymerase chain reaction (PCR) was used to amplify DNA for gel
extraction, or for product analysis, to ensure that all primers resulted in a
single, specific DNA fragment being produced. In all cases, NEB enzymes and
buffers were used, and all products were analysed by nucleic acid
electrophoresis. Standard PCRs were set up in 50 μl tubes, and contained the
following:
5    μl 10x KOD hot start polymerase buffer
0.7 μl 10 μM Forward primer
0.7 μl 10 μM Reverse primer
5    μl 2 mM dNTP
3    μl 25 mM MgSO4
1 unit KOD hot start DNA polymerase
50 ng DNA template
The solution made up to 50 μl with sterile H2O, and the following cycling
conditions were used:
95 °C 2 minutes
95 °C 20 seconds
55 °C 30 seconds                       20 cycles
70 °C 2 minutes 30 seconds
72 °C 10 minutes
1 μl of Dpn1 enzyme was added to 5 μl of PCR product and the sample
incubated at 37 ºC for 1-2 hours. 5 μl samples of PCR product and PCR
product post Dpn1 digestion were run on a 1 % agarose gel. Gels were made
by dissolving 400 mg Agarose in 40 mL hot TAE Buffer (400 mM TRIS-
acetate, 10 mM EDTA, pH 8.4) and 2 μl of SYBR® Safe DNA gel stain, set in
a DNA gel bracket and comb. If a band did not disappear post Dpn1 digestion,
the DNA was successfully amplified
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6.2.14 DNA Extraction and Quantification
A single colony of E. coli XL10 was selected from an agar plate to
inoculate 5 mL of LB media containing the necessary antibiotic. This overnight
culture was incubated overnight at 37 ºC with 200 rpm shaking prior to use for
large scale protein overexpression (BL21 Gold) or used to extract it’s DNA
(XL10). DNA Extraction was performed using QIAprep® Spin miniprep kit
following its accompanying manufacturer’s protocol.
6.2.15 Periplasmic Extraction of MBL
E. coli BL21 Gold cells were cultured as in general protein
overexpression (section 6.2.4). Pelleted cells were re-suspended in 8 mL of
sucrose solution (20% sucrose, 30 mM TRIS-HCl, 1 mM EDTA, pH 8) at 24
ºC, shaken for 15 mins at 180 rpm. Cells were then pelleted by centrifugation
(13, 000 xg, 10 mins, JA-10 rotor). Supernatant was decanted and the cells
were re-suspended in cold 15 MΩ purified H2O, the cells were then shaken on
ice for 20 mins at 180 rpm. Cells were pelleted by centrifugation (13,000xg,
10 mins, JA-10 rotor), and the supernatant was concentrated by ultrafiltration.
6.2.16 Expression Study
pINIIIompA2 plasmid DNA expressing MBL (provided by Kurt
Drickamer, Imperial College London) was transfected into Rosetta cells, which
were then plated out onto LB-Agar containing ampicillin (50mg L-1) and
chloramphenicol (34 mg L-1), and incubated overnight at 37 ºC. A single or
three colonies from the plate were picked to inoculate 5 mL LB media
containing ampicillin (50mg L-1) and chloramphenicol (34 mg L-1). At the same
time glycerol stocks of hMBP33 E. coli BL21 Gold DE3 cells were used to
inoculate 5 mL LB media with ampicillin (50 mg L-1). These overnight cultures
were used to inoculate 100 mL LB media with the relevant antibiotic
concentrations. as the mentioned above. The cultures were incubated at 37
ºC in air at 200 rpm shaking. Once both cultures had reached an OD550 = 0.8,
2 mL IPTG (5 mg mL-1) was added along with 10 mL CaCl2 (1M) and the cells
were left to express the target protein for 2 hours. 1 mL of cells from each flask
was flash frozen, and the rest of the cells were incubated overnight as before.
1 mL of cells from each flask were taken and flash frozen. Cells were pelleted
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(4,500 xg, 10 mins). The supernatant was decanted and 10 mL ethanol added
to precipitate out any proteins in the media, then the insoluble proteins were
pelleted by centrifugation (4,500 xg, 10 mins). Cell pellet was then re-
suspended in BugBuster® (Novagen) and allowed to react at RT for 20 mins.
This was then repeated for all flash frozen cell stocks. Samples analysed by
SDS-PAGE.
6.2.17 TEV-H6 protease overexpression
A flake of frozen glycerol stock of expression strain of E. coli BL21 Gold
containing plasmid pET-28A containing genetic information for the expression
of a his-tagged TEV protease (Appendix B) was used to inoculate LB media
(5 mL, 80 mg L-1 kanamycin). This culture was incubated overnight at 37 ºC
in air, with shaking (200 rpm, Orbital incubator, Stuart Equipment). The cells
in the overnight culture were isolated by centrifugation (3000 xg, 10 min, 20
ºC, Multifuge 3 S-R centrifuge, Heraeus™), the pellet retained and the
supernatant discarded. The cell pellet was re-suspended in LB media (10 mL,
80 mg L-1 kanamycin) and then used to inoculate LB Media (6 x 1 L, 80 mg L-
1 kanamycin), cells were allowed to grow at 37 ºC in air, 200 rpm for 4 hours
until OD600 reached ~0.5. Protein overexpression was then induced with
addition of IPTG (final concentration 0.5 mM), the cultures were incubated
overnight at 20 ºC. Cells were isolated by centrifugation (10,000 rpm, 20 mins,
JA-10 rotor, 4 ºC), pellet retained and supernatant discarded. Pellets were
either frozen or immediately harvested for purification.
6.2.18 TEV-H6 Protease purification
Bacteria pellets were re-suspended in 15 mL of lysis buffer (20 mM
TRIS, 200 mM NaCl, 10 mM imidazole, 2 mM mercaptoethanol, 0.2% Triton
X-100, pH 8). Cells were then sonicated on ice (3 x 3 mins, 50 W, 50% pulse
cycle). The lysate was then cleared by centrifugation (20,000 rpm, 30 mins,
JA-30.5 rotor, 4 ºC), the pellet discarded and the supernatant retained.
Supernatant was then passed over a nickel affinity resin (10 mL) equilibrated
with lysis buffer. The column was then washed with 3 x CV of low salt buffer
(20 mM TRIS, 200 mM NaCl, 10 mM imidazole, 2 mM mercaptoethanol, pH
8), then 3 x CV of high salt buffer (20 mM TRIS, 1 M NaCl, 10 mM imidazole,
2 mM mercaptoethanol, pH 8), then a further 3 x CV of low salt buffer. Protein
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was then eluted from the column using elution buffer (20 mM TRIS, 200 mM
NaCl, 300 mM imidazole, 2 mM mercaptoethanol, pH 8). Fractions were
analysed by SDS-PAGE (appendix B). Fraction showed to contain TEV-
protease were pooled and loaded onto a Superdex 75 16/ 60 size exclusion
column. Fraction corresponding to peaks on the UV Chromatogram were
analysed by SDS-PAGE. Bands showing the presence of only TEV-Protease
were pooled and concentrated by ultracentrifugation to 83 µM (1.5 mL).
Aliquots were flash frozen in liquid nitrogen and stored in a -80 ºC freezer until
required.
6.2.19 MBP-MBL overexpression and purification.
DNA coding for MBP-MBL expression was order contained in a
pMalp5X vector, named ‘MBP-His-TEV-hMBL_PMAl-p5x’. This plasmid was
transfected into E. coli BL21 Gold cells, plated out onto LB-Agar/ ampicillin
(50 mg L-1) and incubated overnight at 37 ºC. Colonies from the plate were
picked to inoculate 5 mL of LB-Agar/ ampicillin (50 mg L-1), which was
incubated overnight at 37 ºC with 200 rpm shaking (200 rpm, Orbital incubator,
Stuart Equipment). The same overexpression procedure as for MBL was
followed.
The cell lysate was flowed over an amylose affinity resin (10 mL) equilibrated
with MBL lysis buffer. Resin was washed with 3 x CV of lysis buffer. Protein
was eluted from the column with elution buffer (MBL lysis buffer + 10 µM
Maltose). Fraction monitored by SDS-PAGE, fractions shown to contain MBP-
MBL were pooled and dialysed into sortase buffer (150 mM NaCl, 50 mM
HEPES, 5 mM CaCl2, pH 7.5) in 10,000 MWCO dialysis tubing. The contents
on the dialysis bag was then concentrated by immersing the bag in PEG (as
in MBL concentration). Final concentration 321 µM (7 x 1 mL). Aliquots were
flash frozen in liquid nitrogen and stored in a -80 ºC freezer. Stocks analysed
by LCMS, mass = 58918 Da.
6.2.20 MBP-MBL TEV cleavage test reactions.
MBP-MBL (100 µM) was combined with TEV-protease (25 mol%) in
sortase buffer (200 mM NaCl, 50 mM HEPES, 5 mM CaCl2, pH 7.5) to a final
volume of 200 µL. The reaction was then incubated overnight at 4 ºC. Then
loaded onto 3 mL Nickel affinity resin equilibrated with sortase buffer. Column
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was then washed with 3 x CV sortase buffer. Protein on column eluted when
required with elution buffer (sortase buffer + 300 mM imidazole). All fractions
were analysed by SDS-PAGE or ESMS.
6.2.21 MBP-MBL cleavage reaction and purification.
MBP-MBL (100 µM) was combined with TEV-Protease (25 mol%) in
sortase buffer to a final volume of 500 µL. The reaction was then incubated
overnight at 4 ºC. Reaction mixture was then loaded onto a Superdex 75 16/
60 size exclusion column. Protein species eluting from column were monitored
by  A280. Fractions corresponding to peaks at A280 were analysed by SDS-
PAGE.
6.2.22 Protein labelling with fluorescein-5-maleimide
Protein of a known concentration was combined with Fluorescein-5-
malimide (Thermo Scientific) at a 10-fold molar excess to a final volume of
500 µL in a 1.5 mL lidded tube (Eppendorf). The reaction is then incubated
at 4 ºC, overnight.
The formation of products is monitored by ESMS, and the reaction is
considered complete when no peak for unlabelled protein is seen in the
spectra. Peak at +425 Da above protein molecular weight associated with
labelled protein. For all Affimer, 100% labelling was achieved.
Unreacted fluorescein-5-maleimide is the removed from protein
solution using a Sephadex G-25 medium desalting column (GE Life
Sciences). Column equilibrated in desired buffer and product protocol
followed.
6.2.23 Affimer-Biofilm Binding Assay (ABBA)
A flake from each S. aureus strain glycerol stock was used to inoculate
a separate 1 x 5 mL autoclaved BHI Broth in a 25 mL Falcon tube. In these
experiments strains of S. aureus used were SH1000 (donated by Chris
Randall, University of Leeds), USA300 (CCOS666, Culture Collection of
Switzerland) and UAMS1  (CCOS667, Culture Collection of Switzerland.
These tubes were then incubated overnight at 37 ºC in air, 200 rpm shaking.
The following day these stocks were used to make up a 1 in 100 stock by the
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addition of 100 µL the BHI broth cultures to 10 mL of fresh, autoclaved BHI
broth.
200 µL of the suspension above was added to the relevant wells in a
white, opaque, polystyrene 96 well plate (Greiner Biotech). Figure 6.1 shows
the general layout of the plate for all experiments. Cells were added to
highlighted wells in columns labelled ‘protein concentration’ and ‘Plate Purity’.
To the wells highlighted in columns labelled ‘BHI Broth’, 100 µL of sterile,
inoculated BHI broth was added as a biofilm negative control. The plate was
then covered with its accompanying transparent plastic cover and placed in a
37 ºC in air, incubator for 48 hours at 40 rpm shaking.
General format of the two 96 well plates used in biofilm protein binding
assays is shown in Figure 6.1. Each row corresponds to a certain strain of S.
aureus, three strains were screened over two 96 well plates. ‘BHI Broth’
columns correspond to wells that have been incubated with sterile BHI Broth.
The wells highlighted with crystal violet controls have an established biofilm in
them that was then stained with 0.1% Crystal violet solution.
The liquid in wells of the column labelled ‘BHI Broth’ and wells
highlighted in the ‘Plate Purity’ column were used to inoculate a Blood agar
plate. ‘Plate Purity’ wells were streaked out on these plates whereas all ‘BHI
Broth’ wells were used to inoculate the same plate split into 3 sections for each
strain. The purpose of these plates is to ensure each cell strain grows a
homogenous biofilm and that the BHI broth and the well contents remained
sterile. The cells and broth were aspirated from the wells using a 200 µL, 12
channel pipette. Wells were then washed with 3 x 200 µL of phosphate buffer
by gently pipetting the buffer in and slowly aspirating it back out again. To
wells highlighted in columns ‘Protein concentration’, 50 µL of fluorescently
labelled protein was added at each specified concentration (1 in 3 dilution
series). The plate was then covered, wrapped in tin foil to prevent photo
bleaching and incubated at RT for 1 hour. After this the wells were then
washed as described above with 3 x 200 µL of wash buffer.
The plate was then loaded into an envision plate reader and the
fluorescence of each wells was measured by emission of the wells at the
desired wavelength (Fluorescein = 535 nm).
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6.2.24 Protein labelling with NHS-ester
Protein of a known concentration is combined with an NHS-ester
derivative (listed below) at a 10-fold molar excess in buffer containing 0.1M
sodium bicarbonate (pH 8.3-9), to a final volume of 500 µL in a 1.5 mL
Eppendorf tube. Reaction is incubated overnight at 4 ºC.
Degree of labelling is monitored by ESMS, if not all of the protein was
labelled after an overnight incubation the labelled protein solution was
purified regardless of amount converted. Degree of conversion ascertained
by intensities of labelled and unlabelled protein peaks in the mass spectra
(Appendix 7.9).
Unreacted NHS ester is the removed from protein solution using a
Sephadex G-25 medium desalting column (GE Life Sciences). Column
equilibrated in desired buffer and product protocol followed.





A known volume of 2 mL Ni-NTA polystyrene beads (109 beads mL-1,
micromod Partikeltechnologie GmbH, product code: 01-48-203) were pelleted
using ultracentrifugation (13.3 xg, 2 mins) in a 1.5 mL Eppendorf tube. Water
storage solution was decanted away and the beads re-suspended with an
equal volume of the desired buffer. The beads were then pelleted as before
by ultracentrifugation.
Pelleted beads were then re-suspended in 10 µM of protein in the
desired buffer, at the same volume used to wash the beads. The presence of
a His-tag on the protein was essential for conjugation. If protein had
fluorophore attached, the tube was wrapped in foil and incubated at RT for 3-
4 hours with slight shaking.
The beads were then pelleted, protein solution decanted, and the
beads suspended in buffer. Decanting and resuspension steps were repeated
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twice to wash beads of unconjugated protein. Final beads solution is assumed
to be ~109 beads/ mL and diluted to ~108 beads mL-1 for biofilm experiments.
6.2.26 Non-specific bead binding using light microscopy
Biofilms of S. aureus UAMS1 were cultivated as in Section 6.2.23,
using the same volume of inoculum for biofilm growth and buffer for washing.
To each experimental well 50 µL of either buffer, non-conjugated beads or
Affimer bound beads was added and incubated at RT for one hour. After this
wells were washed with 3 x 200 µL of phosphate buffer, by gently aspirating
the buffer in and out with a 200 µL Gilson pipette.
Once washed, the well were treated with paraformaldehyde (4% w/v,
50 µL). During treatment with paraformaldehyde the biofilms were
mechanically disrupted by the end of the pipette tip and the solution aspirated
vigorously to disrupt the biofilm and homogenise the biofilm solution.
A microscope sample was prepared using a 0.8-1 mm microscope
sample slide, upon which 2 × 50 µm spacers are placed roughly 2 cm apart.
On top of these spacers a 22 × 22 mm cover slip was placed. 30 µL of the
biofilm sample taken from the wells was pipetted carefully between the cover
slip and the slide in the opening created by the 50 µm spacers. The sample
fills the space by capillary action. The slides were then mounted on a Nikon
Eclipse 80i Microscope fitted with a Hamamatsu digital camera (Model C4742-
95) and for each well sample, 20 images were acquired at various positions
across the sample slide.
These images were then imported into MATLAB software and MATAB
code developed by Damien Batchelor (University of Leeds) was used to count
spherical species in the sample images. By imputing the physical dimension
of a pixel in the image and the size of the spacers (50 µm) the volume and
concentration was calculated by the software. The MATLAB code then exports
the results as a .csv Excel file and a .tiff image of a histogram showing the
distribution of sizes in each sample.
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6.2.27 Isothermal titration calorimetry
Both ClfA, ClfA1 and AAC proteins were purified for ITC using nickel
affinity chromatography and dialysed into phosphate buffer (50 mM
Na2HPO4/ NaH2PO4, 150 mM NaCl, pH 7.4). Proteins were concentrated by
centrifugal concentration (Amicon 10 kDa MWCO). ITC binding assays were
performed using a Microcal ITC200 (GE Healthcare) thermostated at 25 °C.
The ClfA sample was loaded into the sample cell (200 μL, 16-20 μM), and
the Affimer titrant was loaded into the sample syringe (70 μL, 200 μM). Each
titration experiment consisted of a sacrificial injection of 0.4 μL followed by
19 injections of 2 μL. Titration data were analysed using a one site binding
model in the GE Healthcare Origin 7 ITC software.
6.2.28 Surface plasmon resonance
SPR experiments were performed on a Biacore 3000 instrument using
streptavidin-coated chips (Sensor Chip SA, GE Healthcare). System was
equilibrated with degassed phosphate buffer. The four flow cells of the
sensor chip were conditions with 3 x 40 µL injections of conditioning solution
(1 M NaCl, 50 mM NaOH) at 40 µL min-1. ClfA1-biotin was diluted to 20 µM
and injected over three of the flow cells to derivitise the chip with Affimer.
The sensorgram was observed so that three differing density of Affimer were
observed in each chamber; low, medium and high density. The density of
the surface is defined by the response unit maximum, Rmax, achieved by
flowing the analyte over the surface. For the low density surface the







Where, RL = response level of immobilised ligand (RU), MWL =
molecular weight of ligand (for ClfA1 = 12630 Da), MWA = molecular weight
of analyte (for ClfA = 36979 Da), Rmax is the maximum binding capacity (set
as 100 RU) and s = number of sites per ligand (1 for ClfA1)
For the low density surface, the gold surface was functionalised with
ClfA1- biotin until the RU got as close to 30 (calculated using above
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equation) as possible. The high density surface was set as the maximum
amount of ClfA1 that could coat the surface (ClfA1 being flowed through
chamber until RU reached a plateaux), 2300 RU. The medium density
surface was set as a value that lay between the maximum density surface
and low density surface, 500 RU.
  The fourth lane was left un-derivitized for a control. Experiments were
then carried out using 1 in 2 serial dilution of ClfA starting at 400 nM ending
at 1.56 nM. Flow rate of the experiment was 30 µL min-1.  Analyte was
flowed into the flow chambers for three minutes, then the chamber were
washed for a further seven minutes. Flow chambers were then washed of
analyte until the RU returned to the baseline (RU before introduction of
analyte) ~ 20 minutes. If the RU did not return to baseline, the chambers
would need to be functionalised with the ClfA1 Affimer, again. However, this
was not the case with these experiments as RU returned to baseline.
BIAevaluation (Biacore) software was used to analyse data and perform
curve fittings used to calculate binding kinetics values.
6.3 Microfluidic Methods
6.3.1 Microfluidic device manufacture.
Microfluidic devices were fabricated by Jordan Tinkler (University of
Leeds) and Peng Bao (University of Leeds) using photo and soft lithographic
techniques. A 3-inch diameter silicon wafer (Pi-Kem Ltd, UK) was initially
cleaned by immersing in acetone, isopropanol, distilled water, and then drying
under a stream of compressed air. A layer of SU-8 2075 (Microchem,
Warwickshire, UK) was spin coated on a Photo resist spinner (EMS 6000,
Electronic Microsystems) onto the wafer to a height of 180 μm using the
following speeds: 10 seconds at 200 RPM, 10 seconds at 400 RPM, 10
seconds at 600 RPM, then 40 seconds at 1350 RPM. Microfluidic chip was
designed using AutoCAD (Autodesk) software. Designs are further edited
using CleWin (WieWeb) software before being transferred to the wafer using
a 375 nm laser (MicroWriter ML, Durham Magneto-Optics, Durham, UK).
Laser contact with the SU-8 photoresist causes polymerisation by cross-
linking, creating a silicon master with the ‘negative’ imprint of the microfluidic
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chip design, caused by the now insoluble SU-8 photoresist. Devices were cast
from the silicon master in polydimethylsiloxane (PDMS) using a 1:10 ratio of
cross linker to polymer base (Sylgard 184). The PDMS was left under vacuum
for ~30 minutes to remove air bubbles, and then allowed to set for ~1 hour in
an oven at 75°C. Individual devices were then cut away, hole punched, and
bound to #1 22 x 50 mm glass cover slips using oxygen plasma treatment.197
Flow rate modelling, performed by Jordan Tinkler (University of Leeds) of the
devices during the design phase confirmed that the flow rates within the
growth chambers is comparable to that found in vasculature.
6.3.2 Microfluidic biofilm study system manufacture.
The microfluidic biofilm study system (MBSS) was designed and
manufactured by Dr Ben Johnson in the Department of Physics and
Astronomy.
6.3.3 Piezo pump calibration.
The piezo pump in the MBSS was connected to an Extended
micropump control unit (Bartels microtechnik). Two calibration experiments
were set up at constant frequencies of 50 Hz and 100 Hz. Calibration was
performed with H2O in the media inlet. Microfluidic chip was attached to the
system. The H2O was flowed through at frequency 50 Hz and amplitude 250
Vpp for 5 minutes to fill system with water and check for any leaks in the
system.
10 x 1.5 mL Eppendorf tubes labelled with numbers 1 – 10 and pre-
weighed. For each numbered tube, an amplitude was assigned from 25 to 250
Vpp. Frequency was set to the relevant value for the experiment, and
amplitude set to the right value for that tube number. The pump was then
turned on at the same time as starting a stop watch and water was allowed to
flow into the Eppendorf tube. When the water meniscus reached to the 1 mL
mark by eye, the pump is turned off and the stop watch paused. The tube
sealed and the tube weighed and time taken to fill noted. This process is
repeated for all tubes. Pre-weighed value (in g) is taken away from end weight
value to yield the weight of water in the tube. The resultant weight (in grams)
was divided by density of water (1 g mL-1) to give a volume of water in (mL).
This volume was then converted to microliters and divided by the time taken
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for tube to reach ~ 1 mL in minutes. The final value was reported as a flow
rate in microliters per minute for a given frequency and amplitude.
Frequency 100 Hz
Table 6.1. values for calibration of pump at 100 Hz frequency.
Amp Flow Volume time time
Tube Vdd µl/min µl s min
1 30 97.96026 926.1 567.23 9.453833
2 60 222.2674 964.9 260.47 4.341167
4 90 374.5152 975.3 156.25 2.604167
5 120 521.2667 973.9 112.1 1.868333
6 150 656.7442 917.8 83.85 1.3975
7 180 843.3778 863.9 61.46 1.024333
8 210 1012.841 854.5 50.62 0.843667
9 240 1232.356 917.9 44.69 0.744833
Table 6.2. values for calibration of pump at 50 Hz frequency.
Amp Flow Volume time time
Tube Vdd µl/min µl s min
1 25 67.46686 1076.4 957.27 15.9545
2 50 162.2279 973.8 360.16 6.002667
3 75 273.4438 945.4 207.443 3.457383
4 100 391.609 1000.3 153.26 2.554333
5 125 483.9858 910.7 112.9 1.881667
6 150 632.4762 1053.6 99.95 1.665833
7 175 736.4839 974 79.35 1.3225
8 200 876.8852 891.5 61 1.016667
9 225 995.1749 962.5 58.03 0.967167
10 250 1110.376 989.9 53.49 0.8915
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Flow rates were plotted against amplitude for a given frequency in ‘Origin
2016’ graphical software. For each plot the values are assigned a linear line
of best fit.
Figure 6.2. Graphical plot of flow rate (µL/ min) against amplitude (Vpp) for
frequency 50 Hz.
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Figure 6.3. graphical plot of flow rate (µL/ min) against amplitude (Vpp) for
frequency 50 Hz.
Using the equation for a linear line of best fit (y = mx + c), for a given
flow rate, the amplitude could be calculated (See section 2.7.2.1.).
6.3.4 Standard Operating Procedure for biofilm cultivation
1.1. Preparation of stock cultures
· 1L BHI broth was autoclaved and allowed to cool to room temperature.
· Glycerol stocks were streaked out onto a primary culture plate of
Horse-blood agar (ordered premade from Thermo-Fischer Scientific
UK, LOT 12972568)
· The growth of bacteria was checked on the primary plate culture for
purity, based on colony morphology.
· If there was no suggestion of contamination on the primary culture
plate, three separate colonies of test bacteria were touched using a
flame sterilized or sterile disposable loop and  used to inoculate 100
mL of BHI broth.  This culture was incubated at 37 ºC in air, overnight;
- 205 -
at the same time the culture was used to inoculate an LB-Agar plate to
check sterility of broth culture.
· Bacterial broth was then used to make 100 x 1mL aliquots, flash froze
and stored in a -80 ºC freezer for future cultures.
1.2 Leak Check & Sterilisation
· All apparatus that can be autoclaved was wrapped loosely in aluminium
foil (to prevent contamination during transfer to category 2 safety
cabinet), and autoclaved (see below). Parts which are not were soaked
in 70% ethanol.
· All apparatus was then transported to a category 2 safety cabinet,
removed from foil and irradiated with UV light for 30 minutes.
· Within the safety cabinet, the whole system was assembled. Stopcocks
were all opened and 70% ethanol was flushed throughout the whole
system. This was either be done by drawing liquid through with a
syringe or by loading 70% ethanol into reservoirs and using piezo
pumps to push liquid through. The same was then done with air, pulled
through a 0.2 µm filter, to dry the system.
· The system was then primed using sterilised BHI broth. For priming
reagent loop see below. System was primed by attaching syringes to
luer lock adapters and drawing/ pushing liquid through the system.
· Stopcocks connecting to inoculum and both reagent in ports were
closed, stopcocks connecting media to chip and chip to waste were
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opened. Three way stopcock positioned so only media inlet is feeding
onto the microfluidic chip. Reagent loops were connected post biofilm
cultivation.
· Make sure media reservoir was filled with autoclaved BHI broth.
· System was transported to safety cabinet and checked for leaks. Media
in the waste reservoir was used to inoculate a horse-blood agar
(Thermo Fisher Scientific) and Sabouraud dextrose 4% agar plate
(VWR Chemicals, LOT 1292) using a sterile plastic loop. Lid of waste
reservoir was removed carefully during this step and immediately
placed back on after inoculation.
1.3. Fibrinogen coating of chip1.
· 10 mg mL-1 of human fibrinogen (Sigma-Aldrich) in PBS was made up
to a volume of 2 mL. The solution was then filter-sterilised with a 0.22
µm syringe filter, in a Category 2 safety cabinet.
· All stop cocks were closed, excluding the ones attached to the
inoculum in and waste out ports. In a fresh sterile syringe, the
fibrinogen solution was introduced into the microfluidic chamber by the
inoculum in port.
· All stop cocks were closed and the system in placed in the incubator,
without heat, overnight in air.
1.4 Sterility check of the system
· System was transported to safety cabinet and checked for leaks. Media
in the waste reservoir was used to inoculate a horse-blood agar and
sabouraud agar plate using a sterile plastic loop, incubated at 37 ºC in
air, statically, overnight. The lid of the waste reservoir was removed
carefully during this step and immediately placed back on after
inoculation.
1.5 Inoculation of system
1 Fibrinogen coating step only applicable for experiments proceeding section 3.2.5 of this
body of work.
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· 5 mL of overnight S. aureus cell culture was drawn into a 5 mL syringe.
The syringe was then connected to the system upstream of stopcock 1
by female Luer fitting.
· The one way stopcock was turned to isolate the media reservoir from
the chip.
· Stopcock connecting inoculum syringe to the chip was opened. Syringe
plunger carefully pushed down to allow bacteria to flow through the flow
cell into waste reservoir. Once bacteria had been added the SYRINGE
WAS NOT REMOVED AT ANY POINT!
· System was transferred to incubator and left to incubate statically at 37
ºC for 1 hour.
Begin the flow system
· The three way stopcock was turned so that media can flow through to
chip but the reagent loops are isolated. The one way stopcocks were
closed between inoculum syringe and the chip. The piezo pump was
set to the desired flow rate and media was allowed to flow through chip
- out to waste. Biofilms were cultivated for the desired amount of time.
Staining of Biofilm & Reagent Loop Priming.
· Make 1× solution of desired LIVE/DEAD stain (Viability/ Cytotoxicity
Assay kit, Biotium, LOT 30027) .
· Reagent loop can be primed with buffer using the conformation shown
in figure 6a. Conformation of stopcocks in the Figure 6.4b can be used
to eliminate introduction of bubbles in reagent inlet and outlet. Loop is
primed with LIVE/DEAD stain using conformation shown in Figure 6.4c.
· Once loop is primed with LIVE/DEAD stain, introduce stain by using
conformation in Figure 6.4d, which will flow the reagent into the system
using a piezo pump 2 set at desired flow rate. The three way stopcock
on the system is turned to isolate media inlet from the chip but allow
flow of stain into system.
· Once stain protocol has been performed stop piezo pump 2.
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Figure 6.4. Conformational arrangement of reagent loop 3 way stopcocks for
flow isolation to certain channels.
a) Conformation for ‘media in’ to microfluidic ‘chamber’ omitting the reagent
loop. b) Conformation for media in to ‘sample in’, and ‘waste out’ to chamber
out omitting the reagent loop. c) Conformation for ‘sample in’ to ‘waste out’ via
reagent loop. d) Conformation for ‘media in’ to ‘chamber out’ via reagent loop.
Confocal Imaging
· Transport to imaging facility in sealed box.
· Place box down in confocal microscope room, open box and remove
whole system. Place chip mount on confocal microscope along with
system in the 3-D printed brackets and follow imaging instructions
accompanying the instrument.
· Once finished carefully return system to the sealed box and transport
back to the incubator
Introducing reagents
· Reagent loops can be introduced using Luer fitting at one way
stopcocks connecting to tubing at reagent in ports on the chip. When
attaching tubing make sure no air is introduced into the system.
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· When flowing reagent into a chamber, make sure the necessary
stopcocks are closed in order to isolate the flow to the desired chamber.
Cleaning
· All parts that can be are autoclaved.
· All tubing is thrown into hazardous waste bins, along with chip.
· Duran bottles are sterilised overnight in Virkon before autoclaving.
· Stopcocks are soaked overnight in 70% ethanol.
6.3.5 Microspray microbubble manufacture.
Microbubbles were produced using a multiplexed microfluidic
microspray device, performed by Jordan Tinkler (University of Leeds).198 The
lipid solution was introduced at a flow rate of 80 μL min-1 and combined
perfluorobutane gas stream using a pressure of 1100 mbar. Following
production, samples were removed and diluted 5× in phosphate buffer for
optical microscopy (Eclipse E600, Nikon, Japan) performed using a 50 μm
deep observation chamber. Matlab was used to analyse the MB samples and
obtain sizing and concentration data.
6.3.6 MB-Affimer Attachment and Washing.
AlexaFluor647 tagged ClfA1 and AAC Affimer protein were added to
separate MB samples, mixed gently, and incubated in a fridge at 4°C for 30
minutes to allow binding. The volume of 7.5 μM Affimer protein required for
each sample was calculated based on the number of MBs in each sample and
the maximum packing efficiency of the Affimer. A two-step centrifugation wash
process, applying a RCF of 300g for 10 minutes, to separate buoyant MBs
and unbound Affimer contained in solution. Preliminary work showed this
method to significantly reduce the background fluorescence level whilst
preserving the MB population for use, as unbound Affimer could be decanted




Confocal images were acquired on a Leica DMi8 inverted confocal
microscope. The biofilm images were obtained using a 10× dry objective and
a 100× oil immersion objective (HC PL APO CS2 FWD 0.13 mm NA 1.4). Due
to the spectral overlap between EthDIII and Alexafluor647, biofilms in
subsequent experiments that used Alexafluor647-tagged molecules  were
only stained with the LIVE DMAO dye. DMAO identifies both living and dead
cell components, so allowed for imaging of the biofilm’s biomass, and does
not give any indication as the viability of cells imaged. Confocal z-stacks were
exported at .JPEG files and analysed in ImageJ (FIJI) software. 3-D z-stack
rendering was performed in LasX (Leica) software on the console that
controlled the confocal microscope.
6.3.8 Biofilm- reagent interaction under flow.
6.3.8.1 Biofilm-bead interaction
Once a biofilm has been cultivated using methods outlined in 6.3.4, it
was stained and mounted on the confocal microscope for imaging. The piezo
pump control box was connected to the reagent in pump and reagent was
introduced at ~ 250 µL min-1 via the reagent loop. In static pulse experiments,
the bright field optical lens on the microscope was used to observe the
chamber until the pulse of beads was seen filling the chamber. At this point
the piezo pump was stopped, stop-cocks up and downstream of the chamber
were closed, and the chip left mounted on the confocal for 10 minutes.  After
this time, the stop cocks were opened and flow was resumed for a further 30
minutes at ~ 250 µL min-1. Z-stack images were then acquired of 15 random
positions across the chamber, acquired at a height of 30 µm.
In constant flow experiments there was no pause between introduction
of the beads into the chamber and the 30 minutes buffer wash. The 30 minute
buffer wash was presumed to start once no stream of bead was observed
moving through the chamber.
6.3.8.2 Biofilm-MB interaction
Protocol identical to section 6.3.8.1 up until reagent introduction. At the
time of MB introduction, the system was removed from the confocal mount,
- 211 -
inverted so that all tubing between the reagent loop and the microfluidic chip
was orientated vertically. This meant the buoyant MB could move with the
prevailing buoyant force towards the microfluidic device. Once the MB had
reached the chamber, the system was held vertically with the microfluidic chip
inverted for 10 minutes. After this time the chip was returned to the confocal
microscope mount and washed for 30 minutes with buffer at ~ 250 µL min-1.




7.1 Mannose binding lectin structural information.
Amino acid Sequence:
        10         20         30         40         50         60
GDSSLAASER KALQTEMARI KKWLTFSLGK QVGNKFFLTN GEIMTFEKVK ALCVKFQASV
        70         80         90        100        110        120
ATPRNAAENG AIQNLIKEEA FLGITDEKTE GQFVDLTGNR LTYTNWNEGE PNNAGSDEDC
       130        140
VLLLKNGQWN DVPCSTSHLA VCEFPI




Total number of atoms: 2243
Ext. coefficient    18240
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7.2 MBP-MBL structural information
Amino acid Sequence:
        10         20         30         40         50         60
KIEEGKLVIW INGDKGYNGL AEVGKKFEKD TGIKVTVEHP DKLEEKFPQV AATGDGPDII
        70         80         90        100        110        120
FWAHDRFGGY AQSGLLAEIT PDKAFQDKLY PFTWDAVRYN GKLIAYPIAV EALSLIYNKD
       130        140        150        160        170        180
LLPNPPKTWE EIPALDKELK AKGKSALMFN LQEPYFTWPL IAADGGYAFK YENGKYDIKD
       190        200        210        220        230        240
VGVDNAGAKA GLTFLVDLIK NKHMNADTDY SIAEAAFNKG ETAMTINGPW AWSNIDTSKV
       250        260        270        280        290        300
NYGVTVLPTF KGQPSKPFVG VLSAGINAAS PNKELAKEFL ENYLLTDEGL EAVNKDKPLG
       310        320        330        340        350        360
AVALKSYEEE LVKDPRIAAT MENAQKGEIM PNIPQMSAFW YAVRTAVINA ASGRQTVDEA
       370        380        390        400        410        420
LKDAQTNSSS SSNNHHHHHH NNENLYFQGD SSLAASERKA LQTEMARIKK WLTFSLGKQV
       430        440        450        460        470        480
GNKFFLTNGE IMTFEKVKAL CVKFQASVAT PRNAAENGAI QNLIKEEAFL GITDEKTEGQ
       490        500        510        520        530
FVDLTGNRLT YTNWNEGEPN NAGSDEDCVL LLKNGQWNDV PCSTSHLAVC EFPI




Total number of atoms: 8248
Ext. coefficient    86080
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7.3 Affimer proteins structural information
Amino acid sequence:
        10         20         30         40         50         60
ASGNENSLEI EELARFAVDE HNKKENALLE FVRVVKAKEQ XXXXXXXXXT MYYLTLEAKD
        70         80         90        100
GGKKKLYEAK VWVKXXXXXX XXXNFKELQE FKPVGDACAA AHHHHHHHH
XXXXXXXXX = Variable loop 1














ClfA1 MLTTQVNTR FPSTPLFLY 12630.97 11460
AAC AAAA AA 10774.20 9970
SH6 TQMLSPSQH WIKFWPEYG 12436.14 22460
USA50 PNFKSRWGP NEPWQTNYS 12408.97 22460
SH30 YSYGMIKES APSVWPFLA 12246.96 18450
USA49 GATNGRQHH YDDIWFQSY 12395.89 18450
SH31 LEMLMPSSH LTKFFNTFS 12331.10 9970
ClfA27 VYWQDVVER DHFVYLRLI 12851.57 18450
ClfA16 GATNGRQHH YDDIWFQSY 12696.16 9970
UAMS11 PQDSSEYHT RFGYPYDGH 12356.81 14440




        10         20         30         40         50         60
MKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ VAATGDGPDI
        70         80         90        100        110        120
IFWAHDRFGG YAQSGLLAEI TPDKAFQDKL YPFTWDAVRY NGKLIAYPIA VEALSLIYNK
       130        140        150        160        170        180
DLLPNPPKTW EEIPALDKEL KAKGKSALMF NLQEPYFTWP LIAADGGYAF KYENGKYDIK
       190        200        210        220        230        240
DVGVDNAGAK AGLTFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK
       250        260        270        280        290        300
VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL
       310        320        330        340        350        360
GAVALKSYEE ELVKDPRIAA TMENAQKGEI MPNIPQMSAF WYAVRTAVIN AASGRQTVDE
       370        380        390        400        410        420
ALKDAQTNSS SENLYFQSVH HHHHHGTDIT NQLTNVTVGI DSGTTVYPHQ AGYVKLNYGF
       430        440        450        460        470        480
SVPNSAVKGD TFKITVPKEL NLNGVTSTAK VPPIMAGDQV LANGVIDSDG NVIYTFTDYV
       490        500        510        520        530        540
NTKDDVKATL TMPAYIDPEN VKKTGNVTLA TGIGSTTANK TVLVDYEKYG KFYNLSIKGT
       550        560        570        580        590        600
IDQIDKTNNT YRQTIYVNPS GDNVIAPVLT GNLKPNTDSN ALIDQQNTSI KVYKVDNAAD
       610        620        630        640        650        660
LSESYFVNPE NFEDVTNSVN ITFPNPNQYK VEFNTPDDQI TTPYIVVVNG HIDPNSKGDL
       670        680        690        700        710
ALRSTLYGYN SNIIWRSMSW DNEVAFNNGS GSGDGIDKPV VPEQPDEPGE IEPIPE




Total number of atoms: 10983
Ext. coefficient:   104170
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7.5 ClfA structural information
Amino acid sequence:
        10         20         30         40         50         60
SVHHHHHHGT DITNQLTNVT VGIDSGTTVY PHQAGYVKLN YGFSVPNSAV KGDTFKITVP
        70         80         90        100        110        120
KELNLNGVTS TAKVPPIMAG DQVLANGVID SDGNVIYTFT DYVNTKDDVK ATLTMPAYID
       130        140        150        160        170        180
PENVKKTGNV TLATGIGSTT ANKTVLVDYE KYGKFYNLSI KGTIDQIDKT NNTYRQTIYV
       190        200        210        220        230        240
NPSGDNVIAP VLTGNLKPNT DSNALIDQQN TSIKVYKVDN AADLSESYFV NPENFEDVTN
       250        260        270        280        290        300
SVNITFPNPN QYKVEFNTPD DQITTPYIVV VNGHIDPNSK GDLALRSTLY GYNSNIIWRS
       310        320        330
MSWDNEVAFN NGSGSGDGID KPVVPEQPDE PGEIEPIPE




Total number of atoms: 5141
Ext. coefficient    36330
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7.6 Plasmids
Plasmid Protein Cell lines used Origin






























7.7 Affimer-Biofilm Binding Assay single strain data.
ABBA results for individual Affimer proteins against SH1000, USA300
and UAMS1 S. aureus biofilms. All show correlation between relative

















7.8 Extension of ClfA1 ABBA binding curve.
Plot of fluorescent emission of ClfA1-fluorescein at a given concentration
screened against SH1000, USA300 and UAMS1 strains of biofilm individually.
Biofilms were cultivated then washed with phosphate buffer, 50 µL of Affimer-
fluorescein was added at various concentrations and incubated at RT for 1
hour. After this the wells were washed again with phosphate buffer and the
fluorescent emission of fluorescein at 535 nm measured using an Envision
plate reader. Fluorescent emission at 535 nm is associated with the presence
of ClfA1-fluorescein and is attributed to the binding of the protein to the S.
aureus biofilm and their associated SEM values shown as error bars. The data
points in the orange box correspond to a separate experiment in which the
concentrations were increased. Affimer was screened against three strains of
biofilm; SH1000, USA300 and UAMS1.
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7.9 Alexafluor647 labelling of ClfA1 and AAC
ESMS mass spectra of AAC and ClfA1 labelling reactions used for
experiments in chapter 4. A) shows the AAC Alexafluor647 NHA ester reaction
after overnight incubation at 4 ºC. B) shows the ClfA1 Alexafluor647 NHS
ester reaction after overnight incubation at 4 ºC.
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